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1. INTRODUCTION 
  Siddha system is one of the traditional systems of medicine in India.  In 
Siddha medicine, the individual is a microcosm of the universe.  The human body 
consists of the five primordial elements - earth, water, fire, air and space, the three 
humours-vatha, pitha and kapha and seven physical constituents.  The equilibrium of 
humours is considered as health and its disturbance or imbalance leads to a diseased 
state.  Poet Thiruvalluvar has indicated the same view in this Thirukural, 
“kpfpDk; FiwapDk; Neha;nra;Ak; EhNyhh; 
  tsp Kjyh vz;zpa %d;W” 
- Fws; - 941 
      There is equal emphasis on the body, mind and spirit and strives to restore the 
innate harmony of the individual. 
       Treatment is aimed at restoring balance to the mind-body system.  Diet, 
lifestyle, yoga and meditation play a major role not only in maintaining health but 
also in curing diseases. 
MATERIA MEDICA: 
       This system has developed a rich and unique treasure of drug knowledge in 
which use of metals and minerals is very much advocated some idea about the depth 
of knowledge.  The system possesses in the field of mineral, materia medica can be 
found from the detailed drug classification. 
       The system has classified separately classes of metals and alloys, which melt 
when heated and solidifies on cooling.  These include items like gold, silver, copper, 
tin, lead and iron.  These are incinerated by special processes and used in medicine. 
       There is a group of drugs that exhibit sublimation on heating and includes 
mercury and its different forms like red sulphite of mercury, mercuric chloride and 
red oxide of mercury etc. 
     Sulphur, which is insoluble in water, finds a crucial place in Siddha material 
medica along with mercury for use in therapeutics and in maintenance of health. 
       The above classification shows detailed knowledge and study of minerals that 
this system has evolved for treatment. 
       Siddha system that insists that the physician should enquire the nature of the 
disease, its cause and its method of cure and treat it faithfully envagai thervugal (the 
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eight methods of clinical examination) are used to determine the diagnosis, aetiology, 
treatment and prognosis of diseases. 
       In Siddha system of medicine, diseases are classified into 4448 types 
according to the Siddhar ‘yugimuni’.  Among them Mehaneer noigal is further 
classified into 21 types which include Madhumegam.  Madhumegam is one of the 
challenging diseases in our modern life.   
       As per the literature Siddha Maruthuvam (podhu) author by K.N. Kuppusamy 
mudhaliar the disease madhumegam is defined as it is condition characterized by 
frequent profuse urination (adikkadi siruneer peruvariyaga izhidhal), often flies and 
ants are stacked to the urine (neerizhindha idathil Ee, erumbugal  arithal) and on 
heating, it smells like sugar (adhanai kaachin sarkarai manam veesal) which is 
followed by emaciation of the body day by day (udal naaluku naal izhaithal). 
       In modern science madhumegam symptoms are may be correlated with 
diabetes mellitus. 
       Globally, an estimated 422 million adults are having  diabetes mellitus, 
according to the latest 2016 data from the World Health Organisation (WHO).  
Diabetes prevalence is increases rapidly; previous 2013 estimates from the 
international Diabetes Federation put the number at 381 million people having 
diabetes.  The number is projected to almost double by 2030.  Type 2 diabetes makes 
up about 85-90% of all cases.  Increases in the overall diabetes prevalence rates 
largely reflect an increase in risk factors for type 2, notably greater longevity and 
being overweight or as obese. 
       Diabetes mellitus throughout the world, but is more common(especially type 
2) in the more developing countries.  The greatest increase in prevalence is, however, 
occurring in low-and middle-income countries including in Asia and Africa, where 
most patients will probably be found by 2030.  Prevalence of Diabetes Mellitus 
especially in India (98million) and 10.4% in Tamilnadu. The increase in incidence in 
developing countries follows the trend of urbanization and lifestyle changes, 
including increasingly sedentary lifestyles, less physically demanding work and the 
global nutrition transition, marked by increased intake of foods that are high energy-
dense but nutrients-poor (often high in sugar and saturated fats, sometimes referred to 
as the western pattern diet).  The risk of getting type 2 diabetes has been widely found 
to be associated with lower socio-economic position across countries. 
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       WHO estimates that diabetes resulted in 1.5 million deaths in 2012, making it 
the 8th leading cause of death.  However another 2.2 million deaths worldwide were 
attributable to high blood glucose and the increased risks of associated complications 
(e.g. heart disease, stroke, kidney failure), which often result in premature death and 
are often listed as the underlying cause of death certificates rather than diabetes. 
       Hence an effective and safer therapy is the need of current scenario, therefore 
an effort has been made to preclinically evaluate the ‘KOMOOTHIRA SILASATHU 
PARPAM’ in the literature ofThanjai Vaithiya Raja Sinthamani part-2 page no. 5 
which is exclusively indicated for madhumegam. 
 The mineral formulation especially parpam is superior than herbal formulation 
such as chooranam. 
hx<h!lgqjl<<< !
uQvk<K!lqg<gju!hx<hr<gOt!–!hvq!
givk<K!lqg<gju!hx<hr<gOt!
!! hiVg<Gt<!lieqmI!Ofib<Ohig!–!uV!
!! ! !h{<ckVg<ogz<zi!liOligl<!
uQvgmiiq!–!hq{qg<ogiV!
!!! ! hivGmiiq!–!uqjsohX!
kQvkmiiq!–!uqjeBM!
!! ! $vqg<GP!Ofovik<kK!
!! OlVg<gqje!hivh<Hxl<!!!!!!!!!!!!!!!!!
Okjvbi<!gih<hqbl<!
!
       This dissertation is an endeavour to bring into spotlight the science behind the 
usage of komoothira silasaathu parpam in Siddha system to further reinforcement of 
traditional use for the treatment of madhumegam (diabetes mellitus). 
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2. AIM AND OBJECTIVES 
Aim: 
      The aim of this study is to validate the safety and efficacy of ‘komoothira 
silasathu parpam’  for “madhumegam” (diabetes mellitus) by pre-clinical studies.  
Objectives: 
  The following methodology was adopted to evaluate the safety and efficacy of   
the test drug.          
1. To collect the relevant classical Siddha literature as well as Modern Sciences 
that supports the study. 
2. To standardize the preparation of the drug according to classical siddha 
literature. 
3. To subject the drug into physico chemical & phyto chemical analysis. 
4. To analyze the drug biochemically for the detection of acidic and basic 
radicals. 
5. To Estimate the percentage of elements present in the drug by Instrumental 
analysis. 
6. To Establish the following Pharmacological activities: 
• Hypoglycemia, 
• Anti Dyslipidemic, 
• Antioxidant 
7. To evaluate the acute and sub-acute toxicity studies profile of komoothira 
silasathu parpam according to OECD guidelines.  
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3. REVIEW OF LITERATURE 
3.1. ASPHALTUM  (KOMOOTHIRA SILASATHU)  
3.1.1. Gunapadam aspect: 
Synonyms: 
“jhJ[k; jpjpapNdhL jUrpyh rJTkhFk;  
    jPjW kr; k[e;jhd; epfoj;hpDk; irNyak;Nk  
    XJ [j; tr; k[k;NkAW fphp[hr;k[g; Ngh; 
    Vjkpy; EhNyhh; $Wk; ,UQ; rpyhrj;Jtpd; Nguhk;” 
    -- epfz;L uj;dhfuk; 73> 208 ghly; 
  Thathujam, thithi, silasathu, achmajam, athirajam, salieyam, jath vaja majam, 
kinjach majam, peraicaicum, urainjiyam, silarasam, sayeleyam, kalkasilasathu. 
VERNACULAR NAMES: 
English   :  Asphalt mineral pitch, Juv’s pitch. 
Sanskrit  : Silajit, Silaras. 
Gujarathi  :  Silajata 
Malayalam  :  Silajatu 
Kannadam  :  Silajata 
Bengali  :  Silajatu 
Arabic   :  Hajar-ul-musa 
Persian  : Momiai, Faqurul Yahud 
Hindi   : Ral-Yahudi 
 
Organoleptic character: 
Colour   :  Black colour 
Appearance  :   Black crystal  
Taste   :   Bitter 
Action: 
External:    Internal: 
Anthelmenitic    Tonic 
Deobstruent    Laxative 
Analgesic    Lithotriptic 
Antiseptic    Diuretic 
Deodorant    Expectorant 
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Origin: 
Silasathu is found in many mountain ranges of the world, at attitudes between 
1000-5000 meters, namely in the Himalayas and Hindukush ranges of Indian 
subcontinent, Tibet mountains and in Haridhvar, Simla, Nepal, Hironia. 
      The word silasathu is composed of two parts ‘sila’ means rock and ‘sathu’ 
means having won.  So it literally means conqueror of the mountains.  It is 
blackishbrown material of variable consistency that exudes from layers of rock.  
Komoothira silasathu is one of the ingredients of Attanga dhoopa pillai. 
“Fq;fpypa kfUtfpaPf Kbae;jhW 
    FWk;nghiw apuj kzg;ghy;” 
Types: 
rpyhrj;J tiffs; : 
  gz;nld;w rpyhrj;J tz;zq; NfS ghukhff; fk;gpahd ntSg;G khFk; 
  Fz;nld;w Nfh%j;jpu rpyhrj;J Nfh%j;jpu epwkhff; fl;bahFk; 
  fz;nld;w fdj;jpy; gpwe;j rpyhrj;J fdfe;J nrk;guj;jg; G+ epwe;j jhNk 
  epwkhd nts;spAl rpyhrj;J jhDk; eprkhd kapy; tapw;wpd; ntz;ik Nghyhk; 
  mwkhd mOf;file;j fl;bahFk; mjpa jhk;gpue; jd;dpYw; gtpj;j 
  jpwkhd rpyhrj;J nrhy;yf; NfS rpW ePy tz;zkhd fl;bahFk; 
  Kwkhd Kd; nrhd;d rpyhrj;J jhDk; Kwpe;J Neha; ryf;fl;L ePUe;jhNd 
       -- Nghfh; 7000 %d;whk; fhz;lk; 
 
Velli silasathu  - White Variety 
Aya silasathu  - Cow’s Urine Colour 
Kanaga silasathu - Red Variety 
Tambira silasathu - Light Blue Variety 
Other types are: 
Yema silasathu  
Blue and red silasathu are not found commonly. The aya silasathu is 
considered to be active.  Yema silasathu and thamira silasathu are rare. Yema silsathu 
is used to treat vatha and pitha diseases.Velli silasathu is used in treatment of kapha 
diseases. Aya silasathu is used for treating tridosas and it is also used for rejuvenating 
treatment. 
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  Dhravis are 4 types which comes under komoothira silasathu. 
1. Mangishadhravi 
2. Asthidhravi 
3. Annadhravi 
4.  Sangadhravi 
      Life span of komoorthira silasathu is about 40 years. 
Classical methods to check the purity of SILASATHU: 
       Pure silasathu is obtained from persians. 
A grain of silasathu, if put in water it will disintegrate completely and settle 
down at bottom and turn into red. 
Pure silasathu has a Peculiar smell similar to cow’s urine. It is like resin or can 
be hard but softens if a small portion is rubbed between the fingertips. It is lightweight 
and smooth to touch. 
Pure silasathu will not smoke is put on a fire or charcoal ember.  Silasathu is 
taken as a poppy seed size and heated with a little Ghee and this has to be given for 
the broken legs of hen. If it is pure means it will work within 2 hours. If it is not pure 
means it will work on next day. 
         Since it is a humic material it is bound to be contained with soil, rock particles 
and plant debris at the time of collection.  So it needs to be purified before 
consumption. 
Purification of Komoothira silasathu: 
  Komoothira silasathu is finally grind with milk, and keep it until it gets dry. 
                                                                            -Sarakku suthi muraigal, 
General Characters 
 “Nfh%j; epurpyh rj;jhw; FWfpNa  
Ngh%j; jpunkhpTl; Gz;Nkfk; -- ehNkT 
  ntg;Gjpu ntg;GkWk; tPopKdp tpk;ge; 
  Jg;GkQ;R nky;ypjoha; nrhy;” 
- Gunapadam Thathu Jeeva Vaguppu 
     It cures urinary infection, burning sensation  and wounds in urinary tract, 
peramegam, apthus ulcer and hypertension. 
 “jPUNk Nfh%j;jpu rpyhrj; Jj;jhd; 
  nrakhd thjj;Jf; FWjpahFk;” 
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Usages: 
Traditional Uses: 
1. Komoothira silasathu  is used for skin disorders. It is taken as 65 milligram and 
dissolved into hot water and it is used for diseases that affect tongue, cheeks. 
2. Administration of komoothira silasathu with hot water or rose water droplets 
into ears and nose relieves ear pain and nasal disorders. 
3. Komoothira silasathu, kasthuri, camphor are taken in equal amounts and mixed 
with betal juice. This has to be applied for headache externally. 
4. Komoothira silasathu is mixed with honey and applied for tinnitus. 
5. Chronic otitis and for other ear diseases, Komoothira silasathu is tied in a small 
cloth and have to kept inside ear.  
6. 65 milligram of Komoothira silasathu with donkey's milk gives for Mania 
causes and in hemorrhagic cases. 
7. 130 milligram Komoothira silasathu with ziziphus mauritiana (Indian jujube) 
juice or with honey or with milk and honey mixture given for dry cough twice a 
day. 
8. Komoothira silasathu with cotton seed decoction, coriander decoction is given 
for pitham, stomach tumour. 
9. To stop bleeding from piles, Komoothira silasathu is given by mixing with 
cow’s ghee. 
10. Komoothira silasathu is mixed with Betal decoction and it is used for elongated 
uvula and uterine haemorrhage. 
11.  It is used to treat urinary infections, urinary tract wounds, aphthous ulcers, 
hypertension, sexual disorders and give strength to heart and used as a service 
tonic and impotence. Cough, wheezing, intestinal disorders, infertility, vatha 
diseases and Inflammation. 
12. Decoctions and juices of fruits like lemons and pineapple  may be preserved for 
a long time  by the addition  of silajit.  
13. In various parasitic skin diseases silajit may be used with much benefit.  
14. silajit is used by the vaidyas in acute and chronic bronchitis.Benzoic acid and 
benzoates are administered especially for children .It promotes expectoration 
probably reflexly by causing irritation of the throat and stomach.  
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15. In pulmonary phthisis, silajit is very useful owing to its beneficial effect on the 
digestive and respiratory systems. It is most suitable for those cases where there 
is great thirst and burning sensation as in diabetic phthisis.  
16. In sexual weakness it is generally administered with Aswagandha(withania 
somnifera)and other allied drugs.  
17. In chronic gonorrhea and gleet, silajit is used with prepared oxides of 
tin,lead,silver etc. 
18. Charaka says, there is hardly any curable diseases which cannot be controlled 
or cured with the aid of silajit.It is used by Kavirajas and Hakim's in a great 
variety of diseases.It is specially employed in genitourinary disease and in 
diabetes, gall stones, jaundice, enlarged spleen, fermentative dyspepsia, renal 
and bladder calculi, worms, digestive troubles, piles, anuria, hysteria, 
neurasthenia, epilepsy and insanity nervous diseases.   
 
Medicinal preparations of komoothira silasathu: 
1.Komoothirasilasathuparpam: 
Dosage : 180 mg 
Indication  : madhumegam, All  types of Megam, urinary infections,  
  All types of  Fever.  
Reference : Nam naatu vaithiyam - Pg.No: 171 
 
2. Silasathu Vathi kuligai: 
Dosage : 2 kuligai, 2 times after food per day.  
Adjuvent : Milk,pomegranate juice.  
Indication : madhumegam, anaemia, dropsy, fever, tuberculosis. 
Reference  : Agasthiyar palathiratu. Pg.No: 62 
 
3.Sathathy parpam: 
Dosage : 350-700 mg  
Adjuvent : Honey,ghee 
Indication  : madhumegam, vathasoolai,peripheral neuropathy,  
    peramegam, burning  micturation.  
Reference  : Agasthiyar paripooranam(299). Pg.No: 95 
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4.Komoothira silasathu parpam: 
Dosage  : 200 mg 
Adjuvent : Butter 
Indication  : madhumegam, vatha disease, leucorrhea. 
Reference  : Ramadevar ennum vaithiya sinthamani 7000. Pg.No: 17 
 
 5.Komoothira silasathu chendooram: 
Dosage : 350 mg-700 mg 
Adjuvent : Ghee, Butter 
Indication  : madhumegam, vatha disease, Anaemia.  
Reference  : Nam Nattu vaithiyam -. Pg.No: 7 
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3.1.2. GEO CHEMICAL ASPECT 
Shilajit (Asphaltum) : 
Shilajit (Asphaltum) also known as mineral which is a pale brown to black is 
brown rock exudates found in many mountain ranges of the world, specially the 
Himalayas and hindukush ranges of the Indian subcontinent.   Shilajit is a complex 
mixture of organic humic substances as well as plant and microbial metabolites which 
occur in the rock rhizophore substances identified in Shilajit include moisture, gums, 
albumunoids, resins, vegetable matter, benzoic acid, silica, minerals, vitamins and 
many other substances.   
      It is used for the last thousands of years as rejuvanator and as an adaptogen 
in traditional medicinal systems of many countries and has been attributed with 
miraculous healing properties.  Recent reports have revealed that it has antioxidant, 
anti-inflammatory and anxiolytic activity.  It has also demonstrated for spermatogenic 
and ovogenic effect in mature rats.  
 
Shilajit Odour: 
 The common variety of shilajit has a typical odour resembling that of cow’s 
urine and is branded as the “gomutra shilajit” in has a camphor like smell and is 
known as karpur – gandha shilajit. Extensive researches carried out on these two 
varities of Shilajit/  
 
Taste of Shilajit: 
 Water soluble native shilajit has a slightly bitter, somewhat pungent, salty 
taste purified shilajit produces either acidic or alkaline taste depending on the quality 
and quantity of contained ingredients (Ghosal, 1989). 
 
Ealier Research on chemical constituents of Shilajit: 
 Shilajit was earlier shown to be constituted of benzoic acid, hippuric acid, 
their salts and gums , albuminoids, traces of resins and fathy acids. The protein and 
mineral matters present in Shilajit produced on hydrolysis, glycine, protine, 
hydroxcyproline, Threonine and metal salts compiring of Ca, Na, K, fe sn, cu and si 
(chopra et al , 1958, shakir et al , 1964) 
 
 
 PRE CLINICAL  STUDY OF  KARPOORA  SINTHAMANI  MATHIRAI 
 
   12 
Active ingredients in SILASATHU: 
Table No: 1 Organic Constituents of Asphaltum 
S.No. Organic Constituents Crude Silajit Pure Silajit 
1 Moisture 12.54% 29.03% 
2 Benzoic acid 6.82% 8.52% 
3 Hippuric Acid 5.53% 6.13% 
4 Fatty Acid 2.01% 1.63% 
5 Resin and Waxy matter 3.28% 2.44% 
6 Gums 15.59% 17.32% 
7 Albuminoids 19.61% 16.12% 
8 Vegetable matter, Sand, etc., 28.52% 2.15% 
Table No: 2 Mineral Constituents of Asphaltum 
S.No. The Mineral Constituents Crude silajit Pure silajit 
1 Moisture 12.54% 29.03% 
2 Loss of ignition 64.58% 52.03% 
3 Ash 22.88% 18.34% 
4 Silica (residue insoluble in HCl) 4.60% 2.69% 
5 Iron (Fe2O3) 0.51% 0.67% 
6 Alumina (Al2O3) 2.26% 2.61% 
7 Lime(CaO) 6.83% 4.82% 
8 Magnesia (MgO) 1.29% 1.20% 
9 Potash (K2O) 4.60% 3.81% 
10 Sulphuric Acid (SO3) 0.64% 0.97% 
11 Sodium Chloride (NaCl) 0.26% 0.57% 
12 Phosphoric acid (P2O3) 0.28% 0.24% 
13 Nitrogen (N2) 3.64% 3.36% 
    
  The primary active ingredients in silasathu are fulvic acids, folic acid, 
dibenzo Alpha phones, humins, humic acids, trace minerals, vitamins A, B,C and 
D(citrines), phospholipids and polyphenol complexes terpenoids.  Also, present are 
micro elements (cobalt, nickel, copper, zinc, iron, Chrome, iron, magnesium). 
 - Shilajit in Perspective  
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tetrameric dibenzo-α-pyrones (DBP) having the formulas shown below:
and (b) fulvic acids (FAs) which have repeat units having the formula:
 
-
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 or di-hydroxy or 
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The methanol soluble portion of the purified shilajit composition also includes 
0.1-0.5% 3-OH dibenzo-α-pyrone; 0.3-1.5% 3,8-diOH dibenzo-α-pyrone; 0.001-0.1% 
eicosapentaenoic acid; 0.005-0.01% docosapentaenoic acid; 0.01-0.3% 
docosahexaenoic acid; 0.1-0.2% 2-hydroxyacetophenone; 0.01-0.2% 2,4-
dihydroxyacetophenone and 0.05-0.3% α-lipoic acid. 
The composition of the invention finds particular application in personal care, 
pharmaceutical and nutritional use formulations, suitably at a use level of 0.1 to 60% 
by weight of the composition, preferably about 0.2 to 10% in personal care 
formulations. 
  The purified shilajit compositions of the invention are obtained by an 
extraction procedure from native shilajit rock exdudate, as follows: 
a) powdering native shilajit exdudate and dissolving it in water as solvent, 
b) filtering the mixture to remove insoluble substances, 
c) evaporating water from the filtrate to obtain a brown viscous residue, 
d) extracting the residue with a hot organic solvent, e.g. methanol, to obtain both 
a soluble fraction which includes low Mw bioactive phenolic compounds 
particularly oxygenated dibenzo-α-pyrones, and insoluble shilajit humic 
substances, 
e) adding dilute aqueous NaOH to the insoluble shilajit humic portion to 
precipitate polymeric quinones, 
f) acidifying the filtrate below a pH of about 3 to precipitate humic acids leaving 
a brown acidic solution of fulvic acids, 
g) fractionating said acidic solution by passing it over activated carbon to provide 
a solution of low-to-medium Mw fulvic acids, 
a) passing the fulvic acid solution through a H+ ion-exchange resin to concentrate 
the fulvic acids in solution, evaporating the solution, and 
b) (j) combining the low-to-medium Mw fulvic acids Mw 700-2000, with the low 
Mw bioactive phenolic compounds in a suitable proportion, e.g. 9:1 by weight. 
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3.1.3. LATERAL RESEARCH 
  Effect of silajit on blood glucose and lipid profile in alloxan induces diabetic 
rats. 
Objective: 
      To study the effect of silajit ( a herhomineral preparation) on blood glucose 
and lipids profile in euglycemic and alloxan induced diabetic rats and its effects on 
the above parameters in combination with conventional antidiabetic drugs. 
Materials and methods: 
  Diabetes was induced in Albino rats by administration of a single dose of 
alloxan monohydrate 5 %(125 mg/ kg).  Effects of three different doses of silajit 
(50,100&200 mg/kg/day orally), alone for 4 weeks and combination silajit (100 
mg/kg/day, orally).With either glibenclamide(5 mg/kg/day, orally) or metformin (0.5 
g/kg/day, orally) for 4 weeks was studied on blood glucose and lipid profile. 
Results: 
      In Diabetic rats, all the three doses of silajit produced a significant reduction in 
blood glucose levels and produced beneficial effects on lipid profile. The maximum 
effect was observed with the 100 mg/kg/day dose of silajit. 
Conclusion: 
  Silajit is effective in controlling blood glucose levels and improve the lipid 
profile. 
Author Information: 
 NA trivedi, B Mazumdar, JD Bhatt, KG Hemavathi  
 Department of Pharmacology, Medical College, Baroda – 390001, India 
 20, July, 2004. 
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3.2. Terminalia chebula.Retz (KADUKKAI) 
3.2.1. GUNAPADAM ASPECT 
Synonyms: 
Amutham, Ammai, Arithaki, Arabi, Aviyatha, Amritha, Aparanam, Anthan, 
Anganam, Amalai, Alliyan, Resaki, Yemavathi zyavi, Himavathi, Kadu, Kaayastha, 
Siyurutham, syuraki, Sirotam, Siva, Sethaki, Seya, Divya, Devi, Nandhini, Nechi, 
Pathiyam, Megam, Boothana, Paariyam, Vayatharam, Rarikkai, Vanadurki, 
Vijayavedhan, Rohini, Yeevaniga, Jeevanthi, Jeevapriya, Jeevya, Jeya. 
 
Vernacular names: 
Tamil   : Ammai, Amutham, Aritaki, Pethiyam, Varikkai 
Telugu   : Karakkaya 
Urdu   : Halela 
Bengali  : Haritaki 
Hindi   : Harre, Harad, Harzar 
Kannada  : Alalekai 
Malayalam  : Katukka 
Marathi  : Hirdi, Haritaki, Harda, Hireda 
Punjabi   : Hakeka, Harar 
Sanskrit  : Maritaki, Abhaya, Kayastha, Siva, Pathya 
Assamese  : shilikha 
 
Parts used: 
       Mature fruit and immature fruit. 
Organoleptic character: 
  Taste                : Mainly-Astringent, slightly sweet and sore,  
  pungent, bitter. 
  Potency                     : Hot 
Biological  
Transformation : sweet 
Action: 
   Cardiac stimulant  
   Tonic                                  
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General Characters: 
  “jhil fOj;jf;fp jhY Fwpaptplg; 
   gPil rpypgjKw; NgjpKlk; - Milnal;lhj; 
   Jhykpb Gz;thj Nrhzpfh khiyapuz; 
   lhykpb Nghk;thpf;fh ahy;.” 
- Gunapadam Mooligai Vaguppu 
- Page No: 207 
General characters: 
Kadukkai: 
    It cures excessive urination, aguseia, heart diseases, hypertension, traumatic 
wounds, lip disease, eye disease, cough, jaundice, worm infestation, gastric disorders, 
leprosy, peripheral neuropathy, respiratory disorder, head disease, anaemia,bronchial 
asthma, hoarseness of voice, excessive thirst, impotency, liver diseases, leucorrhea, 
ascites,dryness of tongue, tongue diseases,  vatha diseases, chest diseases,  urinary 
disorders, piles, venereal diseases, abdominal disorders, hiccup, vitiligo, fever due to 
poisoning, tuberculosis, constipation, indigestion, cough, internal body heat, kapha 
vatha diseases, skin disease,  anal fistula, cancer,  stomach tumour and apthus ulcer.  
 
Usages: 
Traditional uses: 
1. chebulic myrobalan cures aguseia 
2. Decoction of Chebulic myrobalan cures eye diseases, polyuria. powder of 
Chebulic myrobalan used as a tooth powder to reduce the pain of gums, 
bleeding gums.  
3. chebulic myrobalan powder inhalation cures sinusitis.  
4. whole plant of Chebulic myrobalan grinds with milk is given for 
eczema,leprosy. 
5. The fruit is mild laxative,stomachic,tonic,alterative,antispasmodic.It is useful 
in opthalmia, hemorrhoids, dental caries, bleeding gums, ulcers oral cavity.  
6. The paste of Chebulic myrobalan with water is found to be anti inflammatory, 
analgesic and having purifying and healing capacity for wounds.  
7. chebulic myrobalan decoctions is used as gargle in oral ulcers, sore throat.  
8. It is good to increase appetite, digestive aid, liver stimulant, stomachic, 
gastrointestinal prokinectic agent and mild laxative.  
 PRE CLINICAL  STUDY OF  KARPOORA  SINTHAMANI  MATHIRAI 
 
   18 
9. The powder of Chebulic myrobalan fruits has been used in chronic diarrhoea. 
It is used in nervous irritability.  
10. chebulic myrobalan is adjuvent in hemorrhages due to its astringent  nature 
and good for chronic cough, chorizo, sore throat  as well as in asthma. Also it 
is  useful in renal calculi, dysurea, retention of  urine and skin disorders with 
discharges like allergies, urticaria and other erythematous disorders.  
11. If chebulic myrobalan is regularly taken in every morning for a period of one 
year grey hair turns black and wrinkles of skin disappear 
12. outer skin of Chebulic myrobalan, Zyzygium Aromaticum taken about 4 gm  
and made into decoction by boiling it for 10 minutes and filtered  and it is used 
for dysentery. 
 
Other preparations in kadukkai: 
1. Muthakasu kulambu: 
Dosage : 500 mg 
Indication : madhumegam, urinary infection 
Reference    : SarbendraVaithiya Rathinavali Pg. No.: 21 
 
2. Keelanelli paste: 
Dosage : 1 gm 
Indication : madhumegam 
Reference    : Sarbendra Vaithiya Rathinavali Pg. No.: 23 
 
3. Kadalurinchiyathi pattai chooranam: 
Dosage : 2-5 gm 
Indication   : madhumegam, piramegam 
Reference : Sarbendra Vaithiya Rathinavali. Pg. No. : 70 
 
4. Avarai vithai chooranam: 
Dosage : 488 mg 
Indication : madhumegam, athimoothiram 
Reference : Mega Nivarana Bodhini Pg. No: 49 
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5. Thettran vithai kudineer: 
Dosage : 35 ml per day, 6 times 
Adjuvent      : Butter milk 
Indication    : madhumegam, soolai 
Reference : Gunapadam Mooligai Vaguppu Pg. No.:551 
 
6. Vithatti chooranam: 
Dosage : 51g (1 kalanchu) 
Indication : 21 types of piramegam, diabetes mellitus (madhumegam),  
  spermatzuria, premature ejaculation, gonococcal infection  
  diseases. 
Reference : Anubooga Vathiya Navaneetham Pg. No:126 
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3.2.2. BOTANICAL ASPECT 
  Botanical name :Terminalia chebula. Retz 
Classification: 
Kingdom  : plant kingdom 
Division  : Angiosperms 
Class                      : Dicotyledons 
Subclass                : Polypetalae 
Series                    : Calciflorae 
Order                     : Myrtales 
Family                    : Combretaceae 
Genus                    : Terminalia 
Species                  : Chebula 
Morphology: 
Distribution:  
             Throughout India in deciduous forests and on hill slopes upto 200m, also 
cultivated in plains.A tree small to medium in size, the average height  being 5-5 
metres. It's bark is usually light brown to black, coming off in thin strips or flakes, 
exposing the fresh surface of a differ colour underneath the older bark.              
                                                                           -   Indian medicinal plants-volume 4 
                                                                                   –  P. No-256  
Leaves:   
Leaf buds, branchlets and youngest leaves with soft, shining, generally rust 
coloured hairs, leaves 7-20 cm, by 4-8 cm glabrous or nearly so when mature come or 
not clustered, distant alternate or sub-opposite, elliptic oblong, rounded or cordate at 
base, penninerved, second nerves 6-8 pairs, arching, prominent. 
Petioles:   
2-5 cm long, pubescent, usually with 2 glands near the top. 
Bracts:   
It is existing in the flowers subulate or lanceolate Hairy. Conspicuous among 
the buds but soon deciduous. 
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Calyx:   
Capitulate, 3 mm long constricted about the ovary flat the base expanding a 
little towards   the mouth glabrous outside, hairy inside teeth short sometimes 
obscure. 
Bark:   
6 mm, dark brown with many generally Shallow vertical cracks exfoliating in 
axales. 
Wood:   
very hard, brownish grey with a greenish yellowish fringe, with a irregular 
small dark purple heart wood, close grained 
-India medicinal plants p.no. 1020-1021. 
Flowers:   
Flowers are hermaphrodite, 4 mm across sessile, dull white or yellow with an 
offensive smell. 
Style:   
Stipulate ending in a small stigma. 
Stamens:   
10 in two series arising from the calyx-tubes. 
Fruit :  
Fruit is simple and drupaceous. It is pendulous, 2 to 4 cm  long and is mostly 
egg shaped. Oblong or elongate, elliposidal 15 to 25 me, wide at the broadest part. It 
is glabrous and obscurely or faintly 5 ridged that are 2 to 3 mm wide and 1 to 2 mm 
thick. The surface colour varies from light yellowish  brown to a nearly uniform 
brown with yellowish markings or patches here and there. In some fruits, the basal 
portion is narrower and some what elongate or tapering. When  the fruit is dry, it is  
bony hard, very thick and obscurely angled. Seeds are hard and pale yellow in colour.  
          The cross section of the dried fruit shows mainly two parts.  
         pericarp 
         seed 
Pericarp:  
Pericarp comprises of the rind, which is  composed of the very thin and 
closely adhering skin or epicarp and the medical, and a hard or stony endocarp.  On  
account of presence of ridges and furrows on the the surface of the fruit the thickness 
of the rind epicarp and mesocarp varies from  2 to 4 mm at the furrows to 4 to 6 mm 
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at the  ridges. The relative thickness of the rind with that of the bony endocarp often 
varies in different fruits. The  colour of the  mesocarp is greyish yellow and that of 
the  endocarp is pale yellow.  
Seed: 
   The seed has a thin brownish skin or testa and the embryo within whitish.  
Collection of fruits: 
The fruits are to be  collected  in first half  of January  from the ground as soon 
as they have fallen or the matured fruits are to be collected during January to April  by 
shaking  the trees  and then they are dried in shade and store. 
Chemical constituents: 
           Terminalia chebula contains chebulin MP 249 from flowers, a purgative 
glycoside of an anthraquinone derivative isolated, a tannin terchebin from fruits.  
                                                   -compendium of Indian medicinal plants volume 1                                               
Anthraquinine, glycoside, chebulinic acid, chebulagic acid, tannin acid, 
tercgebulin, tetrachebulin, vitamin c, arachidic, behenic, linoleic, oleic, palmitic and 
stearic acids(fruit kernels), chebulin (flowers)2 -alpha hydroxy minor medic acid, 
maslinic acid and 2- alpha- hydroxy ursolic acid (leaves).  
 
Phytochemical aspect: 
Flowers          :  chebulin 
Fruit               : phenolic compounds, punikala, terflavin A, Ellagin,  
tannin terchebulin 
                           Terchebin   
   Gallic acid  
Kernels           :  Fatty oil 
Tree                :  Gum 
Myrobalan      :  30-32% Tannic acid  
                           Mucilage  
                           Chebulinic acid 
   Brownish yellow colouring matter 
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3.2.3. LATERAL RESEARCH 
      Anti-diabetic activity on Ethanolic extracts of fruits Terminalia chebula.  
Alloxan induced diabetic rats.  
 
Abstract: 
      The present study intended to evaluate the beneficial  effects of ethanolic extracts of 
terminalia chebula fruits(EETC) by using alloxan monohydrate induced diabetic control by 
using wistor Albino rats.  The toxicity study was performed on aliquot drones of EETC 
(100_500 mg /kg bwt) and predetermined the LD 50 value on 30 days evaluation; also the 
behavioral changes symptoms and mortality have been  checked.  The EETC show the 
toxicity up to(500 mg/kg btw). The effect of EETC was compared with the glibenclamide 
(600 mg/ kg btw) that is often used as a standard drug and the anti_diabetic activity has 
been conducted for 30 days.  After the completion of the study the animals were dissected 
through cervical and and collected the blood serum and pancreas. The collected samples 
were performed under parameters like biochemical and antioxidant enzymes related to 
diabetes such as weight variation, blood glucose, plasma insulin, serum and liver protein 
serum cholesterol, serum and liver protein, serum and liver phospholipids, SGOT(serum 
glutamate oxaloacetic transaminase), ACP( acid phosphatase),ALP( Alkaline 
phosphatase),GSH(Gluta reductase),GPT( glutamate pyruvate transaminase),GPX                          
( glutathione peroxidase), CAT( catalyst) and histopathologic and sections of the pancreas.  
The above parameters calculated and showed that the significance at P<0.001 to 0.05.  The 
histopathological changes caused after induction of alloxan show the granular cytoplasm 
dilation, shrunken nuclei and inflammation, which were reduced after the treatment of 
EETC (200 mg kg b.wt). Excess proliferation of epithelium in the pancreas was observed in 
Diabetic rats which was reduced after administration of EETC having the pharmacological 
action against the diabetic condition even the mechanism of the action is unknown, also it 
can be used to further molecular compound analysis and define the chemical action. 
Author Information: 
V. Rajesh Kanna, G. Stalin Rajasekar, P. Rajesh, V. Balasubramanian,         
N. Ramesh, E. King Solomon, D. Nivas and S. Chandru 
Department of Microbiology, Bharathidasan University, Thiruchirappali – 
620024, Tamil Nadu, India.  
American Journal of Drug Discovery & Development 2(3) 135 - 142,2012 
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3.3. Phyllanthus emblica dried(Nelli mulli) 
3.3.1. GUNAPADAM ASPECT 
Synonyms: 
  Amalukam, Soolakam, Ambal, Amarigam, Thatharis, Korangam, Miruthubala, 
Meerthinthu. 
                                                              -Gunapam-Mooligai Vaguppu 
                                                            -P. No.: 620 
 “mJntd;w te;jpNfhu nkd;Wk; NgU rd;djkh kayejp fhundd;Dk; NgU 
 aJntd;w thkyf;fp nad;Wk; NgU mWthd mKh;j nkd;Dk; NgU 
 kJntd;w khkyf;fh nkd;Dk; NgU kfj;jhd khyf nkd;Dk; NgU 
 tJntd;w yTlhQ;rp Jj;jphpf nkd;Dk; mUspNdhk; ney;ypf;fha; mjw;Fk; NgNu” 
 nghopg;Giu : 
  me;jpNfhuk;> Mkyf;fp> mKh;jk;> Jj;jphpfk;> Mkyfk; 
    --Njiuah; fhg;gpak; 
      gf;fk; 105 
Vernacular names: 
English  :  Emblic Myrobalan Tree 
Arabic   :  Ambily, Amlaj 
Assameese  :  Amlaki, Amluki, Sohmyralin, Amlaku, Amalaki,  
Amulakh, Amlakhi,  
Bengal   :  Amla, Ambolatti, Amlaki, Amlati 
Hindi                     :  Amalaci, Amla, Amlika, Anola, Anli, Anvula,  
Anvurah,  Aungra,  Aunra, Daula 
Malayalam          :  Amalakam, Nelli 
Marathi               :  Anvala, Aonli, Avala, Arola, Bhuiawali 
Sanskrit            : Adhiphala, Akara, Amalaki, Amamalakam,  
Anlika, Amruphala,  Amrita, Amritaphala, 
Dhatri, Dhatriphala, Jatiphala, Shanta, Shiva, 
Shriphali, Tishya, Tishyaphala, Vrishya, 
Vayastha 
Telugu                 : Amalakamu, Amalaki, Nelli, Pullayusprika,  
Uirika, Usirikaya 
Urdu                 :  Anwala 
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Parts used: 
Leaf, Bark, Root, Seed, Fruit 
Organoleptic character: 
Taste               : Astringent, sweet, sour 
Potency          : Neutral 
Biological transformation : Sweet 
Action: 
Fruit 
Diuretic, Refrigerant, Laxative 
Flower 
Refrigerant, Laxative 
Leaves, bark, dried fruit- 
Astringent 
General Characters: 
“ney;ypf;fha; Ngh;jidNa epfo;j;jf;NfS NjakhQ; rgykhQ; rpJgykhFe; 
 jy;ypf; fhe;jphpgy khe; ryKkhFe; rkhd thkq; fjwprpa gykhFk; 
 tpy;ypf;fha; rpwpgykh NktrKkhFk; tpsq;fpaNjhh; gQ;rrhtW\ gykhUk; 
 ney;ypf;fha; rpwpNjh\ gzpakpFQ; nrg;gpaNjhh; ney;ypf;fha; NgFkhNk” 
      --Nghfh; epfz;L 
      gf;fk; - 284 
 
     It gives good taste to the tongue.It cures internal excessive  body heat, rickets, 
hypertension,menorrhagia,psychiatric disorder, oliguria, vomiting, leucorrhea, penieal 
vesicle. If apply the paste of nellimulli to the  hair it can be gives cooling effect of eye. 
Types: 
Tamil Name   English Name  Botanical Name 
1.  Nilla Nelli   Lowly Nelly   Pyllanthus madraspatensis   
2. Thoopu Nelli  Garden Nelly    Emblica officinalis   
3. Kattu Nelli   The same as Nelly  Emblica officinalis 
4. Karu Nelli   Black honey shrub  Phyllanthus reticulates  
5. Kodi Nelli   an unknown variety 
6. seemainelli   1. Barbadoes cherry  Eugenia uniflora 
2. Common ovate leaved 
 barbadoes 
 PRE CLINICAL  STUDY OF  KARPOORA  SINTHAMANI  MATHIRAI 
 
   26 
Cherry – Malpeghia coccigera 
7. Arunelli   Country star goose berry Phyllanthus distichus  
8. Sennelli    a red variety of nelli 
9. Mellanelli    Same as Karunelli 
10. Kellanelli            Indian annual phyllanthus   Phyllanthus niruri 
11. Neernelli               Same as karunelli 
12. Nilanelli                 Same as Arunelli 
13. Vennelli                 whitenelli     Phyllanthus pendulous 
                                         
 -Tamil English dictionary, T. V. Sambasivam pillai  
volume-4 
Traditional uses:  
 
1. Prepare thuvaiyal using phyllanthus emblica and eat along with regular food. 
This will remove tasteless and vomiting sensation. 
2. Make decoction out of dried phyllanthus emblica fruit and drink. This will 
remove excessive thirst, giddiness and vomiting sensation.. 
3.  Boil leaves of phyllanthus emblica in water.Gargle with water.  Mouth ulcers 
will be cured. 
4. Mix15ml each of the juice of phyllanthus emblica, lemon, honey and drink 
only in the morning.  This will cure Diabetes mellitus. 
5. Grind the tender leaves of phyllanthus emblica and mix with buttermilk and 
drink this can cure dysentery. 
6.  Make decoction out of dried phyllanthus emblica. To this add milk and sugar 
and drink. This will cure internal heat vomiting and also pustles in the penis. 
7. Take 20 gram each of dried phyllanthus emblica and green gram and add one 
litre of water boil till the volume is reduced to 200 ml.  1 100 ml in the 
morning and remaining in the evening.  This will cure blood pressure 
associated with giddiness. 
8. Take half litre is of the juice of phyllanthus emblica, Altementhera sessions 
(ponnaangkanni), Aloe Vera, Amaranthus polygamus(chirukeerai) and milk.  
Take 2litres of coconut water and 1.5 litres of gingelly oil and mix them well. 
To this add 15 grams each of the following: licorice, cardamom, costus 
spiceosus, curcuma zedoraia, curcuma aromatica, nutmeg, maze, dried ginger, 
pepper, long pepper, terminalia chebula and bellerica.  Boil to consistency.  
 PRE CLINICAL  STUDY OF  KARPOORA  SINTHAMANI  MATHIRAI 
 
   27 
Use this oil for taking oil bath twice a week. This will cure jaundice Eye 
diseases, night blindness, dandruff, falling of hair etc. 
- Medicinal plants of India- Volume II. 
 
9. The fruit is useful in burning sensation, vomiting,  urinary discharges, thirst, 
leprosy, constipation, inflammations, crisscross,piles, anaemia, stangury, very, 
anuria, poisoning ophthalmia incident blindness. 
10. The seed is useful in biliousness asthma, bronchitis, leucorrhoea, vomiting 
                                                   - Indian medicinal plants volume 3 
11. Acute bacillary dysentery may be arrested by drinking a sharbat of Amla with 
lemon juice. 
12. Triphala consisting of equal parts of powdered emblic myrobalan, belleric 
myrobalan used as laxative and in headache, biliousness, dyspepsia, 
constipation, piles, and large liver and acscites. 
13. The oxidation from insistence on the fruit is used as external application for 
inflammation of eye. 
14. Dried fruit is a detergent and is used as shampoo for the hair. 
15.  A Fixed oil extracted from the fruits is reported to have the property of 
promoting hair growth. 
       - The wealth of India  
volume 3 
16. If Nellikai is taken internally gives younger appearance. 
17. Nellikai thuvaiyal can cure anorexia, vomiting. 
18. Decoction of Nellikai cures fainting, thirst, nausea. 
19. Taste of tender leaves mixed with buttermilk and is given for dysentery. 
Decoction of Nellivatral mixture with sugar and milk can be given internally 
for excessive 130  heat, wounds in male genitalia and vomiting. 
 
-Gunapadam mooligaivaguppu 
P. No. 392 
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Medicinal Preparations of Nellimulli: 
1.Aya chendooram: 
   Dosage :10gm-50gm 
    Indication  :Madhumegam 
    Reference  :kannusamiyam ennum vaithiya Rogam. Pg.No: 50 
 
2.Maruthampattai Kasayam: 
    Dosage :30ml -60ml 
   Indication  :madhumegam 
    Reference  :sarabendra vaithiya rathina vali. Pg.No: 22 
 
3.Nelliyathi kasayam: 
     Dosage :30 ml 
     Adjuvent :Honey 
     Indication  :diabetes Mellitus, urinary infections Pg.No: 127 
 
4.Avaraivithai chooranam: 
    Dosage :5gm - 10gm 
    Adjuvent :Buffalo curd 
     Indication  :diabetes mellitus 
     Reference  :sarabendra vaithiya rathna vali. Pg.No: 185 
 
5.Thirikadugu orundai: 
     Dosage : 6.022gm  
      Adjuvent :.Honey,daily two times a day 
     Indication  : diabetes mellitus 
      Reference  : sarabendra vaithiya rathna vali. Pg.No: 96 
 
6.oorkuruvi ilagam: 
     Dosage :4.16gm  
     Indication  : peramegam, general weakness, spermaturia, Pitham, burning  
               micturation, cough,tuberculosis,diabetes Mellitus.  
     Reference  :Anubooga vaithiya navaneetham. Part 2. Pg.No: 75 
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7.Abraga chendooram: 
     Dosage : 260 – 340 mg 
      Adjuvent :Honey,ghee,butter 
     Indication  :21 types of megan, 21 types of madhumegam, all types of  
 vatha, pitha disease.  
      Reference  :Anubooga vaithiya navaneetham. Part 2. Pg.No: 106 
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3.3.2. BOTANICAL ASPECT 
Botanical name : Phyllanthus emblica 
Classification: 
     Kingdom  : Plantae 
     Division  : Angiospermae 
     Class  :  Dicotyledonae 
     Order  : Geraniales 
     Family  : Euphorbiaceae 
     Genus  : Phyllanthus 
     Species  : Emblica 
 
Morphology: 
Habit:  
It is a small to medium sized deciduous tree, reaching 8 to 18 m in height with 
the crooked trunk and spreading branches.  Its bark is usually light brown to black 
coming of in thin strips of flakes, exposing the fresh surface of a different colour 
underneath the older bark.  The average girth of the main stem is 70 in most cases the 
main trunk is divided into 2 - 7 scaffolds very rear to the base. 
 
Leaves:  
Leaves simple, subsessile closely set along the branchlets, distichous, light 
green having the appearance of pinnate leaves. The leaves develop after the fruit set. 
 
Flowers:   
Flowers unisexual, pale green, 4 to 5 millimetre in length, born in leaf-axils in 
clusters of 6 - 10. 
 
Staminate Flowers: 
Tubular at the base having a very small stalk, gamosepalous, having six lobes 
at the  top.  stamens 1 - 3 polyandrous filaments 2 mm long. 
 
Distillate Flowers:  
Disc Cup shaped edge toothed having a gamopetalous Corolla arid to 
branched style, ovary 3 celled. 
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Fruit:  
Fleshy globose, ½ - 3/4 inx diameter with 6 vertical furrows, pale yellow, 
sometimes it is 3 celled and 6 seeded. 
                                                                                         - 1. Indian trees 
pg. no. 570 
                                                                                             -  2. Indian Medicinal plants vol. 4 
pg. no. 256 
Macroscopic description of dried fruit: 
     It consists of curled pieces of pericarp of dried fruit occurring either as 
separated single segment 1_2 centimetre long or united segments.  Grey to black 
pieces showing a broad highly shrivelled and wrinkled external convex surface to 
somewhat concave, transversely wrinkled lateral surface.  External surface shows a 
few white specks occasionally some pieces show a portion of stony testa.  Texture is 
rough, cartilaginous and tough. 
Microscopic description of dried fruit: 
       Transverse section of fruit shows epicarp consisting of a single layer 
epidermis cells appearing tubular and polygonal in surfaceview, cutide present; 
mesocarp cells tangentially elongated,parenchymatous  and crushed, differentiate 
roughly into a peripheral  8_9 layers of tangentially elongated smaller cells, rest 
consisting of mostly isodiametric larger cells. 
Phytochemistry: 
Fruit: 
Rich source of vitamin C, phyllembin from fruit pulp is identified as ethyl 
gallate. Fruit also contains curcurminoides.  the edible fruit tissue contains protein 
concentration three fold and ascorbic acid concentration 160 fold compared to that of 
the Apple.  The fruit also contains considerably higher concentration of most minerals 
and amino acids than Apple.  Fruit juice contains nearly 20 times as much as Vitamin 
C as orange juice and a single fruit is equal in antiscorbutic value of one or two 
oranges. 
Glutamic acid  -29.6% 
Propline  -14.6% 
Aspartic acid  -8.1% 
Alanine  -5.4% 
Lysine   -5.3% 
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     The dried pulpy portion of the fruit contains. 
Gallic acid  -1.32% 
Tannin   -36.1% 
Sugar   -36.1% 
Gum   -13.75% 
Albumin  -13.08% 
Crude cellulose -17.08% 
Mineral matter -4.5% 
Moisture  -3.83% 
The fresh fruit pulp contains 
Moisture  -81.2% 
Protein   -0.5% 
Fat   -0.1% 
Mineral matter -0.7% 
Fibre   -3.4% 
Carbohydrates  -14.1% 
Ca   -0.05% 
P   -0.02% 
Fe   -1.2mg/100g 
Micotinic acid  -0.2mg/100g 
Vitamin C  -600mg/100g 
Superoxide dismutase -482.14 units/g 
      Apart from L-Ascorbic acid, emblica fruits also contain ‘ascorbigen’, an 
indole containing descriptive od L-ascorbic acid (Vitamin C).  Ascorbigen and its 
derivative N- Methyl ascorbigen representa new class immunomodulators. 
Fruit ash: 
Chromium  - 2.5 ppm 
Zinc   - 4 ppm 
Copper  - 3 ppm 
Fruits and leaves - Tannins, polyphenolic compounds 
-  Trigauopyl glucose,  Terchebin, Corilagin, 
Ellagic, Phyllenbic                                
   acids.  Alkaloids - Phyllantidine and phyllantine. 
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Leaves and stem -  Lupeol and Beta sistosterol. 
Seeds   -  Linnoleic acid and it closely resembles 
linseed oil. 
Roots   -  Ellagic acid and Lupeol. 
 
Chemical constituents: 
       These fruits are reputed to contain high amount of ascorbic acid (Vitamin C) 
and have bitter taste that may derive from a high density of ellagitannins, such as 
emblicanin A(37%), emblicanin B(33%), punigluconim (12%) and pedunculagin 
(14%). Amla also contains punicafolin and phyllanemblinin A phyllanemblin other 
polyphonic, such as flavonoids KaempFerol, ellegic acid, Gallic acid. 
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3.3.3. LATERAL RESEARCH 
Antidiabetic and antioxidant potential of Emblica officinalis Gaertn. Leaves 
extract in streptozotocin induces type -2 diabetes mellitus (T2DM) rats. 
Abstract: 
      In traditional Indian Medicine all parts of Emblica officinalis Gaertn.  Plant 
including the fruit seed leaves fruit bark and flowers are used in various herbal 
preparation for the treatment of diabetes mellitus. 
Aim: 
     To evaluate the effects of  hypoglycemic effects of the hydro methanolic(20:80) 
extract of leaves  of emblica officinalis in streptozotoxin induced diabetic rats. 
Author information: 
 Nain P,et.al. J. Ethnopharmacol. 2012. 
Authors 
 Nain P1, Saini V, Sharma S, Nain J 
M.M. College Of Pharmacy, M.M. University, Mullana – Ambala,  
Hariyana – 133207, India, parminder –nain 26@gmail.com 
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3.4. Terminalia Bellarica (Thandrikkai) 
3.4.1. GUNAPADAM ASPECT 
Synonyms: 
             Aksham, Akhandam, Amudham, Ambhalathi, Aaraamam, Erikatpalam, 
Kandhakatpalam, kandhukan, sakadham, Thabamari, vandhiyam, vithiyam, 
Bhoodhavasagam, Thanikai, Thrilingam, vipeethagam. 
Vernacular names :  
 
English  :Belleric myrobalan, Beddanut tree.  
Hindi  :Bhaira,Bahera. 
Kannada  :vibhita,Taremera,Tharo,Taarekaayi Mara, Thani, vibhitaka.  
Malayalam :Thani, Thannikka, Adamarutha, Thanni.  
Marathi  :kalidruma,vehala,Behada,Thannymathan,Thaanni. 
Sanskrit  :Bibhitakah, Bahuvirya, vibhitakah, kasaghnah, karshah.  
Telugu  :Bhutavasama,vibhitakamu,Tandrachettu. 
Urdu  :Behera. 
Gujarathi :Bhaira,Bahera. 
Organoleptic characters: 
Taste                          : Astringent  
Potency    : Hot 
Biological transformation  :Sweet  
Action : 
        Astringent  
       Expectorant  
        Laxative  
        Tonic.   
General Characters: 
  “rpye;jptplk; fhkpag;Gz; rPohd Nkfq; 
  fye;JtUk; thjgpj;jq; fhNyh- lyh;e;Jlypy; 
  Cd;wpf;fha; ntg;g Kjpugpj; Jq;fuf;Fe; 
  jhd;wpf;fha; ifapnyLj;jhy; 
 
  Mzpg;nghd; Nkdpf; foFk; xspAkpFk; 
  Nfhzpf;fnfhs; thjgpj;jf; nfhs;ifNghk; jhdpf;fha; 
  nfhz;lth;f;F NkfkWk; $wh mdw;wzpAk; 
  fz;lth;f;F thjk; Nghk; fhz;.” 
- G{h<himl<!&zqjg!uGh<H 
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 It cures poison of spider bite, wounds in the penis, leucorhea, hypertension, 
disease due to excessive vatham and Pitham. It gives brightness and beauty to body as 
well as it can neutralise Tridosas.  
 
 Usages: 
Traditional uses: 
1. For tooth ache the outer covering of Thandrikai and make it as a fine powder and 
mix it with same amount of sugar can be given 4 grams per day with lukewarm 
water. 
2.  Powder of Thandrikai mixed with honey can be administered for chickenpox. 
3. Decoction should be prepared from 170 ml of water with 17.5 grams of skin of 
Thandrikai then decoction mixed with 20 gram of honey given for bronchial 
asthma. 
4. Powder of Thandrikai mixed with equal amount of white sugar and honey is given 
for gram daily for the improvement of vision. 
5. Seed of Thandrikai is rubbed and the paste is applied over the wounds. 
6. Powder of Thandrikai, mixed with equal amount of rock salt and powder of long 
pepper then the above mixture is grinded with buttermilk and given for hoarseness 
of voice. 
7. Decoction of kadukkai, nellikai, Thandrikai is used for wound washing. 
- Gunapadam mooligai vaguppu. 
Medicinal Preparations of Thandrikai:  
1.Thetrankottai leghyim: 
Dosage  : 2-5 gm 2 times per day 
Adjuvent  : Naga parpam(65 mg)   
Indication  : madhumegam.  
Reference  : Anubooga vaithiya navanitham part 2 
 
2.Maha vinthathi kuligai: 
  Dosage  :1 -2 kuligai 
  Indication   : madhumegam, piramegam, Thanthumegam, 9 types of  
 Moolam, 6 types of powthiram.  
  Reference   :Anubooga vaithiya navanitham part 2. 
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3. Visuvasi chooranam: 
  Dosage  :2 gms twice a day, after food 
  Indication   :madhumegam 
  Reference   :yugi muni vaithiya Kaviyam p. No-263. 
 
4. Sooriya mantha kudineer:  
  Preparation   :Aavaripattai, Thetanvithai, kadalalinjil patti, kadukkai,  
seeragam are powdered and add 8 part of water to the 
powder and boil to make 1 part of decoction.  
Dosage  :100 ml two times  a day before food.  
Indication   :madhumegam 
Reference  :yugimuni vaithiya kaaviyam p. No-664. 
 
5.Aya cheendoram:   
  Dosage  :200 -400 mg. 
  Adjuvent  :Ghee,honey 
  Indication    :madhumegam, Anaemia, body heat.  
  Reference   :pathartha guna vilakam, Thathu-jeeva Vargam.  
6. Santhanathy ennai: 
  Dosage  :Externally used 
  Indication  :neerelivu,kallaidupu,Tuberculosis,Asthma,urinary tract  
 infection. 
Reference   :Agasthiyar 2000 P. No-13. 
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3.4.2. BOTANICAL ASPECT 
Botanical Name : Terminalia Bellarica 
Classification: 
Kingdom : Plantae 
Subkingdom : Tracheobioneta 
Division : Magnoliophyta 
Class  : Mangnoliopsida 
Subclass : Rosidae 
Order  : Myrtales 
Family  : Combretaceae 
Genus  : Terminalia 
Species : Bellarica 
Morphology: 
  A large tree, grows upto 20-25 meters high, rust coloured pubescence on 
young branchlets. 
Leaves:   
Simple, opposite alternate clustered at the tip of the branchlets, estipulate, 
petiole 15-80 mm, stout slightly grooned above, glabrous, lamina 9-35 *  5-16 cm.  
Absolute, elliptic or obovate-elliptic; base obliquely cuneate, attenuate or acute; apex 
intensely accuminate, margin entire, both surface pubescent when young, glabrous at 
maturity, coriaceous, eglandular, lateral nerves 7-10 pairs, innate, prominent, 
intercostae reticulate. 
Flowers:   
Bisexual, greenish yellow , 5-6 mm across axillary spikes, peduncle 
puberoulous, bracteoles 0.5-2mm long, linear_lanceolate, caducous, calyx tube 2-
2.5*1-3.2 mm, rusty pubescent, constricted above the ovary, lobes 5, cream, 
triangular, tomentose, disc 5 lobed, petals absent, ovary 1.5mm  inferior, tomentatse, 
1-celled, couples 2-3, pendulous, style 4mm, subtulate, stigma small. 
Fruit:  
A drupe 2-2.5*1.8 cm, obovoid, obscurely 5-ridged, yellowish-Brown, hoved, 
not winged, softly tomentose. 
Seed: 
      One, ellipsoid. 
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Growing season and type: 
1. Pale yellow with an offensive order in axillary spikes. 
2. They Blossom in the month of May. 
3. Fruits ovoid grey. Fruits are 1.5 to 2.5 cm in diameter. 
4. The kernels are sweet, but narcotic.  
                     -www.jnkuv_aromedicinal plants.in 
Phytochemistry: 
Fruits :  chebulagic acid, ellagic acid and its ethyl ester, fructose, galactose,     
   glucose and its galloyl derivative, mannitol and rhamnose and beta      
   sitosterol.  
Bark  :  Chebulagic acid and ellagic acid  
Seed coat :  Gallic acid. 
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3.4.3. LATERAL RESEARCH 
Antidiabetic and antioxidant activity of terminalia bellerica: Roxb 
Abstract: 
     Effect of continuous administration of dried 75 % methanolic extract of fruits of 
terminalia bellerica(combretacease) suspended in water was studied in alloxan 
induced hyperglycemia and antioxidant defence mechanism in rats.  Terminalia 
bellerica prevented alloxan induced hyperglycemia significantly from 6thof 
Administration and near was 54 %reduction on 12th day.  Oxidative stress produced 
by alloxan was found to be significantly lowered by the administration of terminalia 
bellerica extract.  This was evident from a significant decrease in thiobarbituric acid 
reactive substances. 
Conjugated dienes and hydroperoxide in blood and liver respectively, 
similarly, decreased glutathione level produced by alloxan was increased by the 
administration of the extract in blood and liver.  However the increase was not 
significant.  Superoxide dismutase which was decreased by alloxan were significantly 
increased from 9th day in blood and liver of drug treated group.  Similarly there was 
significant increase in the activity of catalase in blood and liver.  Decrease in 
glutathione peroxidase biolox and administration was found to be increased 
significantly in the blood and liver from the 9th day by extract treatment.  Glutathione 
reductase was also found to be increased in blood and liver.  These results suggest that 
terminalia bellerica fruit extract pocessed Anti Diabetic and antioxidant activity and 
these activities may be interrelated. 
  Antidiabetic and antioxidant activity of terminalia bellerica: Roxb 
   Sabu MC,et.al.Indian exp Biol.2009 
Author information: 
  1. Amala cancer research centre, Amala Nagar,  Thirussir, Indina, 680 553. 
Citation: 
           Indian JExp Biol.2009 Apr; 47(4) 270_5. 
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3.5. DISEASE REVIEW 
3.5.1. Madhu Megam - Siddha Aspect 
Synonyms: 
  Madhu premegam  
Inippu Neer  
Neerizhivu 
  Meha neer  
Definition: 
            Madhumegam is a clinical condition characterized by frequent urination 
resulting in deterioration and diminution of  seven thathus and loss of weight, 
enormous ants and flies on the place where urine is expelled and on heating it gives 
the smell of sugar. 
           Abdomen distends like sea, slurring of speech, peripheral neuritis, lassitude, 
dyspnoea are the symptoms of madhumegam.  
 
Etiology: 
1.Dietary causes:  
 “Ogijkbv<!gzuq!OhijkogiPk<klQ!eqjxs<sqOhijk!
!hiKuib<!ofb<Bl<!hiZl<!hiqUmE{<hQ!vigqz<!
!Osikhi{<!MVu!lqg<g!Sg<gqz!hqvOlgf<kie<!
!!!!YKfQ!iqpqUOsv!U{<ome!nxqf<K!ogit<Ot               
 - Agasthiyar – 1200 
  Excessive intake of fatty fish, meat, alcoholic, toddy , etc., causes diabetes  
Milk, ghee, sweet foods, uncooked food, chilled rice when taken in large quantity 
leads to this disease. 
 
2. Sexual indulgence: 
1/!!! ^<kqiq!Ohigl<!osb<kkqeiz<!OuU!ogi{<M!
sqvS!lm<Ml<!ouf<KMgqg<!geOz!lQxqg<!
GxqBmOe!Olgf<kie<!ogiMjl!osb<K!
Gjxf<K!uVl<!kiKouz<zil<!Ge<xqh<!OhiGl <!!!<<< !
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!- Guru Nadi!
ge<eq!lbg<gk<kiz<!g{<cM!OlgOl!fic!F~z<!
!………………!!!!!……………!lr<jg!Ogim               
 - Yugi Vaithiya Chindhamani 
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“fqjx!H,k<K!ogir<jgbie<!fibge!<Oligk<kiz<!!!!
ljx!Ohix<Xl<!gVh<hk<kqz<!utik<K!OlgOl”!!
“gqvf<kq!H{<{qve!Olgg<!gQsgoeEf<!Ke<lii<g<ge<!!
nVf<kkq!we<El<!hiR<sizq!be<jejbg<!g{<[x<xiOe”!
                                                                                      -Thaeran arundhu Bharadham 
Excessive sexual indulgence may leads to diabetes.   
Humoral changes: 
!“hgi<hqk<k!uqf<jkbziK!Olgl<!uviK”!!
 Unless pitham rises no one is affected by megam. 
“-eqg<gqe<x!uikk<kqjm!Osiqz<!Jbf<kie<!
leqg<gqe<x!gt<Th<!hkeqOhiz<!fQOviMl<!!!
geqg<gqe<x!Oleq!gjvf<K!ouTh<OhiKl<!!
keqg<Gl<!lKOlgf<!kh<hiOk!jhbOl”              
- Thirumoolar Vaithiyam – 600 
  If vatham is accompanied by kapham urine excreted resembles kallu or 
padhini. Body gets emaciated and becomes pale and Madhu megam will develop 
without fail. 
Karma noi: 
“Nlh<hi!leqki<!osb<k!gil<k<kiOz!!
nvgvi!Olg!ole<x!visiuiOz!!
gilh<hi!zkqeiz<!hsqBh<h!fiZr<!!! !
jgg<gmr<gz!Ofib<gt<!uVl<!gil<k<kiOz”!!!!!!!!!!!!!!      
  -Agasthiyar 
  Deeds of a man are responsible for the development of Megam, which 
presents with increased hunger and by the disease gets out of control. 
 
 Psychosomatic Factor: 
 “lkr<ogi{<M!ohiqObijv!jujgbiZl<!!
liki<!gx<Hfqjzjl!ke<je!npqg<jgbiZl<!!
hkr<ogi{<m!squObigq!sihk<kiZl<!
hk<Kujg!sqOzx<her<gt<!OlgfQvil<”                                                    
   -Yugi Muni  
  Getting mad and scolding elderly people, abusing female, curse of a devotee 
of Lord Shiva causes 10 types of selaerpana mega neer. 
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Signs andSymptoms:      
  “lqg<gie!sml<!ouTk<K!Oleq!g{<[l << <<”!!!!!!!!!!                  
 -Yugi Muni   
Body becomes pale and emaciated.               
“GxqBmOe!Olgf<kie<!ogiMjl!osb<K!!
Gjxf<K!uVl<!kiK!ouz<zil<!Ge<xq!OhiGl << <<”                   
- Guru Nadi 
  The body humors decreases, hence it gets emaciated 
 
CLASSIFICATION OF DISEASE:  
Yugi vaithiya chindamani-20 types  
Vadham-4  
     Achiyakandhi megam 
    Sutha megam 
   Vatha pramiya megam 
   Mamisa siravi megam 
Pittham-6  
   Appiya megam  
  Pitha pramiya megam 
  Savirana megam  
 Madhu megam  
 Chandira megam  
 Arakka megam  
 
Kapha megam: 10 
 Vasa megam 
 Uthama megam 
 Maghai megam 
 Adhikka megam 
 Sura megam 
 Sukkila megam 
 Udhaya megam 
 Presa megam 
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 Sara megam  
Thaithiya megam 
Madhu Mega Avathaigal (Complications of Diabetes): 
!gi{Ou!Lkzuk<jk!siqvf<!fiEl<!g{ligh<!hvk<kqx<G!fQi<k<K!uivl<!
!Ou{Ou!ou{<mig<gq!bgzl<!h{<[l<!lqg<guqv{<!hiluk<jk!uqtl<hg<!Ogtib<!!!
!&{Ou!Lk<vhk<!jmBlis<!Sg<z!LglPgq!Ok\Skie<!lqgOu!Ge<El<!!
!fi{Ou!&e<xiG!luk<jkg<!Gf<kie<!kiuiTl<!uiUuK!lQXf<!kiOe!!
!“kieie!fizuk<jk!br<g!kigl<!se<eqbK!hikL{<mijlf<k!uk<jk!!
!Okeie!fQi<ohVGf<!kiK!fm<ml<!fqjzbixi!lUk<jkBmx<!gqjmogit<tiK!!
!&eie!&i<s<js!uVOlt!uk<jk!lqg<guOvi!sqge<R<Susf<!Okgsim<bl<!
!Reie!wm<miu!kuk<jk!kiOe!wPgqvf<kq!hqtjuBf<kie<!lqgU{<miOl/!
!d{<miG!olie<hki!luk<jk!Ogtib;!yPg<gie!Nsivr<!gqVlq!B{<mil<!
!l{<mie!hk<kif<ki!euk<jk!Ogtib<!hivlil<!%cbr<g{<M!hvk<Kg<!OgMl<!
!ou{<miG!Olgf<ki!eqVh!Kg<Gl<!uqtr<gqbOkii<!ks!nuk<jk!uqhvR<!osie<Oeil<”!!!
                                                                                         -Yugi Vaithiya Chindhamani  
1st Avathai - Body becomes obese and urethra gets dilated. 
2nd Avathai - Increased urination and quality of sperm is affected.  
3rd Avathai - Dryness of tongue, fullness of stomach. 
4th Avathai - Increased thirst and delirium develops. 
5th Avathai - Increased micturition and destruction of sperm. 
6th Avathai - Difficulty in lying down and dyspnoea  
7th Avathai - Tumors develop in the body.  
8th Avathai - Nausea, loss of appetite, hyper apnea and lethargy 
9th Avathai - Microorganisms develop in the body and it becomes thin 
10th Avathai -  TB develops.  
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3.1 MODERN ASPECT 
Diabetes Mellitus (Madhu Megam) 
Definition: 
Diabetes mellitus is a chronic metabolic disorder characterized by 
hyperglycemia with or without glycosuria, resulting from an absolute or relative 
deficiency of insulin. This is brought about by an impairment of insulin production or 
its release by the beta cells of the islets of Langerhans. [Diabetes (Greek)-to pass 
through, Mellitus (Latin)-honeyed or sweet.] 
Types: 
1. Primary Diabetes:  
     Type 1 (IDDM) 
     Type II (NIDDM)  
2.  Secondary Diabetes: 
Etiology:  
 Pancreatic Diseases (pancreatitis, cystic fibrosis, neoplastic diseases, 
pancreatomy, haemochromatosis, fibrocalculus pancreatopathy) 
Viral Infections (Congenital rubella, Mumps, Coxsackie-B virus) 
 Drug Induced(Corticosteroids, Phenytoin, Thiazide diuretics) 
Associated with genetic syndrome (Down’s syndrome, Turne’s syndrome, 
Wolfram’s syndrome). 
Production of hormonal antagonists to insulin (Growth hormone-acromegaly, 
Glucogon-glucogonoma,  
Glucocorticoids-cushing’s syndrome, Thyroid hormone-thyrotoxicosis, 
Catecholamines- phaeochromocytoma) 
3.Gestational Diabetes:  
About 4% pregnant women develop DM due to metabolic changes during pregnancy. 
Although they revert back to normal glycemia after delivery, these women are prone to 
develop DM later in their life. 
Normal Insulin Metabolism: 
The major stimulus for both synthesis and release of insulin is glucose.  The steps 
involved in bio synthesis, release and actions of insulin are as follows  
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Synthesis: 
Insulin is synthesized in β cells of pancreatic islets of Langerhans 
It is initially formed as pre pro insulin. 
Subsequent proteolysis removes the amino terminal signal peptide, forming pro 
insulin. 
Further cleavage of proinsulin give rise to A (21 amino acids) and B (30 amino acids) 
Chains of insulin, linked together by connecting segment called C peptide. 
Release:  
 Glucose is the key regulator of insulin secretion from β cells by a series of steps: 
Hypoglycemia (glucose level below 70 mg/dl) stimulates transport into β cells of a 
glucose transporter, GLUT2. 
An islet transcription factor, glucokinase causes glucose phosphorylation. 
Metabolism of glucose to glucose 6- phosphate by glycolysis generates ATP. 
Generation of ATP alters the ion channel activity on the membrane which stimulates 
insulin release.   
Action:   
Half of insulin is secreted from βcells into portal vein is degraded in the liver while 
the remaining half enters the systemic circulation for action on the target cells. 
                                                                        -Harsh mohan text book of pathology 
Prevalence: 
 Type 1                                    -      5-10% 
 Type 2                                     -     90-95%  
Gestational diabetes                  -     2-5%  
Other specific types               -     2%            
On digestion, carbohydrates are converted into glucose and absorbed into the 
blood. When intestinal glucose absorption declines between meals; hepatic glucose 
output is increased. The glucose in the blood is essential for all the cells as it acts like 
a fuel. The glucose uptake occurs by two different mechanisms.   
Insulin dependent-most of the organs require insulin for glucose uptake  
Insulin independent- some tissue like nerve, lens, kidney, blood vessels, beta 
cells of pancreas. 
As stated above β-cells of pancreas do not require insulin for glucose uptake. 
Hence when blood sugar rises, it enters the β-cells of pancreas and stimulates the 
release of a substance called pre-pro insulin by the process of translation of messages 
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present in m-RNA which occurs in rough-endoplasmic reticulum. It is proteolytically 
cleaved in the golgi apparatus, to form insulin and C-Peptides. Both of them are 
stored in secretory granules. Again insulin acts as a trigger for insulin release. 
 Type 1 Diabetes (IDDM) 
 This form of diabetes results from a severe, absolute lack of insulin caused by 
reduction in the beta –cells mass. IDDM usually develops in childhood, becoming 
severe at puberty. Hence it was previously known as Juvenile- onset diabetes mellitus. 
The patient depends on insulin for survival. Without insulin, they develop acute 
metabolic complications, such as ketoacidosis and coma. Hence it is usually called 
ketosis –prone diabetes. 
Pathogenesis: 
 Three interlocking mechanisms are responsible for islet cell destruction.  
1.Genetic Susceptibility: 
 Genetic factors account for one-third of the susceptibility to type I diabetes. 
The short arm of chromosome 6 contain a human leucocyte antigen (HLA) region.The 
HLA class 2 genes code for proteins on surface of cells, which present normal β-cell 
antigens to T lymphocytes. Defective presentation of these auto antigens underlies 
susceptibility to autoimmune disease. 
2.Autoimmunity: 
  Approximately 10% of persons who have type 1 DM also have other organ-
specific autoimmune disorders, such as Grave’s disease, Addison’s disease, 
Thyroiditis and Pernecious anaemia. In these patients, there appears to be a broad of 
immune regulation. 
Environmental Factors:  
Reduced exposure to microorganisms in early childhood, limits maturation of 
immune system and increased susceptibility to autoimmune diseases. Viruses cause 
mild β cell injury, which is followed by autoimmune reaction against altered β cells in 
persons with HLA susceptibility. Cow’s milk contain Bovine Serum Albumin (BSA), 
which when fed to children cross the neonatal  gut and raise antibodies , which not 
only destroys BSA but also β cells, because of close homology or resemblance 
between the two (i.e) destruction by the process of molecular mimicry. Nitrosamines 
found in smoked meat and coffee has been proposed as potential diabetogenic toxin. 
Stress may precipitate type 1, by stimulating secretion of counter-regulatory 
hormones and also modulating immune activity. 
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Type 2 Diabetes:  
It was previously called as adult-onset diabetes. Initially insulin resistance 
appears and leads to elevated insulin secretion in order to maintain normal blood 
glucose level. However, in susceptible individuals the pancreatic β cells are unable to 
sustain the increased demand for insulin and a slowly progressive insulin deficiency 
develops. 
Pathogenesis: 
   The underlying causes are largely unidentified genetic factor and the effects of 
a western lifestyle such as obesity and overeating. 
1.Insulin Resistance: 
   The primary cause of insulin resistance remains unclear but presence of 
obesity is a powerful amplifier of insulin resistance. Decrease in number of insulin 
receptors, postreceptor defect, reduced synthesis or translocation of GLUT-4 in 
muscles and fat such as Free Fatty Acids (FFA’s), found in large quantities in obese, 
competes with glucose as a fuel supply for oxidation in the periphery. Certain 
hormones from visceral adipose tissue drain into the portal vein and affects insulin 
sensitivity in liver. Inactivity is associated with down regulation of insulin-sensitive 
kinases and also increased accumulation of FFA’s within skeletal muscles. Sedentary 
people are therefore more insulin –resistant.  
2. Pancreatic β cell Failure: 
 Amylin, a polypeptide is secreted together with insulin. So that, in presence of 
insulin resistance, excessive demand for insulin secretion also results in formation of 
excess amylin which forms insoluble fibrils of amyloid and ultimately destroy β cells. 
Reduction of GLUT-2 transporters, which facilitate glucose entry into β cells, is 
caused by chronic hyperglycemia, referred to as glucose toxicity. 
3.Genetic predisposition: 
 Genetic factors are important in the etiology of type2 diabetes. Unlike type 1, 
however, the disease is not linked to any HLA haplotype and there is no evidence that 
autoimmune mechanisms are involved. Regions that contain susceptible loci on 
chromosome 1q,12q and 20q have been identified. But the underlying gene have not 
been identified. In MODY, there is autosomal dominant inheritance of a single gene 
linked to chromosome 7 and 20 
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4.Environmental Factors: 
Overeating, especially when combined with obesity and under activity causes 
type2 DM. Sweet foods rich in refined carbohydrate ,consumed frequently may 
increase the demand for insulin secretion, while high-fat food may increase FFA’s 
and exacerbate insulin resistance.  
Gestational Diabetes:  
Glucose metabolism changes during normal pregnancy, reflecting altered 
glucose handling by the mother and nutritional demands of developing fetus. In 
normal women, marked insulin resistance develops, particularly by the second half of 
the placental hormone activity. Fasting glucose decreases slightly while blood glucose 
may be increased post-prandially.  
Gestational diabetes is defined as diabetes with first onset or recognition 
during pregnancy. While this includes women with preexisting type 1 and type 
2diabetes. The majority can expect to be restored to normal glucose tolerance 
immediately after pregnancy. Repeated pregnancy may increase the likely hood of 
developing irreversible diabetes, particularly in obese women. 80% of women with 
gestational diabetes ultimately develop permanent diabetes.  
Main Clinical Features:   
1. Polyuria  
2. Polydipsia  
3. Polyphagia  
4. Fatigue  
Other Clinical Features:   
1. Unexplained weight loss:  
Though they eat more, they are unable to process many of the calories in the food. 
Factors contribute to weight loss:  
                Losing sugar and water in urine and accompanying dehydration 
                Lipolysis which deplete fat stores. 
2.Poor wound healing:  
             Impaired WBC function (due to increased glucose levels)  
Decreased peripheral blood flow. 
Glucose laden tissue which offers a media to grow. 
3. Very dry skin due to dehydration.  
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4. Sudden vision changes.  
5. Tingling or numbness in hands or feet.  
6. Recurrent infections due to decreased immunity.  
7. Nausea, vomiting and stomach pain may develop abrupt onset of type I  diabetes.  
8. Altered mental status   
Other Agitation, unexplained irritability, lethargy and confusion may develop due to 
that the brain cells cannot oxidize free fatty acids and is easily affected by increased 
blood sugar, hyper osmolarity and hypoglycemia 
- K.V.Krishna Das text book of medicine  
Table No: 3 Diagnostic criteria of pre diabetes 
 
Table No: 4 Clinical Features of Type 1 and Type 2 DM 
Clinical features Type 1 Type 2 
Usual age at onset 5-30 years 35-65 years 
Sex M:F 1:1 F>M in India 
Prevalence Among 
diabetes 
15-18% in Caucasians 1% 
in  Indians 
95-98% of Indians 
 
Genetic 
Hereditary+StrongHLA 
association 
Hereditary +No HLA 
association 
Nutrition Lean Often obese 
Usual onset 
Rapid with classic 
symptoms 
Slow, insidious, often with 
only mild symptoms 
Ketosis Prone Not prone 
Islet cell antibodies 
Maybe present within 1yr 
of  onset 
Absent 
Treatment modality 
Almost all require insulin 
for control of sugar 
Majority can be controlled by 
oral hypoglycemic drugs 
Criteria for Diagnosis of Pre Diabetes 
Category 
Fasting plasma 
glucose 
Postprandial 
(2 hours) 
1.Normal 
2.Impaired fasting glucose (IFG) 
3. Impaired glucose 
tolerance(IGT) 
 
<100 mg/dl 
100-125mg/dl 
 
<100 mg/dl 
 
< 140    mg/dl 
< 140mg/dl 
 
140-200mg/dl 
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Complications: 
1.Diabetic Microangiopathy:  
It is most marked in type 1, developing in early life but also occurs in type2. 
Various factors like endothelial damage, increased plasma viscosity, erythrocyte 
aggregation, reduced red cell deformability and increased platelet adhesion lead to 
micro-angiopathy.  It affects several organ systems. The main lesions are seen in the 
retina, kidneys, peripheral nerves and heart giving raise to diabetic retinopathy, 
nephropathy, many forms of diabetic neuropathy and cardiomyopathy.  
2. Atherosclerosis:  
HDL levels are reduced in type 2, possibly enhancing susceptibility to 
atherogenesis. AGE formation also contributed to atherosclerosis. Diabetics have 
increased platelet adhesiveness and most of type2 patients are obese.  
3.  Diabetic Nephropathy:  
It is common complication and and a leading cause of death in DM. 
Diabetic glomerulosclerosis   
Vascular lesions  
Diabetic pyelonephritis and necrotizing renal papillitis  
Tubular lesions or Armanni-Ebstein lesion  
4. Diabetic Neuropathy:  
Disordered glucose metabolism and micro angiopathy affecting nutritional 
maintanence of peripheral nerves are responsible for neuropathies. Glove and 
stocking impairment of all other modalities of sensation developes. Toes may be 
clawed. Callus skin develops at metatarsal heads due to increased pressure.  
5. Diabetic Retinopathies:   
  DM produces a classical retinopathy. A specific change occurs in the vessels 
leading to loss of mural cells (pericytes) and the formation of micro aneurysms. Once 
initiated the fundus changes are usually progressive. The early changes are venous 
dilation and the appearance of small dot like micro aneurysms in the perimacular area. 
Atrial blood is shunted and this leads to ischemia of the retina.   
Large subhyaloid hemorrhages and vitreous hemorrhages may develop and the 
vision is seriously impaired. Such hemorrhages are due to rupture of newly formed 
blood vessels. As these hemorrhages are absorbed, organization by fibrous tissue 
results and multiple bands of retinitis proliferation develop. These lead to permanent 
visual impairment. Retinopathy is usually associated with advanced neuropathy. 
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Some times in DKA with severe hyperlipidemia the fat gives a milky white 
appearance to the retinal arteries called “lipemia retinalis.”   
6. Diabetic foot:   
Foot problems give raise to severe morbidity in diabetic patients. DM accounts 
for up to 50-80% for non-traumatic amputations. The factors contribution to the foot 
problems are:  
Neuropathy - sensory, motor and autonomic. 
Ischaemia  
Trauma – physical, mechanical, thermal, continuous mechanical stress, uneven 
weight bearing. 
Infection  
Ulceration of the foot in a diabetic usually results from the combination of 
neuropathic damage, tissue ischaemia and excessive pressure loading, often with 
supreme post infection.  
7. Complications in Pregnancy and Neonates:   
There may be miscarriages and abortions, toxaemias of pregnancy, 
hydraminosis, etc. Herculian (macrosomia) child may be born of diabetic mother due 
to excess of growth hormone and maternal hyperglycaemia.  
8. Diabetic ketoacidosis:  
The three cardinal biochemical features of DKA – hyperglycaemia, ketosis 
and acidosis results from the combined effects of deficient circulating insulin activity 
and the excessive secretion of counter regulatory hormones. The end results are 
hyperglycemia (>250 mg/dl), ketoacidosis (pH<7.30), and an osmotic diuresis that 
promotes dehydration and electrolyte loss.  
9. Non-ketotic hyperglycemic hyperosmolar coma:  
It is a serious emergency seen occasionally in the elderly diabetes. It is 
commonly precipitated by infections, MI, burns, trauma, surgical stress, renal failure, 
pancreatitis and the use of certain medications.  
10. Lactic acidosis  
Normal level of serum lactate is between 0.4 and 1 mmol/L in the fasting state 
and it may go upto 2mmol/L, after meals 5-18mg/dl this is maintained by the balance 
between production and utilization of lactate. In diabetic lactic acidosis the blood 
lactate level is increased above 5mmol/L  
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The hypoxic state produced by aberration in tissue metabolism probably 
contributes to the lactic acidosis associated with severe diabetes.  
Side effects of insulin therapy:  
Hypoglycemia  
Weight gain 
Peripheral oedema insulin treatment causes salt and water retention in the 
short term 
Insulin antibodies local allergy rare 
Lipodystrophy at injection sites. 
                                                   - davidsons principle and practice of medicine 
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3.6. PHARMACEUTICAL REVIEW 
3.6.1. SIDDHA ASPECT 
PARPAM (CALX)  
Definition: 
Parpam is equivalent to calx, which is prepared by the process of calcination.  
The correct Tamil translation would be “Neeru” which would mean an ash. 
“Saambal” is another word equivalent to an ash or calx. 
Metals, uparasas or paashanas are made into white powder by the process of 
pudam, burning, frying, blowing and by grinding them with juices, ceyaneer etc. 
Equipment required: 
Mortar and pestle. 
Vessels and spoons to handle liquids. 
Long ribbons of tough cloth and fine clay. 
Pairs of shallow earthen discs of identical dimensions. 
Cow dung cakes, sufficient numbers and well dried. 
Fine cloth pieces for filtering juices and decoction. 
Spatulae for handling powders. 
General method of preparation: 
The drugs are ground according to the particular recipe, with other drugs, 
juices or decoctions, and the resultant mass is made into small, thin circular cakes and 
dried .When they are well dried, they are taken for calcination.  
The material ready for calcination, is put into an earthen disc described earlier, 
and covered by inverting another disc and sealing the rim with the cloth ribbon one 
side of which is smeared with wet clay. This makes a capsule type crucible. When the 
seal is dry, the capsule is placed in the kiln for calcination. 
The kiln or “pudam” as it is called in Tamil, is made by digging a pit of 
appropriate dimensions in the soil, and filling it with the recommended number of 
cowdung cakes, which is the fuel. It is better that the interior of the pit is lined with 
bricks, so that the pit could be used repeatedly. 
Seventy five percent of the recommended numbers of dung cakes are arranged 
in the pit and then the capsule is placed in the centre. The rest of the dung cakes are 
arranged above this and the top is somewhat dome shaped. When some burning 
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charcoal pieces are placed on the dome, the dung cakes below them catch fire and the 
fire spreads all around in a uniform manner. 
The kiln will burn for a long time, until all the dung cakes are burnt and 
converted into ashes. When the kiln cools down, the ashes are very carefully removed 
and the capsule is taken out without damaging the seat. The exterior of the capsule is 
thoroughly brushed to remove the ashes and the seal is scraped off and removed. 
The contents of the capsule are recovered, and the remnants that adhere to the 
walls are gathered by great scraping and brushing. 
For the complete transformation of the material into “parpam” state, the process 
of grinding, drying and calcination may have to be repeated several times or atleast as 
many times as directed in the recipe. However, the calcination is repeated until a 
satisfactory product is obtained. But in those instances where the number of 
calcinations is definitely indicated, the process should be repeated accordingly, even 
if a satisfactory “parpam” is obtained within a few calcifications. 
 
Colour: 
In general parpam are always white in colour but Tankaparpam (calx of Gold) 
is light yellow in colour. 
Character and tests for parpam: 
The final product should not have any glitter or shine. 
If a small quantity is pinched and rubbed between the thumb and index finger, 
the particles should be so fine as to enter and reside in the furrows and folds. 
If a pinch of parpam is gently put on the surface of water kept in a container, 
the material should not sink, but it should float.  
If the parpam is put into a crucible and heated, it should not be reverted into 
its metallic state. 
Preservation and storage: 
 Parpam should be stored in a clean dry and air tight glass containers. 
Shelf life: 
 Parpam keep their potency for 100 years. 
Note: 
The colour effect and fineness of the parpam will be enhanced according to 
the degree of grinding and so it should be ground very finely. 
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If the discs are not well dried, the parpam will not attain the specific colour 
specific for the particular parpam. 
When the discs (Dried villai) are arranged in the pans they should not be 
heaped up and should not be arranged in more than one layer. Only then the heat will 
react on the material properly. The pans should not be disproportionately big when 
compared to the quantity of the drugs and they should not be very deep also. 
The kiln is constructed by making circular excavations of suitable dimensions 
in places with optimum aeration and the sides are lined with bricks. Kilns should not 
be constructed in places where strong winds blow. 
Half of the numbers of cow dung cakes are spread at the bottom of the kiln 
and the calcination earthen vessels are placed over this at the centre. The remaining 
cow dung cakes are arranged over this and are to be ignited all around. 
Usually cow dung cakes are used as fuel in kilns. However in some specified 
instances some barks or goat dung and other materials are also recommended. 
 In cow dung cakes there will be an appreciable admixture of sand or 
mud.Depending upon the degree to which there is such admixture the number and 
weight of the cow dung cakes are increased.One can determine this correctly only by 
adequate practical experience.  
Materials like sulphur and yellow orpiment which do not withstand strong 
heating are hidden in specified ashed when being calcined. In such cases the ash is 
spread in the pan, the discs placed over and then covered with more ash, after which 
the other pan is inverted over and scaled along the seam. 
The calcination capsules and the contents there in should be taken only when 
the kiln has cooled down by itself. 
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4. MATERIALS AND METHODS 
4.1 PREPARATION OF THE TRIAL DRUG 
Selection Of Drug: 
 The Drug “komoothira silasathu parpam” has been selected for 
Hypoglycemic, Anti Dyslipidemic and Anti oxidant activitities from the Classical 
Siddha literature“Thanjai vaithiya Raja Sinthamani authored by Rajasree Sathrapathi 
Saraboji maharaj Saheb. Page no: 5. 
Ingredients Of The Drug: 
 1. Komoothira silasathu(Asphaltum)   
 2.Kadukkai(Terminalia chebula) 
3. Thandri thol(Terminalai bellarica) 
4. Nelli mulli(Phyllanthus emblica) 
Collection Of The Drugs: 
The Komoothira silasathu (Asphaltum) was bought from the raw drug shop at 
Ramaswamy chetty traders, Chennai, Tamilnadu. 
The Kadukkai (Terminalia chebula), Thandri thol (Terminalai bellarica), Nelli 
mulli (Phyllanthus emblica)were also bought from Ramaswamy chetty traders, 
Chennai, Tamilnadu. 
Identification And Authentication: 
All raw drugs were identified and authenticated by the experts of Gunapadam 
(pharmacology) and Medicinal botany department in Government Siddha Medical 
College Palayamkottai, Tirunelveli. 
The specimen samples of the identified raw drugs were presented in the 
laboratory of PG Gunapadam for future references.  
PURIFICATION OF RAW DRUGS: 
Komoothira silasathu(Asphaltum): 
First komoothira silasathu was taken, powdered then dissolved in hot water, 
filtered in a white cloth and is kept in a glass bowl.  Then this is exposed to sunlight.  
The outer layer is collected and stored. 
Kadukkai: 
      Remove the seed from Kadukkai and dried. 
Thandri thol: 
Remove the seed from thandrikai and dried. 
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Nelli MullI: 
      Remove the seed from Nellikai and dried. 
Method Of Preparation: 
Process of preparation : 
Dried pericarp of Terminalia chebula, Terminalia bellarica, Emblica officinalis 
each weighing about 42 gm taken in a clean pot and add 1600ml of water. It was 
boiled and reduced upto 200ml and filtered. And then 84 gms of purified komoothira 
silasathu is placed in a stone mortar and triturated with above prepared decoction for 
about 3 hours and made onto small cakes and dried in sunlight. 
    Then dried cakes (villai) were placed with  in a earthern plate and covered 
with another earthen plate and subjected to incineration process by using dried cow 
dung cakes. After incineration process it is allowed to cool. The cakes are taken and 
grind into fine powder. The above incineration process is repeated for 5 times by 
grinding with aove said decoction.Finally the white coloured Komoothira Silasathu 
parpam is obtained and stored in a container  
Shelf Life:  
 100 years. 
Dosage:  
 Panavedai (488mg) , 2times 
Adjuvent: 
Nerinjil mul kasayam 
Indication:  
Madhumegam ,megam 21, muthirakiricharam, Jeeranasuram, Hashmarirogam. 
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Fig No: 1 
INGREDIENTS OF Komoothira Silasathu Parpam 
 
Komoothira Silasathu                                Kadukkai
                
 
Nellimulli                                                   Thandrikkai 
     
 
 
 
PURIFICATION PROCESS 
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Fig No: 2 
FINAL PRODUCT 
Komoothira Silasathu Parpam    
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4.2.STANDARDIZATION OF THE DRUG 
4.2.1 .AS PER SIDDHA CLASSICAL LITERATURE: 
Standardization of drug means confirmation of it’s quality and purity and 
detection of the nature of adulterant of various parameters like morphological, 
microscopic, physical, chemical and biological observations. 
1. Colour:  
The finished form of parpam is generally white in colour. 
2. Odour: 
Wherever a specific odour has been observed it has been mentioned, where a 
characteristic odour is said to be present it is examined by smelling the drug directly 
after opening the container.if such an odour is discernible, the contents are rapidly 
transferred  to an open and re examined after 15 minutes. If odour persists to be 
discernible, the sample complies with the description for odour 
3. Taste: 
The taste of a drug is examined by taking a small quantity of drug by the tip of 
moist glass rod and allowing it on tongue previously moistened with water. This does 
not apply in the case of poisonous drugs.   
4. Finger Print Test: 
Well prepared parpam should be very fine. A pinch of parpam was taken and 
rubbed in between the thumb and index finger. It entered into the depressions and 
furrows of the fingers.It confirmes the fineness of parpam. 
5. Floating on Water:  
A pinch of parpam was sprinkled over the water in a glass container. The 
parpam particles did not sink but floated on the water surface. It indicates the liteness 
of parpam. 
6. Lustre: 
If any glowing particles seen in the parpam , it shows that the drug is not 
prepared properly and possess unchanged substances like metals and other toxic 
substances. So, there should be no glowing particles present in the properly prepared 
parpam. The parpam was taken in a Petri dish and observed for any lustre in daylight 
via magnifying glass. 
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4.2.2. STANDARDIZATION OF TEST DRUG BY USING 
MODERN TECHNIQUES: 
Standardization of drug helps to authenticate and determine its quality and 
efficiency. Thus, the process involves qualitative and quantitative analysis by means 
of physico – chemical properties such solubility test, Ash test, Flame test etc and 
instrumental analysis. 
The physico – chemical analysis of Komoothira silasathu parpam has been 
done in IIT Lab- chennai 
The chemical finger prints are engaged by using modern analytical technique Fourier 
Transform Infra –Red Spectroscopy (FTIR) and Powder X-ray diffraction methods. 
The particle size and qualitative analysis of chemical elements of Komoothira 
silasathu parpam are also assessed by Scanning Electron Microscope (SEM) and 
Inductively Coupled Plasma Optical Emission Spectroscopy (ICP-OES).  
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4.2.2.1. PHYSICO – CHEMICAL ANALYSIS: 
Solubility test:  
A. A little amount of the sample was taken in a dry test tube and shaken well with 
distilled water.   
B. A little amount of the sample was taken in a clean dry test tube and then 
shaken well with con HCl and Con.H2SO4. Sparingly soluble character of the 
sample indicates the presence of Silicate. 
Action on heat: 
  A small amount of the sample was taken in a clean dry test tube and heated 
gently. If strong white fumes evolve indicate the presence of Carbonate. 
Flame test: 
  A small amount of the sample was taken in a clean dry watch glass. It was 
made into paste with concentrated HCL. And then it was introduced into non-
luminous part of the Bunsen flame. If bluish green flame appears, it indicates the 
presence of copper.  
Ash test:  
  A small amount of sample was mixed with the cobalt nitrate solution. A filter 
paper was soaked into the mixture. Then it was introduced into the Bunsen flame and 
ignited. If yellow colour flame appears, it reveals the presence of sodium. 
Determination of Total Ash: 
  Incinerate about 2 to 3 g accurately weighed, of the ground drug in a tared 
platinum or silica dish at a temperature not exceeding 450º until free from carbon, 
cool and weigh. If a carbon free ash cannot be obtained in this way, exhaust the 
charred mass with hot water, collect the residue on an ash less filter paper, 
incinerate the residue and filter paper, add the filtrate, evaporate to dryness, and 
ignite at a temperature not exceeding 450º. Calculate the percentage of ash with 
reference to the air-dried drug. 
Determination of Acid Insoluble Ash: 
  Boil the ash obtained in above test for 5 minutes with 25 ml of dilute 
hydrochloric acid; collect the insoluble matter in a Gooch crucible, or on an ash 
less filter paper, wash with hot water and ignite to constant weight. Calculate the 
percentage of acid-insoluble ash with reference to the air dried drug.  
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Determination of Moisture Content (Loss on Drying): 
  Procedure set forth here determines the amount of volatile matter (i.e., 
water drying off from the drug). For substances appearing to contain water as the 
only volatile constituent, the procedure given below, is appropriately used. 
  Place about 10 g of drug (without preliminary drying) after accurately 
weighing (accurately weighed to within 0.01 g) it in a tared evaporating dish. For 
example, for underground or unpowdered drug, prepare about 10 g of the sample 
by cutting shredding so that the parts are about 3 mm in thickness. 
  Seeds and fruits, smaller than 3 mm should be cracked. Avoid the use of 
high speed mills in preparing the samples, and exercise care that no appreciable 
amount of moisture is lost during preparation and that the portion taken is 
representative of the official sample. After placing the above said amount of the 
drug in the tared evaporating dish dry at 105º for 5 hours, and weigh. Continue the 
drying and weighing at one hour interval until difference between two successive 
weighings corresponds to not more than 0.25 per cent. Constant weight is reached 
when two consecutive weighings after drying for 30 minutes and cooling for 30 
minutes in a desiccator, show not more than 0.01 g difference.  
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4.2.2.2 MICROBIOLOGICAL CONTAMINATION 
Evaluation of Total Aerobic Bacterial Count 
1.1.Preparation of  Sample for Experimental Work 
 Weighed 10 gm of the homogenized drug sample aseptically and dissolved in 
10 ml of sterile water and made up to 100 ml with the sterile water. The insoluble 
drug product was suspended in 100 ml of buffered sodium chloride-peptone solution 
(pH 7.0).   
1.2.  Serial dilution of Sample 
   A serial dilution is the dilution of a sample, in 10-fold dilutions. From the 
sample, 1 ml of the sample was added to 9 ml of sterile distilled water and mixed it 
well. This dilution was denoted as 10-1 dilution. From this dilution, one ml was taken 
from that mixture is added to 9 ml, and designated as 10-2 dilution. The same 
procedure was repeated up to 10-4. 
1.3. Isolation of Total Viable Aerobic Microbial Count 
1.3.1. Isolation of Bacteria by Plate Count Method 
 In this test, the bacteria in sample were made to grow as colonies, by 
inoculating a known volume of sample into a solidifiable nutrient medium (Casein 
Soybean Digest agar or Nutrient agar medium) in petridish. The agar plate was 
prepared by mixing growth medium with agar and then sterilized by autoclaving. 
Once the agar was cooled to 45oC, approximately 15 to 20 ml of medium was poured 
into a sterile Petri dish under aseptic condition and left to solidify for 15 minutes. 
After solidification, each plate was smear with 0.1 ml of sample from the dilution of 
10-1 and 10-2. After inoculations, all the plates were incubated at 37oC for 24 hours. 
After incubation, the bacterial colonies were developed as visible to the naked eye and 
the number of colonies on a plate was counted using Quebec Colony Counter. Plates 
with an average of from 30 to 300 colonies of the target bacterium were selected for 
colony count. Because of the statistical problems, plates with lower than 30 colonies 
greater than 300 colonies were rejected. 
 
1.3.1.1. Composition of Nutrient Agar Media 
Peptone   : 5.0 gm  
Sodium chloride  : 5.0 gm  
Beef extract   : 1.5 gm 
Yeast extract   : 1.5 gm 
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Agar    : 15.0 gm 
Distilled water   : 1000 ml  
pH ( at 25°C)    : 7.4±0.2 
1.3.2. Isolation of Fungi 
From each of the above prepared samples, 0.1 ml of sample was transferred to 
Sabouraud Dextrose agar (SDA) prepared with Chloramphenicol. The plates were 
then incubated for 5 days at room temperature (20 to 25°C). After incubation, the 
fungal colonies were observed and calculated.   
1.3.2.1. Composition of SDA 
Dextrose   ; 40 gm 
Peptone   : 10 gm 
Agar   : 15 gm 
Distilled water : 1000 ml 
1.5. Evaluation of Specified Microorganisms  
1.5.1. Isolation & Identification of Escherichia coli 
One ml of the prepared sample was added in a sterile screw-capped container 
containing 50 ml of nutrient broth and mixed well. Then, it was allowed to stand for 1 
hour and mixed well again. After one hour, the screw caps of the bottle was loosened 
and incubated at 37º for 18 to 24 hours. 
1.5.1.2. Primary Test 
From the above prepared enrichment culture, 1.0 ml was taken and transferred 
aseptically into a tube containing 5 ml of Mac- Conkey broth. Inoculated tubes were 
incubated in a water-bath at 36º to 38º for 48 hours.  
1.5.1.3. Secondary Test 
From the primary test, 1.0 ml of the enrichment culture was taken and 
transferred aseptically in to 5 ml of peptone water. It was then incubated in a water-
bath at 43.5º to 44.5º C for 24 hours and observed the tubes for acid and gas. Then, 
the culture was subjected to biochemical tests of imvic and the results were observed 
and correlated.       
1.5.1.4. Alternative test 
It was done by a loop full of enriched culture in the primary test was streaked 
on a sterile Mac-Conkey agar medium. Then, the plates were inverted and incubated 
at 37 º C for 24 hours. After incubation, the pink or brick red color colonies were 
examined and transfer them individually into the surface of Eosin Methylene Blue 
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agar medium (EMB), on Petri dishes. Inoculated plates were inverted and incubated at 
37 º C for 24 hours. After incubation, the colonies on medium were checked for their 
color appearance like green metallic sheen under reflected light. The colonies were 
subjected to confirmation by further suitable cultural and biochemical tests. 
1.5.1.5. Components of Eosin Methylene Blue Agar Media 
Pancreatic digest of gelatin   : 10.0 g 
Dibasic potassium phosphate   : 2.0 g 
Lactose      : 10.0 g 
Eosin Y      : 400 mg 
Methylene blue    : 65 mg 
Agar       : 15.0 g 
Distilled water     : 1000 ml 
1.5.2. Isolation & Identification of Salmonella sp. 
One ml of the prepared sample was added in a sterile screw-capped container 
containing 100 ml of nutrient broth and mixed well. Then, it was allowed to stand for 
1 hour and mixed well again. After one hour, the screw caps of the bottle was 
loosened and incubated at 37º for 18 to 24 hours. 
1.5.2.1. Primary Test  
From the above prepared enrichment culture, 1.0 ml was taken and transferred 
aseptically into a tube containing 10 ml of Selenite F broth. Inoculated tubes were 
incubated in a water-bath at 36º to 38º for 48 hours. After incubation, the culture was 
subcultured on two of the agar media namely Bismuth sulphate agar and Deoxy 
cholate citrate agar and incubated the plates at 36º to 38º for 18 to 24 hours. After 
incubation, colonies were observed on the medium and confirmed the genus 
Salmonella based on guidelines. 
1.5.2.2. Secondary test 
The suspected colonies of the primary test were subcultured on the slant of 
triple sugar-iron agar in test tube and in urea broth. Both media were incubated at 
37ºC for 24 hours. After incubation, the results were observed according to the 
development of color change and acid / gas in media.  The presence of Salmonella 
was confirmed by agglutination tests. 
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1.5.2.3. Composition of Salmonella Shigella Agar Media 
Beef Extract     : 5.0 gm 
Enzymatic Digest of Casein   : 2.5 g 
Enzymatic Digest of Animal Tissue  : 2.5 gm 
Lactose     : 10 gm 
Bile salts     : 8.5 gm 
Sodium Citrate     : 8.5 gm 
Ferric Citrate     : 1.0 gm 
Brilliant Green    : 0.00033 gm 
Neutral Red     : 0.025 
Agar      : 13.5 gm 
Distilled water     : 1000 ml 
1.5.3. Isolation and Identification of Pseudomonas aeruginosa 
From the above prepared enrichment culture, 1.0 ml was taken and transferred 
aseptically into 100 ml of fluid soyabean-casein digest medium and mixed well.  The 
inoculated tubes were incubated at 37º C for 24 hours. After incubation, the growth of 
bacteria was checked. From this, a loop full of culture was streaked on the surface of 
Cetrimide agar medium and Pseudomonas Isolation Agar medium and incubated at 
incubated at 37º C for 24 hours. After incubation, the colonies from the agar surface 
of these two media were checked for detection of fluorescein and pyocyanin. 
1.5.3.1. Composition of Cetrimide Agar Media 
Pancreatic digest of gelatin   : 20.0 g 
Magnesium chloride    : 1.4 g 
Potassium sulphate    : 10.0 g 
Cetrimide     : 0.3 g 
Agar      : 13.6 g 
Glycerin     : 10.0 g 
Distilled Water t   : 1000 ml 
1.5.4. Isolation and Identification of Staphylococcus aureus 
From the above prepared enrichment culture, a loop full of culture was taken 
and transferred aseptically on Mannitol salt agar and incubated at 37º C for 24 hours.. 
After incubation, the colonies were subjected to confirmation by hem agglutination 
test.  
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1.5.4.1. Composition of Mannitol Salt Agar Media 
Pancreatic digest of gelatin   : 5.0 g 
Peptic digest of animal tissue  : 5.0 g 
Beef extract     : 1.0 g 
D-Mannitol     : 10.0 g 
Sodium chloride    : 75.0 g 
Agar      : 15.0 g 
Phenol red     : 25 mg 
Distilled Water    : 1000 ml 
4.2.2.3. BIO CHEMICAL ANALYSIS 
PROCEDURE: 
 100mg of  the drug was wighted accurately and placed into a  clean beaker 
added a few drops of cons. hydrochloric acid and evaporated it well. After evaporated 
cooled the content and added a few drops of concentrated nitric acid and evaporated it 
well. After cooling the content add 20ml of distilled water and dissolved it well. Then 
it is transformed it to 100 ml of volumetric flask and made upto100 ml with distilled 
water. Mix well. Filtered it.Then it taken for analysis. 
QUALITATIVE ANALYSIS FOR BASIC RADICALS: 
Test for Calcium: 
2ml of the above prepared extract is taken in a clean test tube. To this add 2ml 
of 4% Ammonium oxalate solution. Formation of white precipitate indicates the 
presence of calcium. 
Test for Iron (Ferric): 
The extract is acidified with glacial acetic acid and potassium ferro cyanide. 
Formation of blue colour indicates the presence of ferric iron. 
Test for Iron (Ferrous): 
The extract is treated with concentrated Nitric acid and ammonium thio-
cyanate solution. Formation of blood red colour indicates the presence of ferrous iron. 
Test for Zinc: 
The extract is treated with potassium ferro-cyanide. Formation of white 
precipitate indicates the absence of zinc. 
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QUALITATIVE ANALYSIS FOR ACIDIC RADICALS: 
Test for Sulphate: 
2ml of extract is added to 5% barium chloride solution. Formation of white 
precipitate indicates the presence of sulphate. 
Test for Chloride: 
The extract is treated with silver nitrate solution. Formation of white 
precipitate indicates the presence of chloride. 
Test for Phosphate: 
The extract is treated with ammonium molybdate and concentrated nitric acid. 
Formation of no yellow precipitate indicates the absence of phosphate. 
Test for Carbonate: 
On treating the extract with concentrated hydrochloric acid giving brisk 
effervescence indicates the presence of carbonate. 
Test for starch: 
The extract is added with weak iodine solution. Formation of no blue colour 
indicates the absence of starch. 
Test for albumin: 
The extract is treated with Esbach`s reagent. Formation of no yellow 
precipitate indicates the absence of albumin. 
Test for tannic acid: 
The extract is treated with ferric chloride. Formation of  nobluish black 
precipitate indicates the absence of tannic acid. 
Test for unsaturation: 
The extract is treated with potassium permanganate solution. The dis-
colourization of potassium permanganate indicates the presence of unsaturated 
compounds. 
Test for the reducing sugar: 
5ml of Benedict`s qualitative solution is taken in a test tube and allowed to 
boil for 2 minutes and added 8-10 drops of the extract and again boil it for 2 minutes. 
Any colour change indicates the presence of reducing sugar. 
Test for amino acid: 
One or two drops of the extract is placed on a filter paper and dried it well. 
After drying, 1% Ninhydrin is sprayed over the same and dried it well. Formation of 
violet colour indicates the presence of amino acid. 
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4.2.2.4.INSTRUMENTAL ANALYSIS 
 Scanning electron microscope (SEM) 
 
Fig No: 3 scanning electron microscope (sem) 
Introduction: 
The microstructure of the powders was examined using a Hitachi S 3000H 
scanning electron microscope The SEM is capable of examining objects at very low 
magnification. This feature is useful in viewing particle size and shape of any 
composition at various stages of preparation in Siddha system as well as other 
fields.The large depth of field available in the SEM makes it possible to observe 3-
dimensional objects in stereo. 
The scanning Electron Microscope is one of the most versatile instruments 
available for the examination and analysis of the micro structural characteristics of 
solid objects. The primary reason for the SEM’s usefulness is the high resolution 
which can be obtained when bulk objects are examined; values of the order of 5nm 
(50degreeA) are usually quoted for commercial instruments. Advanced research 
instruments have been described which have achieved resolutions of about 2.5nm (25 
degree A). Any solid material can be studied. Sample size is limited to specimens less 
than about 10µm in diameter. 
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Principle:  
The beam is then rastered over the specimen in synchronism with the beam of 
a cathode ray tube display screen. The eleastically scattered secondary electrons are 
emitted from the sample surface and collected by a scintillator, the signal from which 
is used to modulate the brightness of the cathode ray tube. In this way the secondary 
electron emission from the sample is used to form an image on the CRT display 
screen. (Goldstein, et. al., 1992) 
SEM MECHANISM 
Procedure: 
An electron beam passing through an evacuated column is focused by 
electromagnetic lenses onto the specimen surface. Since an electron is a charged 
particle, it has a strong interaction with the specimen (due to coulomb interaction).So 
when an electron beam images on a specimen, it is scattered by atomic layers near the 
surface of the specimen. As a result, the direction of electron motion changes and its 
energy is partially lost. Once an incident electron (primary electron) enters a 
substance, its direction of motion is influenced by various obstructions (multiple 
scattering), and follows a complicated trajectory which is far from a straight line. 
Also, when electrons with the same energy are incident on the specimen surface, a 
portion of electrons is reflected in the opposite direction (back scattered) and the 
remainder is absorbed by the specimen (exciting X- rays or other quanta in the 
process). If the specimen issufficiently thin, the electron can pass all the way through 
the specimen (transmitted electrons, scattered or non-scattered). 
The depth at which various signals are generated due to electron beam – specimen 
interaction indicates the diffusion area of the signals in the specimen in addition to the 
local chemistry of the specimen. Secondary electrons mainly indicate information 
about the surface of a specimen. Since secondary electrons do not diffuse much inside 
the specimen, they are most suitable for observing the fine-structures of the specimen 
surface. That is to say, sharp scanning images with high resolution can be expected 
from secondary electrons, because of the smaller influence on resolution by their 
diffusion.  
As the incident electron energy increases, the probability of incident electrons 
Colliding with elemental components of the specimen and releasing secondary 
electronsalso increases. In other words, as the incident energy increases, the emission 
of electrons from the specimen also increases. However, as the energy increases 
 PRE CLINICAL  STUDY OF  KARPOORA  SINTHAMANI  MATHIRAI 
 
   73 
beyond a certain level, the incident electrons penetrate deeper into the specimen with 
the result that the specimen derived electrons use up most of their energy to reach the 
specimen surface. Consequently, the electron emission yield decreases. Therefore, the 
peak secondary electron emission yield occurs at a specific entry level of the incident 
electrons. 
In order to verify the existence of a substance and recognize its shape, the 
image contrast must be well defined. In other words, even if a system boasts 
extremely high resolution, if image contrast is poor, it would be extremely difficult to 
determine the existence of a substance, let alone recognize its shape. Another 
important feature of the SEM is the three-dimensional appearance of the specimen 
image, which is a direct result of the large depth of field.  
Applications: 
  Today, a majority of SEM facilities are equipped with X-ray analytical 
capabilities. Thus topographic crystallographic and compositional information can be 
obtained rapidly, efficiently and simultaneously from the same area. 
The author was chosen this analysis for detecting Particle size of the classical Siddha 
herbo-mineral drug Komoothira silasathu parpam. SEM results of Komoothira 
silasathu parpam were represented in results section. 
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FOURIER TRANSFORM-INFRA RED SPECTROSCOPY (FT-IR) 
 
Fig No 4: FOURIER TRANSFORM-INFRA RED SPECTROSCOPY (FT-IR) 
Introduction: 
Vibrational spectroscopy is an extremely useful tool in the elucidations of 
molecular structure .The spectral bands can be assigned to different vibrational modes 
of the molecule. The various functional groups present in the molecule can be 
assigned by a comparison of the spectra with characteristic functional group 
frequencies. As the positions of the bands are directly related to the strength of the 
chemical bond, a large number of investigations including intermolecular interactions, 
phase transitions and chemical kinetics can be carried out using this branch of 
spectroscopy. In IR spectroscopy, the resonance absorption is made possible by the 
change in dipole moment accompanying the vibrational transition. The Infrared 
spectrum originates from the vibrational motion of the molecule. The vibrational 
frequencies are a kind of fingerprint of the compounds. This property is used for 
characterization of organic, inorganic and biological compounds. The band intensities 
are proportional to the concentration of the compound and hence qualitative 
estimations are possible. The IR spectroscopy is carried out by using Fourier 
transform technique.  
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Principle: 
Infra red spectroscopy involves study of the interaction of electromagnetic radiation 
with matter. Due to this interaction, electromagnetic radiation characteristic of the 
interacting system may be absorbed (or emitted). The experimental data consist of the 
nature (frequency of wave length) and the amount (intensity) of the characteristic 
radiation absorbed or emitted. These data are correlated with the molecular and 
electronic structure of the substance and with intra- and inter molecular interactions. 
Source   : Nernst Glower 
Beam splitter  :  It is made up of a transparent material. Thin  
films of  Silicon deposited on  Potassium  
bromide (KBr) Bromide (KBr) Detectors:   
Deutrated TriGlycine Sulphate (DTGS). 
Scan Range  :  MIR 450to 4000 cm-1 
Resolution  :   4.0 cm-1 
Sample required : 50mg, solid or liquid 
Sampling Techniques : There are a variety of techniques for sample  
preparation physical form of the sample to be  
analyzed. 
Solid   : KBr or Nujol mull method. 
Liquid   : Csl / TIBr Cells 
Gas   : Gas cells 
Measurements Techniques: 
The procedure for recording the %T or %A is as follows: 
Air is first scanned for the reference and stored. The sample is then 
recorded and finally the ratio of the sample and reference data is computed 
to give required %T     or %A at various frequencies. 
Study of substances with strong absorbance bands and weak absorbance 
bands as well as possible. 
Small amount of samples are sufficient 
High resolution is obtained. 
Procedure: 
  Typically,1.5 mg of protein, dissolved in the buffer used for its purification, 
were centrifuged in a 30 K Centric on micro concentrator (Amicon) at 3000_g at 4oC 
until a volume of approximately 40 Al. 
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1. Then, 300 Al of 20 mM buffer, prepared in H20 or 2H20, pH or p2H 7.2, were added 
and the sample concentrated again. The p2H value corresponds to the pH 
2. meter reading + 0.4. The concentration and dilution procedure was repeated several 
times in order to completely replace the original buffer with the this buffer. 
3. The washings took 24 h, which is the time of contact of the protein with the 2H20 
4. medium prior FT-IR analysis. In the last washing, the protein was concentrated to 
fine a volume of approximately 40 Al and used for the infrared measurements. 
5. The concentrated protein sample was placed in CaF2 windows and a 6 Am tin 
spacer or a 25 Am Teflon spacer for the experiments in H20 or 2H20, respectively. 
FT-IR spectra were recorded by means of a Perkin-Elmer -Spectrum-1 FT-IR 
spectrometer using a deuterated triglycine sulfate detector. 
6. At least 24 h before, and during data acquisition, the spectrometer were 
continuously purged with dry air at a dew point of 40oC. Spectra of buffers and 
samples were acquired at 2 cm_1 resolution under the same scanning and 
temperature conditions. In the thermal denaturation experiments, the temperature 
was raised in 5oC steps from 20 to 95oC. 
7. Before spectrum acquisition, samples were maintained at the desired temperature for 
the time necessary for the stabilization of temperature inside the cell (6 min).Spectra 
were collected and processed using the SPECTRUM software from Perkin-Elmer. 
Correct subtraction of H20 was judged to yield an approximately flat baseline at 
1900-1400 cm_ 1, and subtraction of 2H20 was adjusted to the removal of the 2H20 
bending absorption close to 1220 cm_ 1 
KBr Method 
1. The sample is grounded using an agate mortar and pestle to give a very fine 
powder. 
2. The finely powdered sample is then mixed with about 100mg dried KBr salt. 
3. The mixture is then pressed under hydraulic press using a die to yield a 
transparent disc and measure about 13mm diameter and 0.3mm in thickness. 
Nujol Mull Method: 
1. The sample is ground using an agate mortar and pestle to give a very fine 
powder. 
2. A small amount is then mixed with nujol oil to give a paste and this paste is 
thenapplied between two sodium chloride plates. 
3. The plates are then placed in the instrument sample holder ready for scanning. 
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Liquids: 
1. Viscous liquids can be smeared in the cell and directly measured. 
2. For dilute solutions, liquid cells and variable path length cells are employed. 
Applications: 
   Infrared spectrum is useful in identifying the functional groups like -OH, -CN, 
-CO, -CH, -NH2, etc. Also quantitative estimation is possible in certain cases for 
chemicals, pharmaceuticals, petroleum products, etc. Resins from industries, water 
and rubber samples can be analyzed.  
Mechanism of FTIR analyzer 
Analytical Capabilities: 
 
 
 
Fig No: 5Mechanism of FTIR 
 
1. Identifies chemical bond functional groups by the absorption of infrared radiation 
which excites vibrational modes in the bond. 
2. Especially capable of identifying the chemical bonds of organic materials  
3. Detects and identifies organic contaminants. 
4. Identifies water, phosphates, sulphates, nitrates, nitrites, and ammonium ions  
5. Detection limits vary greatly, but are sometimes <1013 bonds/cm3 or sometimes sub 
monolayer .Useful with solids, liquids, or gases. 
 
 
 
 PRE CLINICAL  STUDY OF  KARPOORA  SINTHAMANI  MATHIRAI 
 
   78 
INDUCTIVELY COUPLED PLASMA OPTICAL EMISSION 
SPECTROMETER (ICP-OES) 
 
Fig No: 6 ICP-OES 
Introduction: 
Inductively coupled plasma optical emission spectrometry (ICP-OES) is an 
analytical technique used for the detection of trace metals. It is a type of emission 
spectroscopy that uses the inductively coupled plasma to produce excited atoms and 
ions that emit electromagnetic radiation at wavelengths characteristic of a particular 
element. The intensity of this emission is indicative of the concentration of the 
element within the sample. 
Mechanism: 
The ICP-OES is composed of two parts:  ICP and the optical spectrometer. 
The ICP torch consists of 3 concentric quartz glass tubes. The output or “work” coil 
of the radiofrequency (RF) generator surrounds part of this quartz torch. Argon gas is 
typically used to create the plasma. 
When the torch is turned on, an intense electromagnetic field is created within 
the coil by the high power radio frequency signal flowing in the coil. This RF signal is 
created by the RF generator which is, effectively, a high power radio transmitter 
driving the “work coil” the same way a typical radio transmitter drives a transmitting 
antenna. The argon gas flowing through the torch is ignited with a Tesla unit that 
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creates a brief discharge arc through the argon flow to initiate the ionization process. 
Once the plasma is “ignited”, the Tesla unit is turned off. 
The argon gas is ionized in the intense electromagnetic field and flows in a 
particular rotationally symmetrical pattern towards the magnetic field of the RF coil. 
Stable, high temperature plasma of about 7000 K is then generated as the result of the 
inelastic collisions created between the neutral argon atoms and the charged particles. 
A peristaltic pump delivers an aqueous or organic sample into a nebulizer where it is 
changed into mist and introduced directly inside the plasma flame. The sample 
immediately collides with the electrons and charged ions in the plasma and is itself 
broken down into charged ions. The various molecules break up into their respective 
atoms which then lose electrons and recombine repeatedly in the plasma, giving off 
radiation at the characteristic wavelengths of the elements involved. 
Within the optical chamber(s), after the light is separated into its different 
wavelengths (colours), the light intensity is measured with a photomultiplier tube or 
tubes physically positioned to “view” the specific wavelength(s) for each element line 
involved, or, in more modern units, the separated colours fall upon an array of 
semiconductor photo detectors such as charge coupled devices (CCDs). In units using 
these detector arrays, the intensities of all wavelengths (within the system’s range) 
can be measured simultaneously, allowing the instrument to analyse for every element 
to which the unit is sensitive all at once. Thus, samples can be analysed very quickly. 
The intensity of each line is then compared to previously measured intensities 
of known concentrations of the elements and their concentrations are then computed 
by interpolation along the calibration lines. In addition, special software generally 
corrects for interferences caused by the presence of different elements within a given 
sample matrix.  
Applications : 
ICP-OES is used in   the determination of metals, arsenic present in 
Traditional medicines, and trace elements bound to proteins. ICP-OES is widely used 
in minerals processing to provide the data on grades of various streams, for the 
construction of mass balances. 
The author used it for elemental identification and quantitative compositional 
information of the Komoothira silasathu parpam. 
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X-RAY POWDER DIFFRACTION 
 
 
Fig-N0:7.X-RAY POWDER DIFFRACTION: 
 
X-ray powder diffraction(XRD) is a rapid analytical technique primarily used 
for phase identification of a crystalline material and can provide information on unit 
cell dimensions the analysed material is finely ground, homogenized, and average 
bulk composition is determined. Max von Laue, in 1912, discovered that crystalline 
substance act as three dimensional diffraction gratings for x-ray wavelengths similar 
to spacing of plants in a crystal lattice. X-ray diffraction is now a common technique 
for the study of crystal structures and atomic spacing 
X-ray diffraction is based on constructive interference of monochromatic X-
rays and a crystaline sample. These X-rays are generated by a cathode ray tube, 
filtered to produce monochromatic radiation, collimated to concentrate, and directed 
toward the sample. The interaction of the incident rays with the sample produces 
concentrative interference(and diffracted ray) when conditions satisfy Brgg’s 
Law(nX=2d sin9). This law relates the wavelength of electromagnetic radiation to the 
diffraction angle and the lattice sapcing in a crystalline sample.These  diffracted X-
rays are then detected, processed and counted. By scaning the sample through a range 
of 29 angles, all possible diffraction directions of the lattice should be attained due to 
the  random orientation of the powdered material. Conversion of the diffraction peaks 
to d-spacings. Typically, this is achived by comparsion of d-spacings with standard 
reference patterns. 
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All diffraction methods are based on generation of x-rays in a x-ray tube these 
x-rays are directed at the sample, and the diffracted rays are collected. A key 
component of all diffraction is the angle between the incident and differacted rays. 
Powder and single crystal diffraction vary in instrumentation beyond this. 
X-ray powder diffraction(XRD) instrumentation 
X-ray diffractometers consist of three basic elements: an X-rative, a sample 
holder,and an x-ray detector 
X-rays are generated in a cathode  ray tube by heating a filament toproduce 
electrons, accelerating the electrons toward a target by applying a voltage, and 
bombarding the target material with electrons. When electrons havesufficiant energe 
to dislodge inner shell electrons of the target material,, characteristics X-ray spectra  
are produced.These spectra consist of several components, the most common being 
Ka and Kp. Ka consists, in part,of Ka1 and Ka2. Ka1 has, as lightly shorter 
wavelength and twice the intensity as Ka2. The specific wavelength are characteristic 
of the target material(Cu,Fe,Cr). Filtering, by foils or crystal monochrometers, is 
required to produce monochromatic X- rays needed for diffraction. Ka1 and Ka2 are 
sufficiently close in wavelength such that a weighted average of the two is used. 
Copper is the most common target material for single – crystal diffraction, with CuKa 
radiation = 1.5418A.These X-rays are collimated and directed   onto the sample. As 
the sample and detector are rotated, the intensity of the reflected X-rays is recorded. 
When the geometry of the incident X- rays impinging the sample satisfies the Brgg 
Equation, constrictive interference occurs and a peak in intensity occurs. A detector 
records and processes this X-ray signal and converts the signal to a count rate which 
is then output to a device such as a printer or computer monitor. 
The geometry of an X- ray diffractometer is such that the sample rotates in the 
path of the collimated X- ray beam at an angle 9 while the X-ray detector is mounted 
on an arm to collect the diffracted X-rays and rotates at an angle of 29. The 
instrument used to maintain the angle and rotate the sample is termed a goniometer. 
For typical powder patterns, data is collected at 29 from -5º to 70º, angle that are 
present in the X-ray scan 
Applications 
X-ray powder diffraction is most widely used for the identification of 
unknown crystalline materials (e.g. minerals, inorganic compounds). Determination of 
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unknown solids is critical to studies in geology, environmental science, material 
science, engineering and biology. 
Other application include: 
• Characterization of crystalline materials. 
• Identification of fine grained minerals such as clays and mixed layer clays that 
are difficult to determine optically. 
• Determination of unit cell dimensions. 
• Measurement of sample purity. 
With specialized techniques,XRD can be used to: 
• Determine crystal structures using riveted refinement. 
• Determine of modalamounts of minerals. 
Characterize thin film samples by:  
• Determine lattice mismatch between film and substrate and to inferring stress 
and strain . 
• Determining dislocation density and quality of the flim by rocking curve 
measurements. 
• Measuring super lattices in multi layered epitaxial structures. 
• Determining the thickness, roughness and density of the film using glancing 
incidence X-ray reflectivity measurements. 
• Make textural measurements, such as the orientation of grains, in a 
polycrystalline sample. 
Strength and limitation of X-ray power diffraction(XRD) 
• Powerful and rapid (<20 min ) technique for identification of an unkown  
mineral. 
• In most cases, it provides an unambiguous mineral determination. 
• Mineral sample preparation is required. 
• XRD units are widely available. 
• Data interpretation is relatively straight forward  
Limitations: 
• Homogenous and single phase material is best for identification of an unkown. 
• Must have access to standard reference file of inorganic compounds (d-
spacing,hkls) 
• Requires tenths of a gram of material which must be ground into a powder. 
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• For mixed materials, detection limit is 2% of sample. 
• For unit cell determination, indexing of patterns for non-isometric crystal 
systems is complicated. 
• Peak overload may occur and worsens for high angle “reflection” 
• Users guide – sample collection and preparation. 
• Determination of an unknown requires the material, an instrument for 
grinding, and a sample holder. 
• Obtain a few tenths of a gram (or more) of the material,as pure as possible 
grind the sample to a fine powder, typically in a fluid to minimize including 
extra strain (surface energy) that can offset peak position, and to randomized 
orientation. Powder less then -102 m (or 200mesh) in size is preferred. 
• Place into a sample holder or on to the sample surface. 
• Packing of fine powder into a sample holder. 
• Smear uniformly on to a glass side, assuring a flat upper surface. 
• Pack into a sample container  
• Sprinkle on double sticky tape. 
• Typically the substrate is amorphous to avoid interference. 
• Care must be taken to create a flat upper surface and to archive a random 
distribution of lattice orientations unless creating an oriented smear. 
• For analysis of clays which require a single orientation, specialized techniques 
for preparation of clay samples are given by usages, 
• For unit cell determinations, a small amount of a standard with known peak 
positions (that do not interfere with the sample) can be added and used to 
correct peak position. 
Data collection, Results and Presentation: 
Data Collection:  
              The intensity of diffracted X-rays is continuously recorded as the sample and 
detector rotate through their respective angles. A peak in intensity occurs when the 
mineral contains lattice planes with d - spacing appropriate to diffract X-rays at that 
value of 9. Although each peak consists of two separate reflections ( ka1 and ka2), at 
small values of 29 the peak locations overlap with ka2 appearing as a hump on the 
side of ka1. Greater separation occi=urs at higher values of 9. Typically these 
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combined peaks are treated as one. The 21 position of the diffraction peak is typically 
measured as the center of the peak at 80%peak height. 
Data Reduction: 
            Results are commonly presented as peak positions at 29 and X-ray 
counts(intensity) in the form of an x-y plot. Intensity (I) is either reported as peak 
height intensity, that intensity above background, or as integrated intensity, the area 
under the peak. The relative intensity is recorded as the ratio of the peak intensity to 
that of the most intense peak ( relative intensity = 1/11×100). 
Determination of an unknown: 
             The d-spacing of each peak is then obtained by solution of the Bragg equation 
for the appropriate value of 1. Once all d-spacing have been determined, automated 
search match routines compare the d-spacing of the unknown to those of unknown 
materials. Because each mineral has a unique set of d-spacing, matching these d-
spacing provides an identification of the unknown sample. A systemic procedure is 
used by entering the d-spacing in terms of their intensity beginning with the most 
intense peak. Files of d-spacing for hundreds of thousands of inorganic compounds 
are available from the International Centre for Diffraction Data as the Powder 
Diffraction file ( PDF). Many other sites contain d-spacing of minerals such as the 
American Mineralogist Crystal Structure Database. Commonly this information is an 
integral portion of the software that comes with the instrumentation. 
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4.3. PHARMOCOLOGICAL STUDIES 
4.3.1. HYPOGLYCEMIC ACTIVITY OF KOMOOTHIRA 
SILASATHU PARPAM IN STREPTOZOTOCIN INDUCED 
WISTAR ALBINO RATS(IN VIVO STUDY): 
EXPERIMENTAL MODELS 
            For the study of anti-diabetic an experimental model is selected in such a way 
that it would satisfy the following: 
The animal should develop hyperglycemia rapidly. 
Pathological changes in the site of induction should result from pancreatitis or 
damage of   β-cells. 
The symptoms should be ameliorated or prevented by a drug treatment 
effective in human beings. 
Materials: 
Animals    :Male albino wistar rats (180-220gm) 
Drugs        : Powder of KSP 
Chemical:  STREPTOZOTOCIN(SPZ) (S. D Fine. Chem. Ltd, Mumbai) 
Selection & acclimatization of animals: 
 Wistar strains of male albino rats weighing between 180-220gm are used for 
this study. The animals were housed in large spacious cages and they were fed with 
commercial pellets and access to water ad libitum. The animals were well 
acclimatized to the standard environmental condition of temperature (220c ± 50c) and 
humidity (55 ±5%) and 12 hr light dark cycles throughout the experimental period. 
INDUCTION OF DIABETES MELLITUS 
            Diabetes mellitus is induced in wistar rats by single intraperitoneal injection of 
freshly prepared solution of SPZ (150mg/kg BW) in physiological saline after 
overnight fasting for 12hrs.[1] 
 SPZis commonly used to produce diabetes mellitus in experimental animals 
due to its ability to destroy the β-cells of pancreas possibly by generating the excess 
reactive oxygen species such as H202, 02 and H2 .The development of hyperglycemiain 
rats is confirmed by plasma glucose estimation 72 hrs post SPZ injection. The rats 
with fasting plasma glucose level of 160-220mg/dl were used for this experiment. 
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Experimental procedure: 
 In the experiment a total of 30 rats (24 diabetic surviving rats & 6 normal rats) 
were used. Diabetes was induced in rats 3 days before starting the experiment. The 
rats were divided into 6 groups after the induction of SPZ diabetes. In the experiment 
6 rats were used in each group. 
TREATMENT PROTOCOL: 
Group-I :   (Normal control) consist of normal rats given with  
10ml/Kg of normal saline, orally. 
Group-II :   (Toxic control) Diabetic control received 150mg/Kg of  
Streptozotocin through I.P. 
Group-III : Diabetic control receivedglipizide at a dose of  
(10mg/Kg orally) for 28 days. 
Group-IV :  Diabetic control received powder ofKSPat a dose of  
(200mg/Kg orally) for 28 days. 
Group-V : Diabetic control received powder of KSP at a dose of  
(400mg/Kg orally) for 28 days. 
METHODOLOGY: 
Sample collection: 
  After 28 days of treatment, body weight, blood glucose, haemoglobin, 
glycosylated haemoglobin, plasma insulin, total cholesterol, triglycerides, HDL-
cholesterol and phospholipids were determined. Blood was collected from the eyes 
(venous pool) by sino-ocularpuncture in EDTA coating plasma tubes for the 
estimation of blood parameters. 
BIOCHEMICAL ANALYSIS: 
Estimation of blood glucose:   
 Blood glucose was estimated by commercially available glucose kit (One 
Touch Ultra) Johnson based on glucose oxidase method. 
Plasma insulin:  
 Plasma insulin was determined by ELISA method using a Boehringer–
Mannheim kit with an ES300 Boehringeranalyzer (Mannheim, Germany). 
Estimation of total haemoglobin and glycosylated haemoglobin: 
 Total haemoglobin was determined by the method of Drabkin and Austin 
(1932) and glycosylated haemoglobin was determined by the method of 
SudhakarNayak and Pattabiraman (1981).  
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Estimation of lipid & lipoprotein: 
  Plasma lipids were determined by auto analyzer according to the method of 
Parkeh and Jung (1970) (total cholesterol), Gidez and Webb (1950) (HDL-
cholesterol),  Zilversmith and Davis (1950) (phospholipids) and Rice (1970) 
(triglycerides).  
Statistical analysis: 
  The data for various biochemical parameters were analyzed using analysis of 
variance (ANOVA), and the group means were compared by Newman-Keuls multiple 
range test (NKMRT). Values were considered statistically significant at p<0.01. 
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4.3.2 ANTI DYSLIPIDEMIC ACTIVITY OF KOMOOTHIRA 
SILASATHU PARPAM in Wistar Albino Rats (in Vivo study) 
ANTI DYSLIPIDEMIC MODELS OF WISTAR ALBINO RATS (IN VIVO STUDY): 
Animals 
Wistar albino adult male rats weighing 150-200gm from animal housing 
facility of Vels University were housed in polypropylene cages maintained with 
temperature 27°C ±1°C and 12 hrs light and dark cycles. The animals were allowed to 
adapt to the environment for seven days and supplied with a standard pellet diet (Sai 
Durga foods, Bangalore) and water ad libitum. The experimental protocol has got the 
approval IAEC bearing no 
PharmacologicalEvaluation 
All animals starved for 18 hours and provided water ad libitum before the 
experiment. The animals were divided into five groups of six rats each. Group I served 
as normal control administered with 2% CMC only. Group II served as anti 
dyslipidemic control given a single dose of triton was administered 400 mg/kg only. 
Group III and IV served as test groups received KC 250mg/kg and KC 500mg/kg 
respectively. Group V served as Lovastatin (10mg/kg/day) considered as standard. All 
the groups except the normal control group administered a single dose of Triton 
dissolved in 0.9% Normal saline intraperitonially. After inducing the hyperlipidemia, 
the respective treatment was continued for 7 days. Animals were given standard pellet 
diet and water adlibitum. 
Collection ofblood 
The next day after the completion of experimental study, the blood was taken 
from the rats under mild anesthetic state by retro orbital sinus puncture. The collected 
blood samples were centrifuged (2500 rpm) for 10 minutes. Then serum samples were 
separated and it was used for various biochemical analyses. Then animals were 
sacrificed and the liver, heart and kidney were taken for histopathological study and 
for the analysis of organ weight. 
Liver lipid extraction 
The liver was homogenized in cold 0.15M KCl and extracted with CHCl3: 
CH3OH (2% v/v). This lipid extract was used for the estimation of lipid parameters. 
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Biochemical analysis 
The serum and liver were analyzed for serum total cholesterol, triglycerides, 
high-density lipoprotein (HDL), low-density lipoprotein (LDL), very low-density 
lipoprotein (VLDL) by standard  enzymatic calorimetric methods. 
Histopathology 
All rats were sacrificed after the collection of blood sample. Liver was 
excised from the rats to visually detect gross lesions, and weighed to determine 
weight variation and preserved in 10% neutral formalin for histopathological 
assessment. The tissue was embedded in paraffin, and then sectioned, stained with 
haematoxylin and eosin and were examined microscopically. 
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4.3.3 INVITRO ANTIOXIDANT ACTIVITY KOMOOTHIRA 
SILASATHU PARPAM ON DPPH (2,2-DIPHENYL-1-PICRYL 
HYDRAZYL):RADICAL SCAVANGING METHOD: 
The antioxidant activity of KSP was determined using the 2, 2-diphenyl-1 
picrylhydrazyl (DPPH) free radical scavenging assay[70].100µl of KSP extract was 
mixed with 2.7ml of methanol and then 200µl of 0.1 % methanolic DPPH was added. 
The suspension was incubated for 30 minutes in dark condition. Initially, absorption 
of blank sample containing the same amount of methanol and DPPH solution was 
prepared and measured as a control subsequently, at every 5 min interval, the 
absorption maximum of the solutions were measured using a UV double beam 
spectra scan (Chemito, India) at 517nm. The antioxidant activity of the sample was 
compared with known synthetic standard of 0.16% Butylated Hydroxy Toluene 
(BHT). The experiment was carried out in triplicates[71,72]. 
 
  Free radical scavenging activity was calculated by the following formula: 
 
      (Abs of Control – Abs of Test) 
% Inhibition =  ------------------------------------------------- x 100  
                                               Abs of Control 
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4.4 MICROBIOLOGICAL ANALYSIS 
   Antimicrobial activity was performed by agar well diffusion method on agar. 
Preparation of drug extracts solutions for the experiment  
The dried drugs were weighed and dissolved in sterile distilled water to 
prepare appropriate dilution to get required concentrations of about 10, 20 and 
30µg/ml. They were kept under refrigerated condition unless they were used for the 
experiment. 
 Procedure for the Agar Well Diffusion Test 
   The antibacterial screening of the drugs were carried out by determining the 
zone of inhibition using agar well diffusion method. All the drug extracts were tested 
against four pathogenic bacterial strains of gram positive and gram negative organism 
by agar well diffusion method. 
Bacterial Inoculums Preparation 
 Inoculums of Staphylococcus aureus, Escherichia coli, Klebsiella 
pneumoniae, Proteus vulgaris, and Bacillus substilis were prepared in nutrient broth 
medium and kept for incubation at 37°C for 8 hrs. 
Agar well-diffusion method  
This method was followed to determine the antimicrobial activity. Muller-
Hinton Agar media plates were swabbed (sterile cotton swabs) with 8 hour old - broth 
culture of respective bacteria. After inoculation, wells with the size of 10 mm diameter 
and about 2 cm a part were made in each of these plates using sterile cork borer. Stock 
solution of each drug extract was prepared at a concentration of 1 mg/ml in water. 
About 100 µl of different concentrations of drug solvent extracts were added into the 
wells and allowed to diffuse at room temperature for 2 hrs. The plates were incubated 
at 37°C for 24 hrs. After incubation, the diameter of the inhibition zone (mm) was 
measured and the activity index was also calculated.  
Composition of Muller Hinton Agar Media 
  Beef Extract     : 02.00 gm 
  Acid Hydrolysate of Casein   : 17.50 gm 
  Starch      : 01.50 gm 
  Agar     : 17.00 gm 
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4.5. TOXICOLOGICAL STUDIES 
4.5.1. ACUTE TOXICITY STUDY OF KOMOOTHIRA SILASATHU 
PARPAM IN FEMALE WISTAR ALBINO RATS 
OBJECTIVES: 
The aim of this Study is to evaluate the toxicity of the test medicine 
komoothira silasathu parpam, when administered orally to Female Wistar Rats with 
different doses, so as to provide a rational base for the evaluation of the toxicological 
risk to man and indicate potential target organs. 
GUIDELINES FOLLOWED: 
  OECD Guidelines No. 423. 
STUDY DESIGN AND CONTROLS: 
1. Female WISTAR Rats in controlled age and body weight were selected. 
2. The test drug Komoothira silasathu parpam was administered at 5mg/kg, 
50mg/kg, 300mg/kg, 1000mg/kg, and 2000mg/kg body weight of animal 
as suspension along with water. 
3. The results were recorded on day 0, with single oral dosing and observed 
for a period of 14 days.  
EXPERIMENTAL PROCEDURE 
1.ANIMALS  
1.1 . Supply: 
 A total of 15 Female wistar Rats with an approximate age of 6 weeks and 
purchased from Tiruvandrum medical college, Tiruvandrum. On their arrival a sample 
of animals was chosen at random and weighed to ensure compliance with the age 
requested. The mean weights of Female WISTAR Rats were 100-150 g respectively.  
The animals were housed in metabolic cages (55 x 32.7 x 19 cm), with sawdust litter, 
in such a way that each cage contained a maximum of 3 animals of the same sex. 
1.2.Housing: 
All animals underwent a period of 20 days of observation and acclimatization 
between the date of arrival and the start of treatment. During the course of this period, 
the animals were inspected by a veterinary surgeon to ensure that they fulfilled the 
health requirements necessary for initiation of the StudyThe Female wistar Rats were 
housed in metabolic cages (55 x 32.7 x 19 cm), placed on racks. From the week 
before initiation of the treatment, each cage contained a maximum of  3 rats of the 
same sex and treatment group. 
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Each cage was identified by a card, color coded according to the dose level. 
This card stated the cage number, number and sex of the animals it contained, Study 
number, test substance code, administration route, dose level and Study Director's 
name, date of the arrival of the animals and initiation of treatment. 
The temperature and relative humidity were continuously monitored. Lighting 
was controlled to supply 12 hours of light (7:00 to 19:00 hours) and 12 hours of dark 
for each 24-hour period. 
The cages corresponding to each experimental group were distributed on racks 
in such a manner that external factors, such as environmental conditions, were 
balanced as far as possible. 
2.DIET:  
All the rats had free access to a pelleted rat diet. The diet was analyzed by the   
manufacturer to check its composition and to detect possible contaminants. 
2.1. Water: 
The water was offered adlibitum in bottles.  
 
3. NUMBERING AND IDENTIFICATION: 
The animals were marked on body with picric acid solution prepared in water. 
The marking within the cage was as below. 
 Table no-5 Acute Toxicity Numbering and Identification of Animals 
 
 
 
 
 
Table no 6.Numbering and Identification of Animal 
Cage No Group No Animal Marking Sex 
1 I H,B,T Female 
2 II H,B,T Female 
3 III H,B,T Female 
4 IV H,B,T Female 
5 V H,B,T Female 
The group no., cage no., sex of the animal and animal no. were identified as 
indicated below using cage label and body marking on the animals 
  
Group No Animal Marking 
1 Head 
2 Body 
3 Tail 
 PRE CLINICAL  STUDY OF  KARPOORA  SINTHAMANI  MATHIRAI 
 
   94 
3. ADMINISTRATION ROUTE AND PROCEDURE: 
 The test substance was administered orally. The Female WISTAR Rats 
belonging to the control group were treated with the vehicle (Water) at the same 
administration volume as the rest of the treatment groups. 
3.1. Doses 
The doses for the study were selected based on literature search and range 
finding study. Following the period of fasting, the animals were weighed and then 
drug was administered orally as single dose using a needle fitted onto a disposable 
syringe of approximate size at the following different doses. 
Table no 7. Doses 
GROUP DOSE 
GROUP DOSE 
Group-I 5  mg/kg 
Group-II 50  mg/kg 
Group-III 300  mg/kg 
Group-IV 1000  mg/kg 
Group-V 2000  mg/kg 
The test drug was administered as single dose. After single dose 
administration period, all animals were observed for  14days. 
DOSE PREPARATION: 
 Komoothira silasathu parpam was added in distilled water and completely 
dissolved to form oral for administration. The dose was prepared of a required 
concentration before dosing by dissolving, in distilled water. It was mixed well. The 
preparation for different doses was vary in concentrations to allow a constant dosage 
volume. 
3.2.ADMINISTRATION: 
The test medicine was administered orally to each Female WISTAR rats as 
single dose using a needle fitted onto a disposable syringe of appropriate size at the 
following different doses. The concentration was adjusted according to its body 
weight. The volume was not exceeding 10 ml/kg bodyweight. Variability in test 
volume was minimized by adjusting the concentration to ensure a constant volume at 
all dose levels. 
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3.3. OBSERVATION PERIOD: 
All animals were observed for any abnormal clinical signs and behavioral 
changes. The appearance, change and disappearance of these clinical signs, if any, 
were recorded for approximately 1.0, 3.0 and 4.0 hours post-dose on day of dosing 
and once daily thereafter for14 days. Animals in pain or showing severe signs of 
distress were humanely killed. The cageside observation was included changes in 
skin, fur, eyes and mucous membranes, occurrence of secretions and excretions. 
Autonomic activity like lacrimation,  piloerection, pupil size and unusual respiratory 
pattern, changes in gait, posture, response to handling, presence of clonic or tonic 
movements, stereotypes like excessive grooming and repetitive circling or bizarre 
behavior like self-mutilation, walking backwards etc were observed. At the 14th day, 
sensory reactivity to stimuli of different types (e.g. auditory, visual and proprioceptive 
stimuli) was conducted. Auditory stimuli responses were measured by clicker sound 
from approximately 30 cm to the rats; visual stimuli response were measured with the 
help of shining pen light in the eye of rats and placing a blunt object near to the eye of 
rats. Response to proprioceptive stimuli was measured by placing anterior/dorsal 
surface of animals paw to the table edge. The responses of reactions for these three 
exercises were normal in animals belonging to both the controls as well as drug 
treatment dose groups. 
3.4.MORTALITY AND MORBIDITY: 
All animals were observed daily once for mortality and morbidity at 
approximately 1.0, 3.0 and 4.0 hours post dose on day of dosing and twice daily 
(morning and afternoon) thereafter for 14 days. 
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4.5.2 SUB-ACUTE(Repeated Dose) TOXICITY STUDY OF 
KOMOOTHIRA SILASATHU PARPAM 
IN WISTAR ALBINO RATS 
1. OBJECTIVE 
The objective of this ‘Sub-Acute Toxicity Study of komoothira silasathu 
parpam  WISTAR Rats’ was to assess the toxicological profile of the test item when 
treated as a single dose daily. Animals should be observed for 28 days after the drug 
administration. This study provides information on the possible health hazards likely 
to arise from exposure over a relatively limited period of time.  
2.TEST GUIDELINE FOLLOWED 
      OECD 407 Method - Sub-Acute Toxic Class Method (Repeated Dose 28-Day 
Oral Toxicity Study in Rodents) 
3. TEST ITEM DETAIL 
Komoothira silasathu parpam 
4.TEST SYSTEM DETAIL 
The study was conducted on 5 male 5 female WISTAR rats for each group. 
These   animals were selected because of the recommended rodent species for oral 
studies as per followed guideline and availability of Animals 8-12 weeks old male and 
female rats were selected after physical and behavioral examination. The body weight 
range was fallen within ± 20% of the mean body weight at the time of Randomization 
and grouping. The rats were housed in standard laboratory condition in Polypropylene 
cages, provided with food and water adlibitum in the Animal at Animal house, KLU 
college of pharmacy, Madurai. The experimental protocol was approved by 
Institutional Animal Ethical Committee as per the guidance of Committee for the 
Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Ministry 
of Environment and Forest, government of India. 
5.  ACCLIMATIZATION 
The animals were selected after veterinary examination by the veterinarian. 
All the selected animals were kept under acclimatization for a week. 
6. RANDOMIZATION& GROUPING 
One day before the initiation of treatment (days 0- last day of acclimatization), 
the selected animals were randomly grouped into three different groups containing 
minimum 5 male and 5 female animals per group.  
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7.NUMBERING AND IDENTIFICATION 
The animals were marked on body with picric acid solution prepared in water. 
The marking within the cage was as below.  
Table No:8 
Cage 
No 
Group no & 
Concentration/Dose 
mg/kg/day 
Animal Marking Sex No of 
rats 
1 1. Control 
H,B,T,HB,NM               
H,B,T,HB, NM 
Male 
Female 
5 
5 
2 
2. Low dose of 
KSP(200mg/kg) 
H,B,T,HB,NM                   
H,B,T,HB, NM 
Male 
Female 
5 
5 
3 
3.Middledose  of 
KSP(400mg/kg) 
H,B,T,HB,NM                  
H,B,T,HB, NM 
Male 
Female 
5 
5 
4 
4. High dose of KSP(600 
mg/kg) 
H,B,T,HB,NM                  
H,B,T,HB, NM 
Male 
Female 
5 
5 
The group  no., cage no., sex of the animal and animal no. were identified  as 
indicated below  using cage  label and body marking on the Above 
8. HUSBANDRY 
8.1 HOUSING: 
The WISTAR rats were housed in standard polypropylene cages with stainless 
steel top grill. Paddy husk was used as bedding. The paddy husk was changed at least 
twice in a week. From the week before   initiation of the treatment, each cage 
contained a maximum of 10 rat of the differnt sex and treatment group. 
8.2 ENVIRONMENTAL CONDITIONS: 
The animals were kept in a clean environment with 12 hour light and 12 hour 
dark cycles. The air was conditioned at 22±30C and the relative humidity was 
maintained between 30-70% with 100% exhaust facility. The cages corresponding to 
each experimental group were distributed on racks in such a manner that external 
factors, such as environmental conditions, were balanced as far as possible. 
8.3 FEED & FEEDING SCHEDULE: 
‘Sai Durga Animal Feed, Bangalore. Feed was provided adlibitum throughout 
the study period, except over night fasting (18-20 hours) prior to dose administration. 
After the substance has been administered, food was with held for a further 3-4 hours. 
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8.4 WATER: 
The water was offered adlibitum in bottles. There was periodically analyzed to 
detect the presence of possible contaminants 
8.5 DOSES: 
The doses for the study were selected based on literature search and range 
finding study. Following the period of fasting, the animals were weighed and then 
extract was administered orally as single dose using a needle fitted on to a disposable 
syringe of approximate size at the following different doses. 
The test item was administered as single dose daily. After single dose 
administration period, all animals were observed for 28 days. 
DOSE PREPARATION 
Komoothira silasathu parpam was added in distilled water and completely 
dissolved  for oral  administration. The dose was prepared of a required concentration 
before dosing by dissolving komoothira silasathu parpam in distilled water. It was 
mixed well. The preparation for different doses was vary in concentrations to allow a 
constant dosage volume. 
8.6 ADMINISTRATION 
The test item was administered orally to each rat as single dose using a needle 
fitted on to a disposable syringe of appropriate size at the following different doses. 
The concentration was adjusted according to its body weight. The volume was not 
exceeding 10 ml/kg body weight. Variability in test volume was minimized by 
adjusting the concentration to ensure a constant volume at all dose levels. 
9. OBSERVATIONS  
These observations were also performed on week-ends. The observations 
included   but were not limited to changes in skin and fur, in the eyes and mucous 
membranes, in the respiratory, circulatory, central nervous and autonomous systems, 
somatomotor activity and behavior. 
9.1. CLINICAL SIGNS OF TOXICITY  
All the rats were observed at least twice daily with the purpose of recording 
any symptoms of ill- health or behavioral changes. Clinical signs of toxicity daily for 
28 days. 
9.2. FOOD INTAKE  
Prior to the beginning of treatment, and daily, the food intake of each cage was 
recorded for period of 28 days and the mean weekly intake per rats was calculated. 
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9.3. WATER INTAKE 
Water intake was checked by visual observation during the Study. In addition, 
the water consumption in each cage was measured daily for a period of 28 days. 
9.4 BODYWEIGHT: 
The body weight of each rat was recorded one week before the start of 
treatment, and during the course of the treatment on the day of initial, 3rd, 7th, 10th, 
14th, 17th, 20th, 24th and 28th days (day of sacrifice). The mean weights for the 
different groups and sexes were calculated from the individual weights. 
Blood Collection  : 
 Blood was collected through retro-orbital sinus from all the animals of 
different groups on 28th day. The blood was collected in tubes containing 
Heparin/EDTA as an anticoagulant. Animals were fasted over night prior to the blood 
collection. 
LABORATORY STUDIES  
During the 4th week of treatment, samples of blood were withdrawn from the 
orbital sinus of 6 rats from each group, under light ether anesthesia after fasting for 16 
hours. The blood samples are used to evaluate Hematological   parameters like RBC, 
WBC, PLATELETS, MCH, PCV, Hb. The collected blood samples also centrifuged 
10000 rpm in 10 minutes to separate the serum. The separated serum used to evaluate 
biochemical parameters like SGOT, SGPT, ALP, BILIRUBIN, CREATININE, URIC 
ACID and Electrolytes like Sodium, Calcium, phosphorus.  
TERMINAL STUDIES  
 Sacrifice and macroscopic examination 
On completion of the 4 weeks of treatment, 18 WISTAR rats were sacrificed 
by ether inhalation. A full autopsy was performed on all animals which included 
examination of the external surface of the body, all orifices, cranial, thoracic and 
abdominal cavities and their contents both in situ and after evisceration. As the 
number of animals exceeded the number that could be sacrificed in one day, the 
autopsies were carried out over three consecutive days at the end of the treatment 
period.  
Organ weights: 
            After the macroscopic examination the following organs were weighed after 
separating the superficial fat: Brain, Heart, Spleen Kidneys, Testes, Liver, Lungs, 
pancreas and stomach. 
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5.  RESULTS AND DISCUSSION 
 
Many studies have been carried out to bring the efficacy and potency of the trial 
drug Komoothira silasathu parpam.(KSP) The drug KSP. has been selected for 
Hypoglycemic, Anti dyslipidemic, & anti oxidant activity in reference with the text 
“Thanjai Vaithiya Raja Sinthamani” Part – 2 Page No 5. The study includes Literary 
collections, Organoleptic character, Physicochemical and Instrumental analysis, and 
Pharmacological studies. Toxicological studies 
Literature collections about the drug from various text books were done. Siddha 
literatures  related to the drug bring the evidence and importance of its utility in treating 
diabetes mellitus.(madhumegam). 
Botancial aspects explains the identification, description, active principle and 
medicinal uses of the palnts. 
Gunapadam review brings the effectiveness of the drug in treating diabetes 
mellitus. 
Modern and siddha aspect of the disease was also reviewed. 
Pharmaceutical review describes about the Parpam and its properties. 
The pharmacological study explains about the methodology of Hypoglycemic, 
Anti dyslipidemic, & Anti- oxident activites  
 
STANDARDIZATION OF THE TEST DRUG 
Standardizations of the drug is more essential to derive the efficacy and 
potency of the drug, which was analysed by the various methods.  The results of 
physicochemical and biochemical analysis have been done and tabulated. 
Pharmacological activity and toxicological results of the drug were derived. The result 
reveals the effectiveness of the trial drug KSP has been proved by the following 
scientific parameters. 
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PHYSICO CHEMICAL ANALYSIS 
   The following characters have been noted in KSP. 
Table No -9.organoleptic character 
Colour in day  light White 
Odour Pleasant odour 
Taste Astringent 
Appearance Fine powder 
Sense of Touch Fine 
 
Table No –10.Physicochemical properties 
Sl. 
No 
Parameters Values Normal Values 
1 Water soluble ash 7.65±0.011 7.85 % 
2 Acid insoluble ash 0.85±0.011 7.45% 
3 Loss on drying at 70°C 7.10±0.240 5 – 8 % 
4 pH Analysis                                                             8.540 > 7 %  
 
INTERPRETATION:  
Organoleptic character: 
Organoleptic character indicates that the test drug KSP has the following 
characters, fine powder, White in colour, Pleasant odour, astringent in taste, fine to 
touch. 
Loss on drying: 
The total of volatile content and moisture present in the drug was 
established in loss on drying. Moisture content of the drug reveals the stability and 
its shelf-life.  High moisture content can adversely affect the active ingredient of 
the drug.  Thus low moisture content could get maximum stability and better shelf 
life. 
The loss on drying test is designed to measure the amount of water and 
volatile matters in a sample when the sample is dried under specified conditions. 
Moisture is one of the major factors responsible for the deterioration of the drugs 
and formulations. Low moisture content is always desirable for higher stability of 
drugs. The percentage loss on drying 7.0% was within acceptable range (5%-8%), 
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thus implying that the formulation can be stored for a long period and would not 
easily be attacked by microbes. 
Ash value: 
Determination of ash value: 
The Ash Limit Tests are designed to measure the amount of the residual. 
Substances when a sample is ignited under the conditions specified in the 
individual monograph. A high ash value is indicative of contamination, 
substitution, adulteration, or carelessness in preparing the drug. The total ash values 
of  KSP  were 68.2% .The value of total ash in the formulation is comparatively 
high. The value of total ash indicates that the inorganic contents of the formulation 
are below the limits. This signifies the ash value determination as an important 
parameter to standardize the herbal drugs. 
The Acid-Insoluble Ash Limit Test is designed to measure the amount of ash: 
 Insoluble to diluted hydrochloric acid.Acid-insoluble ash value of the 
prepared formulation (22.08%) shows that a very small amount of the inorganic 
component is insoluble in acid.It indicates that adulteration of raw ingredients by 
substances, such as silica and rice husk, is very less, and a low acid-insoluble ash 
value may also  affect the amount of the component absorbed in the gastrointestinal 
canal when taken orally. 
Determination of Alcohol-soluble and water-soluble extractive values 
 Alcohol-soluble and water-soluble extractive values of ingredients and 
formulation are depicted in table which shows 81.2% alcohol-soluble extractive value 
and 97.7% water-soluble extractive value of the formulation. Higher water-soluble 
extractive value implies that water is a better solvent of extraction for the formulation 
than ethanol. acid-insoluble ash, and water-soluble ash were found to be 
68%,22.08%,71.2% respectively; the value of total ash indicates that the inorganic 
contents of the formulation are below the limits. The results of Alcoholic and water 
soluble extracts of the formulation show that alkaloids of the formulations are more 
soluble in water than alcohol and a higher water soluble extractive value of the 
formulation depicts that water is a better solvent of extraction for the formulation than 
alcohol. 
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MICROBIAL LIMIT TESTS 
Table No: 11. Results for Microbial limit test : 
S.No Microbes Colony 
measurements 
Normal limits 
1.  Total viable aerobic count 4 x104 col/g 1 x105 col/g 
2. Total fungal count Nil 1 x104 col/g 
 Test for specific pathogen   
1. Salmonella sp Nil Nil 
2. Staphylococcus aureas Nil Nil 
3. E.coli Nil Nil 
4. Pseudomonas aeruginosa Nil Nil 
 
Total viable aerobic counts within the normal level.   
Total fungal count within the normal level. 
Specific pathogens like Salmonella sp., Staphylococcus aureus, E.coli and 
Pseudomonas aeruginosa are Nil. 
Hence, the test drug is free from any microbial contamination. 
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BIO-CHEMICAL ANALYSIS OF KOMOOTHIRA SILASATHU 
PARPAM 
Table No:12.  Result of Preliminary Basic and Acidic Radicals studies 
S.No Test Inference 
1 Test for calcium Present 
2 Test for sulphate Present 
3 Test for chloride Present 
4 Test for carbonate Absent 
5 Test for starch Absent 
6 Test for Iron ferric Absent 
7 Test for iron ferrous Present 
8 Test for phosphate Absent 
9 Test for Albumin Absent 
10 Test for Tannic acid Absent 
11 Test for unsaturation Present 
12 Test for the reducing sugar Absent 
13 Test for amino acid Present 
14 Test for zinc Absent 
 
INTERPRETATION: 
  From the test for basic and acidic radicals studies shows the presence of  
1.Calcium, 
2.sulphate,  
3.Chloride. 
4.Ferrous Iron. 
5.Amino acid  
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1.Calcium: 
It is an essential component of intracellular process that occur within insulin 
responsive tissues like skeletal muscle and adipose tissue. A very narrow range of 
calcium concentration is needed for optimal insulin mediated functioning. 
Concentrated levels of calcium out of optimal range may contribute to 
peripheral insulin resistance.   
2.Sulphates: 
Sulphate has anti bacterial activity and it is one of the macronutrient of cells. 
 Sulphate important role for the anti – microbial activity. 
It is needed to start the cascade of digestive enzymes released from the 
pancreas. Without proteases, lipases and amylases, food is not digested efficiently.  
3.Chloride : 
Chloride regulates the acid base balance of the body fluids, by maintaining the 
osmotic pressure of the body fluids.  
4.Ferrous Iron : 
Iron is easily soluble and readily absorbed from intestine and involved. 
5.Amino acid: 
In diabetes mellitus  atherosclerotic changes occur earlier ,Amino acids, like 
arginine, help the arteries of the body retain elasticity, which prevents them from 
stretching out and allowing fluid to collect. They also help support the expansion and 
contraction of the arteries with each heartbeat. 
The tissues in the body -- muscles, skin, connective tissues, etc. -- need amino 
acids for repair when injured or damaged. They're especially beneficial after exercise 
or difficult training, when the muscles can tear. Taking amino acids like arginine after 
exercise can help the muscles recover and heal properly and more quickly. 
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INSTRUMENTAL ANALYSIS 
SEM (SCANNING ELECTRON MICROSCOPE) RESULT: 
 
Fig.No.8. SEM Picture 30,000 Magnification. 
 
                                   Fig.No.9. SEM Picture 80,000 Magnification. 
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SEM analysis of the KSP shows the particle size varies between 5µm to 10µm. 
The surfaces of the sample grains is uniformly arranged in agglomerates. 
Smaller sized  particles enhance the absorption and bio availability resulting 
efficacy of the drug will be increased.  
The microparticles 
Increase drug therapeutic efficacy  
Increase bio-availability 
Reduces side effect 
In SEM analysis the micro particle present in the test drug results in a better 
bioavailability and facilitates absorption.So very minimal quantity of the medicine is 
enough to treat the disease, resulting better efficacy of the drug. Larger particles could 
not enter in to the target cell because of their size, and it will requires extra digestive 
and absorptive load, resulting they easily cleared from the blood 
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FT-IR  RESULTS OF KSP: 
Fourier Transform Infra-Red Spectroscopy (FTIR) analysis results in 
absorption spectra provide information about the functional group and molecular 
structure of a material. In FTIR the wave numbers between 4000cm-1 _ 600 cm-1 is 
known as functional group area. <600cm-1 wave numbers is known as fingerprint area. 
The corresponding absorption frequency by FTIR shows the presence of alcohol, 
phenol, 10, 20amines, amides, alkanes, 10 amines, aromatics, aliphatic amines and 
alkyl halides are present in  KSP 
 
Fig: no: 10. FTIR image of  KSP 
 
FTIR is a very useful tool in the recognition of the functional groups of bio 
molecules, thus aiding in their structural elucidation, so confirming the presence of 
active molecules responsible for the therapeutic activity of Siddha drugs. KSP has the 
following functional groups. 
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Table 13: FTIR Spectrum- functional groups 
Frequency (cm-1) Bond Functional Groups 
701.80 C = C Bending Alkane 
885.68 C = C Bending Alkane 
1475.54 C – H bonding Alkcane 
2360.87 O = C = O steching Carbondioxide 
2879.72 C – H streching Aldehyde 
3566.38 N – H Streching Primary Amine 
3647.39 O – H streching Alchols. 
 
The test drug was identified to have 10 peaks which represent the 
functional groups present in the test drug, KSP   
Alkanes groups:   
Alkanes have little biological activity. 
It is predominate in plants. They protect against bacteria and fungi.  
Alcohols: 
Alcholic group of substance act as anti microbial and antiseptic agents. 
Amines: 
 Amine groups act as neurotransmitters 
 It is involved in protein synthesis. 
 This group of substance has antihistaminic and analgesic activity. 
Aldehyde: 
             It acts as blood purifier. 
             It effects free radicals from the blood. 
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ICP-OES of Komoothira Silasathu Parpam 
ICP-OES of KSP  
Table No. 14. 
Sl.No Elements Wavelength (nm) Concentration 
1 Al 396.152 BDL 
2 As 188.979 BDL 
3 Ca 315.807 821.170 mg/L 
4 Cd 228.802 BDL 
5 Cu 327.393 BDL 
6 Fe 238.204 BDL 
7 Hg 253.652 BDL 
8 K 766.491 03.071 mg/L 
9 Mg 285.213 01.104 mg/L 
10 Na 589.592 BDL 
11 Ni 231.604 BDL 
12 Pb 220.353 BDL 
13 P 213.617 176.307 mg/L 
14 S 180.731 501.254 mg/L 
 
BDL: Below Detectable Limit(Normal-1ppm) 
     1%  = 10000ppm, 
                        1ppm = 1/1000000 or 0.0001% 
 
Table No 15.Toxic metals and the permissible limits 
 
Heavy metals WHO & FDA limits 
Pottasium (K) 25.621 mg/L 
Sodium (Na) 24.310 mg/L 
Phosporus (P) 126.341 mg/L 
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INTERPRETATION: 
ICP-OES reveals high concentration of Sulphate in KSP  (0.50120 mg/L). It 
also has physiologically important minerals like Calcium, Phosphorus, megnesium, 
sulfer, sodium and Potassium. In KSP , the heavy metals like Arsenic, Mercury, Lead, 
Cadmium and trace element like nikkal were below detectable level. This reveals the 
safety of the drug and it has free from toxic substances and has no side effects.  
Sodium: 
Sodium regulates the acid-base balance of the body fluids. 
Sodium is required for the maintenance of osmotic pressure of the body fluids. 
It is necessary for the normal muscle irritability and permeability of cells. 
Sodium maintains extracellular osmotic pressure. 
Potassium: 
Potassium is required for the regulation of acid-base balance and water 
balance of the body fluids. 
Potassium maintains intracellular osmotic pressure. 
Potassium is required for the transmission of nerve impulse. 
Calcium: 
           Calcium influences the membrane structure and transport of water and several ions 
across it. 
The release of certain hormones (insulin, PIH, calcitonin) from the endocrine 
glands is facilitated by ca2+ 
Sulphur: 
Early research suggests that drinking water from a sulfurous spring three times 
daily for 4 weeks reduces total cholesterol,low- density lipoprotein (LDL or Bad) 
cholestrol, and triglyceride levels. However ,it’s not clear from this study alone if 
sulfur might reduce cholestrol. 
Magnesium:  
Eating a diet with more magnesium is linked with a reduced risk of developing 
diabetes in adults and overweight children. research on the  effects of magnesium for 
people with existing type 2 diabetes shows conflicting results.  
Phosphorus :  
 Phosphorus is important for energy transfer in cells as part of ATP and is 
found in many other biological important molecules. Thus it relieves fatigue. 
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X- RAY POWDER DIFFRACTION: 
 
 
Fig No:11.XRD IMAGE OF KSP 
Interpretation: 
  These XRD fingerprints shows both the similarities and differences of the 
sample successfully and is a valuable primary tool for checking the quality control of 
Herbo mineral medicines. Mordern techniques are necessary to standardize and bring 
out high quality herbal products owing to their complex nature. The different peaks 
shows the presence of minerals in the sample. 
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PHARMACOLOGY STUDY 
HYPOGLYCEMIC ACTIVITY OF KSP IN STREPTOZOTOCIN 
INDUCED IN WISTAR ALBINO RAT IN VIVO STUDY 
 
 
 
Table No: 16 Effect of KSP on initial and final body weight and blood glucose in normal 
and treated animals. 
 
Fig No: 12 Effect of KSPon initial and final body weight and blood glucose in normal 
and treated animals. 
Values are expressed as mean ± SEM. 
Values were compared by using analysis of variance (ANOVA) followed by 
Newman-Keul's multiple range tests.   
 (a) Values are significantly different from normal control G1 at P<0.001. 
 (b) Values are significantly different from Diabetic control G2 at P<0.01. 
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GROUP 
No 
Body weight (g)  Blood glucose 
(mg / 100ml) 
Initial 
Blood glucose 
(mg / 100ml) 
Initial Final Final 
G1 Normal  122 ± 7.30 135 ± 7.60 84.65 ± 3.30 87.70 ± 3.75 
G2 Diabetic  120 ± 6.70 172 ± 4.50**(a) 90.75 ± 3.85 210.45 ± 6.70**(a) 
G3 Standard  130 ± 7.50 125 ± 7.25 87.55 ± 4.22 118.30 ± 4.42**(b) 
G4 Low dose  122 ± 7.25 140 ± 8.10 84.80 ± 3.60 135.45 ± 5.20**(b) 
G5 High dose  130 ± 7.30 132 ± 7.40 86.50 ± 3.80 124.40 ± 4.65**(b) 
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Table no:17 -EFFECT OF KSP ON PLASMA INSULIN, HEMOGLOBIN& 
GLYCOSYLATED HEMOGLOBIN (HbA1C) IN NORMAL AND TREATED 
ANIMALS. 
GROUPS                    Haemoglobin 
(gm/100ml) 
Glycosylated 
haemoglobin[HbA1C(%)] 
Plasma Insulin (µU/ml) 
G1 12.80 ± 1.60 
0.38 ± 
0.06 
33.50 ± 2.90 
G2 7.10 ± 0.70**(a) 
0.89 ± 
0.14**(a) 
10.60 ± 1.70**(a) 
G3 11.10 ± 1.22**(b) 
0.34 ± 
0.06**(b) 
27.45 ± 2.40**(b) 
G4 10.30 ± 0.92**(b) 
0.43 ± 
0.05**(b) 
27.60 ±2.30**(b) 
G5 10.96 ± 1.12**(b) 
0.42 ± 
0.09**(b) 
28.95 ± 2.35**(b) 
 
 
Fig No 13 -Effect of KSP on plasma insulin, Hemoglobin& Glycosylated hemoglobin in 
normal and treated animals. 
Values are expressed as mean ± SEM. 
Values were compared by using analysis of variance (ANOVA) followed by 
Newman-Keul's multiple range tests.   
 (a) Values are significantly different from normal control G1 at P<0.001. 
 (b) Values are significantly different from Diabetic control G2 at P<0.01. 
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Fig No :14. 
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RESULT: 
 INTERPRETATION: 
 BLOOD GLUCOSE LEVEL:  
 SPZ causes massive reduction in insulin release, through the destruction of β-
cells of the islets of Langerhans. The mechanism of SPZ action was fully described 
elsewhere (Lazarow, 1964; Colca et al., 1983). In our study, we have observed a 
significant increase in the plasma insulin level when SPZ induced diabetic rats were 
treated with KSP at a dose of 200mg/kg and 400mg/kgthis could be due to 
potentiation of the insulin effect of plasma by increasing the pancreatic secretion of 
insulin from existing β- cells of islets of Langerhans or its release from bound insulin. 
  In uncontrolled or poorly controlled diabetes there is an increased 
glycosylation of a number of proteins including haemoglobin and α-crystalline of lens 
(Alberti and Press, 1982). Glycosylated haemoglobin (HbA1C) was found to increase 
in patients with diabetes mellitus to approximately 16% (Koenig et al., 1976) and the 
amount of increase is directly proportional to the fasting blood glucose level (Jackson 
et al., 1979). During diabetes the excess glucose present in blood reacts with 
haemoglobin. Therefore, the total haemoglobin level is decreased in SPZ induced 
diabetic rats (Sheela and Augusti, 1992). Administration of KSP at a dose of 
200mg/kg and 400mg/kg  for 28 days prevents a significant elevation in glycosylated 
haemoglobin there by increasing the level of total haemoglobin in diabetic rats. This 
could be due to the result of improved glycaemic control produced by KSP at a dose 
of 200 mg/kg and 400 mg/kg.  
The body weight was decreased in SPZ diabetic rats.Administration of KSP at 
a dose of 200mg/kg and 400mg/kg increases the body weight in SPZ induced diabetic 
rats. The ability of KSP at a dose of 200mg/kg and 400mg/kgto protect massive body 
weight loss seems to be due to its ability to reduce hyperglycemia. 
Table no: 1 illustrates the levels of initial and final blood glucose,and  change in body 
weight , in normal rat,and treatment control animals in each group. The mean body 
weight of diabetic rats (G2) was significantly decreased as compared to normal 
control rats. The body weight of  diabetic  control rats treated with KSPat a dose of 
200mg/kg and 400mg/kg was  increased the body weight non-significantly as 
compared to normal control animals. 
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 Fasting blood glucose level was significantly increased 210.45 ±6.70 in 
diabetic animals as compared to normal animals. However the level of fasting blood 
glucose, returned to near normal range indiabetic rats treated with KSPat a dose of 
200mg/kg and 400mg/kg. 
 Table no: 2 illustrates the levels oftotal hemoglobin, glycosylated hemoglobin 
and plasma insulin in normal ratand treatment control animals in each group. 
The levels of total hemoglobin, and plasma insulin levels were decreased 
significantly where as glycosylated heamoglobin levels were increased significantlyas 
compared to normal control rats. However the level of total hemoglobin, glycosylated 
hemoglobin and plasma insulin,returned to near normal range indiabetic rats treated 
with KSP at a dose of 200mg/kg and 400mg/kg. It reveals the dose dependent efficacy 
of the trail drug. 
HISTOPATHOLOGY: 
Group I:The normal section of pancreas are seen  
GroupII:The pancreas section showing the damaging Islets of langerhans cell  seen  
GroupIII:Normal pancreas  Islets of langerhans are seen compare to SPZ damaging pancreas 
Group IV:The normal pancreas islets of langerhans are seen compare to standard drug. 
Group V:The normal pancreas islets of langerhans are seen compare to low dose of KSP. 
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EFFECT OF KSP ON BODY WEIGHT OF TRITON-INDUCED ANTI 
DYSLIPIDEMIC RATS 
Table 18: Effect of KSP on body weight of Triton-induced anti dyslipidemic rats 
Groups Body Weight (gm.) 
Initial 1st Week 2nd Week 3rd Week 4th Week 
G1 Normal 
control 155±0.87 157±1.3 
159.25 
±1.03** 
161.5 
±2.72** 163.6±3.17** 
Anti dyslipidemic 
Control 
157.17±0
.87 159±1.04 
170.17 
±1.7 
198.5 
±0.66 216±1.1 
G3 Lovastatin 
(10mg/kg/day) 156±1.59 
159.17±1.0
8 
164.5 
±1.18** 
163.17 
±0.91** 167.5±0.8** 
KSP250mg/kg 155.63±0
.9 158±0.97 
164.75 
±1.47* 
167.42 
±1.23** 170.83±2.3** 
KSP 
500mg/kg 
156.5±0.
67 159.5±1.89 
164.33 
±0.80* 
164.67 
±0.76** 168.83±0.7** 
 
Values are as mean ± SEM (n=6). Values are statistically significant at 
*P<0.05, **P<0.01, ***P<0.001. Comparison made between Group II Vs 
Group I and Group III, IV, V Vs Group II. 
 
Effect of KSP on body weight of Triton-induced anti dyslipidemic rats 
 
 
Fig No: 15 Effect of KSP on body weight of Triton-induced anti dyslipidemic rats 
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Table 19: Effect of KSP onBlood lipid profile of Triton-induced anti  
dyslipidemic rats. 
Group Treatment T.C. T.G. LDL HDL VLDL 
I Normal Control 72.81±1.1** 
60.17±1.7*
* 
52.83±1.8*
* 
35.3±1.3 19.3±1.2** 
II Triton Control 174.17±1.35 
115.17±1.4
9 
120.17±1.2
5 28.17±1.08 20.83±1.11 
III KSP 250mg/kg 72.5±1.23** 
69.67±0.99
** 
71.17±1.38
** 
40.33±0.88
* 
14.33±0.80
** 
IV KSP 500mg/kg 
67.30±1.45*
* 
56.83±0.90
** 
56.33±1.02
** 
42.17±1.14
** 
11.17±1.25
** 
V Lovastatin 54.5±1.12** 54.3±1.30*
* 
46.33±1.15
** 
44.33±1.36
** 
12.5±1.87*
* 
 
Values are as mean ± SEM (n=6). Values are statistically significant at 
*P<0.05, **P<0.01, ***P<0.001. Comparison made between Group II 
Vs Group I and Group III, IV, V Vs Group II. 
 
 
Fig No: 16 .Effect of KSP onliver lipid profile 
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Effect of KSP onliver lipid profile of Triton
 
Gr
oup 
Treatment 
I Normal Control 74.17±0.87**
II Triton Control 155.17±1.08
III KSP250mg/kg 82.15±0.92**
IV KSP 500mg/kg 75.3±0.85**
V 
Lovastatin 
(10mg/kg/d
ay) 
67.05±0.97**
 
Values are as mean ± SEM (n=6). Values are statistically significant at *P<0.05, 
**P<0.01,***P<0.001. Comparison made between Group II Vs Group I and 
Group III, IV, V Vs Group II.
 
Table 20: Effect of 
Fig No: 17: Effect of 
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70.75±1.93*
* 
26.17±1.70*
* 
36.17±0.91
 178.82±1.46 105.25±2.42 18.15±1.05
 
64.15±1.03*
* 
23.12±1.01*
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35.9±0.86
 
64.12±0.97*
* 
20.3±1.06** 44.05±1.4*
 
57.25±1.15*
* 
17.93±1.31*
* 
50.1±0.99*
 
KSP onliver lipid profile of Triton-
dyslipidemic rats. 
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dyslipidemic rats. 
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EFFECT OF KSP ON ATHEROGENIC INDEX AND PERCENTAGE 
PROTECTION OF DIFFERENT GROUPS. 
 
Table 21: Effect of KSP on atherogenic index and percentage protection of 
different groups. 
Groups Atherogenic Index % Protection 
Normal control 1.50±0.02 ---- 
Anti dyslipidemic 
Control 5.90±0.10 ---- 
KSP 250mg/kg 0.77±0.01  
KSP 500mg/kg 0.72±0.02  
Lovastatin 1.18±0.02  
Values are as mean ± SEM (n=6). Values are statistically significant at 
*P<0.05, **P<0.01,***P<0.001. Comparison made between Group II Vs 
Group I and Group III, IV, V Vs Group II. 
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EFFECT OF KSP ON
AND BLOOD GLUCOSE LEVELS OF TRITON
Groups SGOT(U/I)
Normal control 148.17±1.08
Anti 
dyslipidemic 
Control 
190.33±1.12
KSP 250mg/kg 176.5±1.67
KSP 500mg/kg 150±1.18**
Lovastatn 
(10mg/kg/day) 155.52±1.74
 
Values are as mean ± SEM (n=6). Values are statistically significant at *P<0.05, 
**P<0.01,***P<0.001. Comparison made between Group II Vs 
III, IV, V Vs Group II. 
 
Table 22: Effect of 
glucose levels of 
Fig No 18: Effect of 
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 SGOT, SGPT TOTAL PROTEIN, UREA 
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 SGPT(U/I) 
Tota 
Protein 
(gm/dl) 
Urea 
(mg/dl)
 61.17±0.87 5.9±0.86* 36±0.97
 120.5±0.76 6.0±0.97 45±1.1
 71±2.03 5.68±1.08* 32.02±1.1
 70.37±0.89** 5.17±1.02 32.6±1.2**
 64.05±1.35 5.13±0.90 28.67±0.6
Group I and Group 
KSP onSGOT, SGPT Total protein, U
Triton-induced anti dyslipidemicrats
KSP onSGOT, SGPT Total protein, Urea and Blood glucose 
levels of Triton-induced anti dyslipidemicrats
SGOT(U/I)
SGPT(U/I)
Total Protein
Urea (mg/dl)
Blood Glucose (mg/dl)
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Blood 
Glucose 
(mg/dl) 
 85.83±0.79 
 92.14±0.74 
 86.83±1.08 
 
85.08±1.30
** 
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Fig No:19. 
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RESULT : 
  The level of serum lipids are usually elevated in diabetes mellitus, and such an 
elevation represents the risk of coronary heart disease (CHD). Lowering of serum 
lipids concentration through diet or drug therapy seems to be associated with a 
decrease in the risk of vascular disease. The abnormal high concentration of serum 
lipids in diabetic subject is mainly due to increased mobilization of free fatty acids 
from the peripheral fat depots, since insulin inhibits the hormone sensitive lipase. 
However, glucagon, catecholamines and other hormones enhance lipolysis. The 
marked hyperlipidemia that characterized the diabetic state may therefore be regarded 
as a consequence of the uninhibited actions of lipolytic hormones on the fat depots. 
Triton has been widely used to block the clearance of triglyceride-rich lipoproteins to 
induce acute hyperlipidemia particularly, in rats it has been used for screening natural 
or chemical hypolipidemic drugs. The results showed that KSP produced a significant 
reduction in cholesterol level and also it reversed Triton induced hypolipidemic in 
rats. Similarly, KSP at a dose of 250 and 500mg/kg significantly lowered both plasma 
triglycerides and cholesterol levels. The reduction of total cholesterol by the KSP at 
the dose level of 250 and 500 mg kg may be associated with a decrease of LDL, which 
is the ultimate aim of many hypolipidemic agents. 
 This study suggests that cholesterol-lowering activity of the KSP may increase 
the fecal excretion of bile acids and neutral sterols with the consequent reduction of 
hepatic cholesterol because of its use in the biosynthesis of these bile acids. These 
fractions also slow down the rate of diffusion through the intestinal mucosa thereby 
reducing the absorption of cholesterol and triglycerides. Anti oxidant constituents of 
Kadukkai, Nellimuli and thandrikai also prevent the endogenous oxidation of 
cholesterol result in decrease in the concentration of low density lipoprotein and again 
confirms the hypolipidemic drug. 
          Table no:19 & 20 shows the KSP has significant anti-dyslipedemic activity and 
the level of serum total cholesterol (TC),  triglycerides (TG), high density lipoprotein 
(HDL),Low density lipoprotein(LDL) and phospholipids of normal and experimental 
animals in each group.  
   The main ‘anti-atherogenic’ lipoprotein (HDL) is involved in the 
transport of cholesterol from peripheral tissues into liver and thereby it acts as a 
protective factor against coronary heart disease (CHD).  
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HISTOPATHOLOGY: 
Group I :  Normal section of hepatic cells are seen. 
Group II : Showing degeneration of hepatocytes in some were  
portal zone.This appear more eosinophilic. 
Group III : Showing normal features of hepatic tissue compared to  
cholesterol induced group. 
Group IV : Showing normal feature of hepatic tissue compared to  
standard group. 
Group V : Normal hepatic cells are seen compared to low dose of  
KSP. 
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IN VITRO ANTIOXIDANT ACTIVITY OF KSP ON DPPH RADICAL 
SCAVENGING METHOD 
Sample 
concentration 
(µg/ml) 
Ascorbic acid KSP 
Drug Standard Drug Standard 
Control 0.5441 0.354 - - 
1.25 0.4921 0.262 9.5% 25% 
2.50 0.3825 0.182 29% 48% 
5 0.2782 0.104 48% 70% 
10 0.1820 0.082 66% 76% 
20 0.1025 0.076 81% 78% 
µg/ml: microgram per millilitre. Drug:  KSP (1.25-20µg/ml). Standard: Ascorbic acid 
(10mg/ml DMSO) 
Table No.23. Anti-oxidant activity of  KSP 
 
Fig  No:20: GRAPICAL REPRESENATION 
 
FIG No.21. Anti-oxidant activity of  KSP 
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INTERPRETATION: 
Antioxidants slow down the oxidative damage of our body. Antioxidants act 
as a freeradical scavengers,  Preventing and repairing damages. Health problems such 
as Heart diseases, cancer and degenerative disorders are all exacerbated by oxidative 
damage. The Antioxidant property of the drug KSP was tested by DPPH assay. The 
results showed that there was a concentration dependent Antioxidant property of 
crude extract of KSP. At the concentration increased from 1.25 to 10 µg/ml, 
percentage of inhibition increased from 48 % to 78 %. At a concentration of 100 
µg/mlthere was an increased percentage of inhibition (78 %) in scavenging the free 
radicals  (DPPH). The IC50 value was obtained at 25.70 µg/ml. It showed that KSP is 
having significant anti oxidant property. Hypoglycemia promotes auto – oxidation of 
glucose to form free radicals, the generation of free radicals beyond the scaving 
abilities of endogenous antioxidant defenses results in macro and mcro vascular 
dysfunction. 
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MICROBIOLOGICAL ANALYSIS 
Table 24. Antimicrobial Activities of Various Samples by Agar Well Diffusion Method 
 
S.No. 
Bacterial 
Pathogens 
Zone of Inhibition (mm) 
Result 
 
 
Positive C-
30ontrol 
Sample Load (µl) 
10 µl 20 µl 30 µl 
1. Escherichia coli 
Chloramphenicol-
30mcg(24 mm) 
R R R Resistant 
2. Klebsiella sps. 
Chloramphenicol-
30mcg (24 mm) 
R R R Resistant 
3. 
Pseudomonas 
aeruginosa 
Chloramphenicol-
30mcg (23 mm) 
R R R Resistant 
4. 
Staphylococcu 
aureus 
Chloramphenicol-
30mcg (25 mm) 
R R R Resistant 
5. Candida sp 
Ketoconazole-
30mcg (24mm) 
R R R Resistant 
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Fig No: 22 Microbiological Analysis of KSP 
S.N
o. 
Bacterial Pathogens Plates 
1. Escherichia coli 
 
2. Klebsiellasps. 
 
3. 
Pseudomonas 
aeruginosa 
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4. Staphylococcu aureus 
 
5. Candida sp 
 
 
INTERPRETATION: 
Both Gram positive and Gram negative bacteria E.coli, Klebsiella 
pneumoniae and Staphylococcus aureus, Pseudomonas aeruginosa and 
Salmonella typhi were found to be resistance when compared to the standard 
drug Gentamycin (Broad spectrum) . Hence the trail drug KSP has not anti 
microbial activity.  
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TOXICITY RESULTS 
EVALUATION OF ACUTE TOXICITY STUDY OF KSP 
Table no –25   Physical and behavioral examinations. 
Group no. Dose(mg/kg) Observation sign No. of animal 
affected. 
Group-I 5mg/kg Normal 0 of 3 
Group- II 50mg/kg Normal 0 of 3 
Group-III 300mg/kg Normal 0 of 3 
Group-IV 1000mg/kg Normal 0 of 3 
Group-V 2000mg/kg Normal 0 of 3 
 
Table no-26    Home cage activity 
Functional 
and 
Behavioural 
observation 
Observa
tion 
5mg/kg 
Group 
(G-I) 
50 
mg/kg 
(G-II) 
300 
mg/kg 
(G-III) 
 
1000 
mg/kg 
(G-IV) 
2000 
mg/kg 
(G-V) 
Female 
n=3 
Female 
n=3 
Female 
n=3 
Female  
n=3 
Female 
n=3 
Body 
position Normal 3 3 3 3 3 
Respiration Normal 3 3 3 3 3 
Clonic 
involuntary 
Movement 
Normal 3 3 3 3 3 
Tonic 
involuntary 
Movement 
Normal 3 3 3 3 3 
Palpebral 
closure Normal 3 3 3 3 3 
Approach 
response Normal 3 3 3 3 3 
Touch 
response Normal 3 3 3 3 3 
Pinna reflex Normal 3 3 3 3 3 
Tail pinch 
response Normal 3 3 3 3 3 
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Table no-27  Hand  held  observation 
Functional 
and 
Behavioral 
observation 
Observati
on 
Control 
5 
mg/ kg 
(G-I) 
50 
mg/kg 
(G-II) 
300 
mg/kg 
(G-III) 
1000 
mg/kg 
(G-IV) 
2000 
mg/kg 
(G-V) 
Female 
n=3 
Female 
n=3 
Female 
n=3 
Female 
n=3 
Female 
n=3 
Female 
n=3 
Reactivity Normal 3 3 3 3 3 3 
Handling Normal 3 3 3 3 3 3 
Palpebral 
closure 
Normal 3 3 3 3 3 3 
Lacrimation Normal 3 3 3 3 3 3 
Salivation Normal 3 3 3 3 3 3 
Piloerection Normal 3 3 3 3 3 3 
Pupillary 
reflex 
Normal 3 3 3 3 3 3 
Abdominal 
tone 
Normal 3 3 3 3 3 3 
Limb tone Normal 3 3 3 3 3 3 
 
Table no-28   Mortality 
Group no Dose no(mg/kg) Mortality 
Group-I 5(mg/kg) 0 of 3 
Group-II 50(mg/kg) 0 of 3 
Group-III 300(mg/kg) 0 of 3 
Group-IV 1000(mg/kg) 0 of 3 
Group-V 2000(mg/kg) 0 of 3 
 
RESULT: 
  From acute toxicity study it was observed that the administration of KSP at a 
dose of 2000 mg/kg to the rats do not produce drug-related toxicity and mortality. So 
No-Observed-Adverse-Effect- Level (NOAEL) of KSPis 2000 mg/kg. 
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DISCUSSION 
  KSP was administered single time at the dose of 5mg/kg, 50mg/kg , 
300mg/kg, 1000mg/kg and 2000mg/kg to rats and observed for consecutive 14 days 
after administration. Doses were selected based on the pilot study and literature 
review. All animals were observed daily once for any abnormal clinical signs. Weekly 
body weight and food consumption were recorded. No mortality was observed during 
the entire period of the study. Data obtained in this study indicated no significance 
physical and behavioural signs of any toxicity due to administration of KSP at the 
doses of 5mg/kg, 50mg/kg , 300mg/kg, 1000mg/kg and 2000mg/kg to rats.  
  At the 14th day, all animals were observed for functional and behavioral 
examination. In functional and behavioral examination, home cage activity, hand held 
activity were observed. Home cage activities like Body position, Respiration, Clonic 
involuntary movement, Tonic involuntary movement, Palpebral closure, Approach 
response, Touch response, Pinna reflex, Sound responses, Tail pinch response were 
observed. Handheld activities like Reactivity, Handling, Palpebral closure, 
Lacrimation, Salivation, Piloercetion, Papillary reflex, abdominaltone, Limb tone 
were observed. Functional and behavioral examination was normal in all treated 
groups.Food consumption of all treated animals was found normal as compared to 
normalgroup. 
  Body weight at weekly interval was measured to find out the effect of KSP on 
the growth rate. Body weight change in drug treated animals was found normal. 
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SUB-ACUTE TOXICITY 
Table :29  EFFECT OF SUB- ACUTE DOSE (28 DAYS)OF KSP ON BODY WEIGHT 
IN GRAM 
BODY 
WEIGHT 
CONTROL 
GROUP 
LOW  DOSE 
GROUP 
MIDDLE DOSE 
GROUP 
HIGH DOSE 
GROUP 
1st day 121.3±1.03 126±2.544 125.4±3.232 127.4±3.24 
7th day 133.4±2.04 132.4±2.344 132±3.114 138±3.21 
14th day 135.2±2.104 103.4±2.22 103.5±3.112 104.5±3.112 
21st day 104.4±3.220 111.3±2.601 105±2.231 106±2.23 
28th day 114.4±2.141 113.4±2.302 144±3.1405 147±3.140 
Values are expressed as mean ± SEM Statisticalsignificance (p) calculated by one way 
ANOVA followed by Dunnett’s(n=6); nsp>0.05, *p<0.05, **p<0.01, ***p<0.001, calculated 
by comparing treated groupswith control group. 
 
 
FIG NO 23: EFFECT OF SUB- ACUTE DOSE (28 DAYS)OF KSP ON BODY 
WEIGHT IN GRAM 
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EFFECT OF SUBACUTE DOSE (28 DAYS)OF KSP 
Table : 30 KSP ON ORGAN WEIGHT (PHYSICAL PARAMETER) IN GRAM 
ON ORGAN WEIGHT (PHYSICAL PARAMETER) IN GRAM 
ORGANS CONTROL LOW MID HIGH 
HEART 0.53±0.03 0.34±0.05 1.11±0.21 0.51±0.03 
LIVER 3.41± 0.33 5.43±0.33 3.30±0.02 3.33± 0.33 
LUNGS 2.31±0.10 0.41±0.15 0.60±0.25 2.43±0.20 
KIDNEY L 0.53±0.03 1.62±0.04 0.53±0.03 0.51±0.03 
 R 0.51±0.025 2.14±0.02 0.51±0.025 0.52±0.025 
 
Values are expressed as mean ± SEM Statisticalsignificance (p) calculated by one 
way ANOVA followed by Dunnett’s(n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groupswith control group.  
 
 
Fig No: 24 KSP ON ORGAN WEIGHT (PHYSICAL PARAMETER) IN GRAM 
ON ORGAN WEIGHT (PHYSICAL PARAMETER) IN GRAM 
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EFFECT OF SUB- ACUTE DOSE (28 DAYS) OF KSP ON 
HAEMATOLOGICAL PARAMETERS 
Table no 31: EFFECT OF SUB- ACUTE DOSE (28 DAYS) OF KSP ON 
HAEMATOLOGICAL PARAMETERS 
 
Values are expressed as mean ± SEM Statisticalsignificance (p) calculated by one 
way ANOVA followed by Dunnett’s(n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groupswith control group.  
       
Fig No: 25: EFFECT OF SUB- ACUTE DOSE (28 DAYS) OF KSP ON 
HAEMATOLOGICAL PARAMETERS 
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Table :33  EFFECT OF SUB- ACUTE DOSE(28 DAYS)OF KSP ON BIOCHEMICAL 
PARAMETER 
 
Drug 
Treatment 
SGPT 
(IU/L) 
SGOT 
(IU/L) 
ALP 
(IU/L) 
Urea 
(mg/dl) 
Creatinine 
(mg/dl) 
Control 43.24±4.03 152.25±5.32 253.13±12.33 36.36±4.00 0.64±0.04 
 LOW 43.14±4.23 151.24±5.02 261.12±13.43 41.54±3.43 0.60±0.05 
MID 41.23±5.45 154.32±3.22 255.46±5.15 40.13±3.23 0.46±0.05 
HIGH 43.22±5.45 150.32±3.22 244.46±5.15 41.13±3.23 0.56±0.05 
 
 
Fig No: 27 EFFECT OF SUB- ACUTE DOSE(28 DAYS)OF KSP ON BIOCHEMICAL 
PARAMETER 
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Table:34 EFFECT OF SUB- ACUTE DOSE (28 DAYS) OF KSP 
BIOCHEMICAL PARAMETERS 
 
Values are expressed as mean ± SEM Statisticalsignificance (p) calculated by one-
way ANOVA followed by Dunnett’s(n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groupswith control group.  
 
Fig No:28 EFFECT OF SUB- ACUTE DOSE (28 DAYS) OF KSP ON 
BIOCHEMICAL PARAMETERS 
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Uric acid
GROUP CONTROL KSP 
(200mg/kg) 
KSP 
(400mg/kg) 
KSP 
(600mg/kg) 
TOTAL 
BILIRUBIN 
(mg/dl) 
1.308±0.2457 1.458±0.2827 0.8198±0.3376 0.104 
±0.199 
 
CREATINI
NE (mg/dl) 
 
0.6133±0.03849 
 
0.63±0.08827 
 
0.47720.0446 
 
0.5872 
±0.02528 
 
 
URIC ACID 
(mg/dl) 
 
1.752±0.2766 
 
1.79±0.160 
 
2.06±0.6617 
 
1.988 
±0.2929 
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Table No:34 EFFECT OF SUB- ACUTE DOSE (28 DAYS) OFON FOOD 
INTAKE IN GRAM 
GROUP CONTROL 
KSP 
(200mg/kg) 
KSP 
(400mg/kg) 
KSP 
(600mg/kg) 
1st DAY 19.33±13.6110 20.1672±15.3 13.10±22.71 18.5±8.62 
7th DAY 16.5±12. 11.863±13.67 17.73±10.853 12.17±15.41 
14th DAY 19.83±8.72 11.83±15.28 11±14.96 20.72±9.981 
21st DAY 12.87±13.4 16±8.466 16.88±10.43 20.17±9.02 
28th DAY 13.10±11.38 19.38±11.50 11±8.90 11±7.57 
Values are expressed as mean ± SEM Statisticalsignificance (p) calculated by one-
way ANOVA followed by Dunnett’s(n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groupswith control group 
 
 
Fig No: 28 EFFECT OF SUB- ACUTE DOSE (28 DAYS) OFON FOOD INTAKE                 
IN GRAM 
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Table No: 35 Effect of Sub- Acute Dose (28 Days) Of KSPOn Water Intake in ml 
GROUP CONTROL KSP (200mg/kg) 
KSP 
(400mg/kg) 
KSP 
(600mg/kg) 
1st DAY 98.3338±13.5110 89.1672±14.3426 102.10±21.7199 67.5±7.6203 
7th DAY 85.5±11.7938 100.863±12.6770 76.6673±9.85363 81.6717±14.4150 
14th DAY 58.3383±8.72817 90.8363±14.2812 80±13.9692 89.1672±8.88981 
21st DAY 91.6687±12.4949 85±8.46662 65.8338±9.43550 89.1717±8.79602 
28th DAY 82.10±11.3840 88.3348±11.5004 80±8.90061 70±7.57773 
 
Values are expressed as mean ± SEM Statisticalsignificance (p) calculated by one-way 
ANOVA followed by Dunnett’s(n=6); nsp>0.05, *p<0.05, **p<0.01, ***p<0.001, calculated 
by comparing treated groupswith control group 
 
 
Figure:29. Effect of Sub- Acute Dose (28 Days) Of KSPOn Water Intake in ml 
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Table No: 36 EFFECT OF SUB ACUTE DOSES (28 DAY) OF KSP 
ONELECTROLYTES: - 
GROUP CONTROL KSP (200mg/kg) 
KSP  
(400mg/kg) 
KSP 
(600mg/kg) 
Sodium 
(mg/dl) 4.10±0.6855 4.30±0.6792 11±0.7571 11.80±0.70 
Calcium(mg/
dl) 
1.580±0.1378
89 
3.20±0.175783
*** 
4.7±0.165299**
* 
6.180±0.19611
*** 
Phosphorus 
(U/L) 
0.278±0.0230
17 
0.3010±0.0199
15ns 
0.35630±0.0354
91ns 
5.037±0.32502
* 
 
Values are expressed as mean ± SEM Statisticalsignificance (p) calculated by one-
way ANOVA followed by Dunnett’s(n=6); NS- non-significant, *p<0.05, **p<0.01, 
***p<0.001,  
 
 
Figure no.30 
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RESULTS 
CLINICAL SIGNS: 
  All animals in this study were free of toxic clinical signs throughout the 
dosing   period of 28 days. 
 Mortality: 
  All animals in control and in all the treated dose groups survived throughout 
the dosing period of 28 days. 
 Body weight: 
  Results of body weight determination of animals from control and different 
dose groups exhibited comparable body weight gain throughout the dosing period of 
28 days. 
Food consumption: 
  During dosing and the post-dosing recovery period, the quantity of food 
consumed by animals from different dose groups was found to be comparable with 
that by control animals. 
Organ Weight: 
  Group Mean Relative Organ Weights (% of body weight) are recorded in 
Table No.22 Comparison of organ weights of treated animals with respective control 
animals on day 29 was found to be comparable similarly. 
Hematological investigations: 
  The results of hematological investigations conducted on day 29 revealed 
following significant changes in the values of different parameters investigated when 
compared with those of respective controls; however, the increase or decrease in the 
values obtained was within normal biological and laboratory limits. 
Biochemical Investigations: 
  Results of Biochemical investigations conducted on the day 29th and recorded 
in Table no 24, 25 revealed the following significant changes in the values of hepatic 
serum enzymes studied. When compared with those of respective control. However, 
the increase or decrease in the values obtained was within normal biological and 
laboratory limits. 
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INTERPRETATION: 
1) All the animals from control and all the treated dose groups up to 2000mg/kg 
survived throughout the dosing period of 28 days. 
2) No signs of toxicity were observed in animals from different dose groups 
during the dosing period of 28 days. 
3) Animals from all the treated dose groups exhibited comparable body weight 
gain with that of controls throughout the dosing period of 28 days. 
4) Food consumption of control and treated animals was found to be 
comparable throughout the dosing period of 28 days 
5) Haematological analysis conducted at the end of the dosing period on day 
29th, revealed no abnormalities attributable to the treatment. 
6) Biochemical analysis conducted at the end of the dosing period on day 29th, 
no abnormalities attributable to the treatment. 
7) Organ weight data of animals sacrificed at the end of the dosing period was 
found to be comparable with that of respective controls. 
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6. SUMMARY 
  The trial drug “Komoothira silasathu parpam" was selected from the text 
“Thanjai Vaithiya Raja Sinthamani” for the validation of safety, efficacy and  its 
potency in hypoglycemic, Anti dyslipidemic & anti oxidant activities  
  The raw drugs Komoothira silasathu, Kadukkai, Nelli Mulli, Thandrikai  were 
purchased  from Ramasamy Chetty Traders, Paris, Chennai. These raw drugs were 
identified and authenticated by  experts of PG Gunapadam department,Govt.siddha 
medical college, Palayamkottai. 
  The trial drug was prepared as per the standard operating procedure. 
  Various literary collections of Siddha and modern sciences  about the 
ingredients of the trial drug supported  the fact that Komoothira silasathu parpam has 
good effect in madhumegam. 
             As in the quote of  “hgv<hqk<k!uqf<jkbziK!Olgl<!uviK” mega disease is 
caused by derangement of pitha humour. Literary evidences show that madhumegam 
comes under the pitha variety of meganoi 20. 
             KSP is in astringent taste. Astringent normalized the pitha humour which is 
the basic cause of madhumegam. It is described as  
 “GVkq!Sk<kqbig<Gl<!!
!ogicb!hqk<kl<!Ohig<Gl<”!
  The results  Physico-chemical analysis confirm that the Komoothira silasathu 
parpam is light white in colour and low moisture content and did not contain free 
metals or microbes. This ensuring the safety of the trial drug. 
           Bio Chemical analysis revealed the presence of calcium, sulphate, chloride, 
ferrous iron,amino acid 
   ICP-OES reveals high concentration of physiologically important minerals 
like, calcium phosphorus, potassium, magnesium, sodium, sulphur study and also it 
reveals below detection limit(BDL) of heavy metals As (arsenic), Hg (Mercury), 
Cd(cadmium), Pb(lead) and Cu(copper). This result also indicates that the formulation 
KSP is extremely safe as it contains heavy metals within WHO specified limits. 
        Calcium release insulin hormone from the islets of Langerhans. 
        Potassium is  required for the transmission of  nerve impulse which control 
numbness. 
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        Phosphorus is important for energy transfer in cells as part of ATP and is 
found in many other biological important molecules. Thus it relieves fatigue which is 
one of the symptom of  madhumegam. 
      Eating a diet with more magnesium is linked with a reduced risk of diabetes in 
adults.  
  FTIR confirms that Komoothira silasathu parpam constitutes Alkane, 
aldehyde, Amines, Alcohols. 
  SEM analysis of the Komoothira silasathu parpam shows the particle size 
varies between 5µm to 10µm. The surfaces of the sample grains is uniformly arranged 
in agglomerates. Smaller sized particles enhance the absorption and the bioavailability 
of the drug resulting efficacy of the drug will be increased. 
  Hypoglycemic activity results showed, fasting blood glucose level is reduced 
from 190.66 mg/dl to 178.25mg/dl in the dose 100mg of KSP and it was further 
decreased to 164.25mg/dl in the dose of 200mg of  KSP and this reveals dose 
dependent decrease of blood glucose. Despite the severity of the disease, 
administration of Komoothira silasathu parpam succeeded in significantly reducing 
blood glucose level in a good manner.   
  In DM , dyslipidemic is common. In rats treated with both doses of Siddha 
formulation KSP and Triton there was significant decrease in the content cholesterol 
TGs, LDL , VLDL and increases HDL when compared with cholesterol controlled 
rats. KSP has significant Anti dyslipidemic effect.  
  The Antioxidant property of the drug Komoothira silasathu parpam was tested 
by DPPH assay. The results showed that there was a concentration dependent 
Antioxidant property of Komoothira silasathu parpam. At the concentration increased 
from 10 to 100 µg/ml, percentage of inhibition increased from 50 % to 78 %. At a 
concentration of 100 µg/mlthere was an increased percentage of inhibition (78 %) in 
scavenging the free radicals  (DPPH). It showed that komoothira silasathu parpam is 
having significant anti oxidant property.  
       The drug Komoothira silasathu parpam has no antimicrobial activity to 
Salmonella typhi, Staphylococcus aureus, Escherchia coli,  pseudomonas. 
            From the acute toxicity study ( OECD guidelines 423), it was observed that 
the administration of Komoothira silasathu parpam at a dose of 2000 mg/kg to the 
rats do not produce drug-related toxicity and mortality. The test drug Komoothira 
silasathu parpam is a safety drug.  
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No toxic effect was observed up to 600 mg/kg of Komoothira silasathu parpam 
treated over a period of 28 days (OECD 407). So, Komoothira silasathu parpam can 
be prescribed for therapeutic use in human being in the recommended dosage for 
prolonged period. 
  Based on the results presented in this study, it can be concluded that 
komoothira silasathu parpam exerts significant Hypoglycemic, Anti dyslipidemic and 
Antioxidant activities. Further studies are needed to isolate the active constituents and 
also to evaluate the exact mechanism  of action. 
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7. CONCLUSION 
 
  It is concluded that the test drug Komoothira silasathu parpam  has significant 
hypoglycemic, anti dyslipidemic and anti-oxidant activities. The anti-oxidant property 
of the test drug shows it is a preventive medicine and inhibits blood vessel damage. 
And the test drug KSP is significantly validated  by modern techniques and siddha 
standard method for madhumegam. The toxicological study of this test drug KSP 
establish the safety of the drug for long time administration. So the test drug of KSP 
hopefully use for human trials. 
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8. FUTURE SCOPE 
 
                The trial drug Komoothira silasathu parpam has its own potency in treating 
diabetes mellitus in animal model which has been established in this study. However, 
the mechanism of action by which Komoothira silasathu parpam produced its effect 
on the diabetes mellitus is needed further study to understand the exact molecular 
mechanisms of action. So it could be used worldwide in treatment of diabetes 
mellitus. 
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